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Lung cancer is the leading cause of cancer death in the U.S. It is a disease with poor 
prognosis that mainly occurring in older population. Treatment options have been increasing for 
lung cancer recently. However, high out-of-pocket costs is a major concern regarding the use of 
novel drug treatments, which could impact patient’s choice of treatment and even poorer patient 
outcomes in the long term. Among all, health insurance is an important modifier of financial 
burden. The study objectives were to examine the extent of Medicare’s benefit designs for drug 
treatments and the effect of cost-sharing support on treatment uptake in advanced non-small cell 
lung cancer (NSCLC). 
We first used Medicare plan formulary files to evaluate the changes in drug prices and 
benefit designs for lung cancer medications. We then used the SEER-Medicare databases to 
examine drug utilization, key factors associate with the use through modified Poisson regression, 
and the effect of cost-sharing support through low-income subsidy on the timing of treatment 
initiation in the advanced NSCLC population through multivariable COX proportional hazards 
regression and propensity score weighting. 
We observed higher entry prices at FDA approval overtime in Part D advanced NSCLC 
drugs while considerable price hike was also found in older drugs. In addition, high adoption 
rates of specialty/top tier and utilization management tools were found among Part D plans and 
across treatment options. The use of Part D medications has been stable but lower than expected. 
 
iv 
Particularly, we found that low-income subsidy served as a critical factor for Part D drug use and 
timely initiation of Part D treatment among the advanced NSCLC population. 
With current plan benefits and ever-increasing drug prices, concerns over affordability of 
and accessibility to Part D treatments could continue for advanced NSCLC patients. Patient out-
of-pocket costs could particularly present a considerable barrier to timely treatment initiation. In 
the context of current evolving health care reform, identifying sustainable strategies to improve 






First and foremost, I would like to thank my dissertation committee for guiding and 
supporting me throughout the development of my doctoral dissertation. I would like to express 
my deepest appreciation for my adviser, Dr. Stacie Dusetzina, for being supportive and 
understanding throughout my graduate studies. Her continuous guidance and advice were vital in 
making this dissertation a reality. I would also like to sincerely thank the other members of my 
dissertation committee, Drs. Jennifer Elston Lafata, Joel Farley, Thomas Stinchcombe, and 
Amber Proctor, for their valuable insights, guidance, and expertise on this research. In addition, I 
wish to thank my fellow graduate students for making my graduate life more enjoyable. Last but 
not least, I would like to express sincere gratitude and love for my family and friends for their 
support throughout the program and beyond. In particular, I would like to thank my husband, 
Eric, for his endless support and always being there for me throughout this journey. I could not 
have come this far without you by my side.  





TABLE OF CONTENTS 
 
LIST OF TABLES .……………………………………………………………………………….ix 
LIST OF FIGURES…….……………………………………………………………………...….xi 
LIST of ABBREVIATIONS……………………………………………………………….……xiii 
CHAPTER ONE: INTRODUCTION ……………………………………………………………..1 
1.1 OVERVIEW ……………………………………………………………………………….1 
1.2 SPECIFIC AIMS AND HYPOTHESIS …………………………………………………...7 
1.3 SIGNIFICANCE AND INNOVATION ………………………………………………….10 
CHAPTER TWO: LITERATURE REVIEW ……………………………………………………12 
2.1 ADVANCED NON-SMALL CELL LUNG CANCER OVERVIEW …………………...12 
2.1.1 EPIDEMIOLOGY …………………………………………………………………...12 
2.1.2 TREATMENT OPTIONS …………………………………………………………...13 
2.2 TREATMENT BURDEN OF MEDICARE BENEFICIARIES WITH 
      ADVANCED NSCLC ……………………………………………………………………15 
2.2.1 HIGH COST OF NOVEL TREATMENTS…………………………………………15 
2.2.2 FINANCIAL TOXICITY AMONG PATIENTS WITH CANCER  ………………...17 
2.3 DRUG COVERAGE UNDER MEDICARE ……………………………………………..17 
2.3.1 MEDICARE PART B ……………………………………………………………….18 
2.3.2 MEDICARE PART D ……………………………………………………………….19 
2.3.3 COST SHARING SUPPORT FOR PRESCRIPTION DRUGS …………………….25 
 
vii 
2.3.4 COST SHARING SUPPORT FOR ACCESS TO CANCER CARE……………….29 
2.4 CONCEPTUAL FRAMEWORK………………………………………………………...30 
2.4.1 PREDISPOSING FACTORS ……………………………………………………….31 
2.4.2 ENABLING FACTORS …………………………………………………………….32 
2.4.3 NEED FACTORS….………………………………………………………………..34 
CHAPTER THREE: RESEARCH METHODS    ………………………………………………...36 
3.1 AIM 1   …………………………………………………………………………………….36 
3.1.1 DATA SOURCE   ……………………………………………………………………36 
3.1.2 STUDY DESIGN  ……………………………………………………………...……38 
3.2 AIM 2  …………………………………………………………………………………….46 
3.2.1 DATA SOURCE  ……………………………………………………………………46 
3.2.2 STUDY DESIGN .…………………………………………………………………..47 
3.2 AIM 3  …………………………………………………………………………………….60 
3.3.1 DATA SOURCE  ……………………………………………………………………60 
3.3.2 STUDY DESIGN  …………………………………………………………………...60 
CHAPTER FOUR: RESULTS ...………………………………………..………………………67 
4.1 AIM 1 ...……………………………………………………………….………………….67 
4.2 AIM 2 ………………………………………………………………….…………………78 
4.3 AIM 3 ...……………………………………………………………….…………….……99 
CHAPTER FIVE: DISCUSSION ……………………………………………………………...108 
5.1 AIM 1 ...…………………………………………………………………………………108 
5.2 AIM 2 …………………………………………………………………………………...113 
5.3 AIM 3 …………………………………………………………………………………...116 
 
viii 
5.4 STRENGTHS AND LIMITATIONS…………………………………………...………119 
5.5 CONCLUSION …………………………………………………………………………122 
5.6 FUTURE RESEARCH…………………………………………………………….……123 





LIST OF TABLES 
 
Table 2.1 Summary of Eligibility and Cost-Sharing for Medicare Part D  
                Benefit for Low-Income Subsidy Groups ……………………………………………..27 
Table 3.1 Advanced Non-Small Cell Lung Cancer Drugs covered under  
                Part D and approved by U.S. FDA by June 2017 ……………………………………..39 
Table 3.2 Advanced Non-Small Cell Lung Cancer Drugs covered under  
                Part B and approved by U.S. FDA by June 2017 …………………………………......40 
Table 3.3 Summary of Unit of Analysis, Covariates, and Outcomes for Aim 1 ………………...45 
Table 3.4 Summary of Outcomes for Aim 2 …………………………………………………….51 
Table 3.5 Summary of Covariates at Baseline for Aim 2…………………………………….….57 
Table 4.1A Patient Characteristics at Baseline…………………………………………………..82 
Table 4.1B Patient Characteristics at Baseline, Part D treated vs. No Part D treated .…………..90 
Table 4.2A Association between Key Factors and Part D Drug Treatment 
                Use for Advanced Non-Small Cell Lung Cancer, among All Patients ...……….…….94 
Table 4.2B Association between Key Factors and Part D Drug Treatment  
                Use for Advanced Non-Small Cell Lung Cancer, among Drug Treated  
                Patients……………………………………………………………………………..….97 
Table 4.3 Baseline Patient Characteristics before and after Inverse  
                Probability Treatment Weight (IPTW) ……………………………………….…..…103 
Table 4.4 Effect of Low-Income Subsidy on Time from Diagnosis to  
                Initiation of Part D Treatments……………………………………………..……..…105 
Table 4.5 Effect of Low-Income Subsidy on Time from Diagnosis to  
                Initiation of Part B Treatments……………………………………………..……..…107 
Appendix Table 3.1 Advanced Non-Small Cell Lung Cancer Drugs  
                covered under Part D and approved by U.S. FDA by June 2017……………………125 
Appendix Table 3.2 Advanced Non-Small Cell Lung Cancer Drugs  
                covered under Part B and approved by U.S. FDA by June 2017……………………126 
Appendix Table 3.3 Oral Anticancer Drug for Advanced Non-Small  
                Cell Lung Cancer by April 2017………………………………………………….…127 
 
x 
Appendix Table 3.4 Infused Anticancer Drug for Advanced Non-Small  
                Cell Lung Cancer by April 2017……………………………………………………..128 
Appendix Table 3.5 Summary of Surgery for Non-Small Cell Lung Cancer…………………..131 
Appendix Table 3.6 Summary of Radiation Therapy for Non-Small Cell Lung Cancer ………131 
Appendix Table 4.1 Median Prices of Advanced Non-Small Cell Lung  
                Cancer Drugs Covered under Part D, 2010Q1-2017Q1 (2017 USD) ……………….132 
Appendix Table 4.2 Average Sales Prices for Advanced NSCLC Drugs  
                Covered under Part B (2017 USD)…………………………………………………..133 
Appendix Table 4.3 Coverage of Advanced Non-Small Cell Lung Cancer  
                Drugs among Part D Plans, 2010Q1-2017Q1 ……………………………………….134 
Appendix Table 4.4 Application of Utilization Management Tools and Drug 
                Tiering in Part D Plans, by Drug, 2010Q1-2017Q1…………………………………135 
Appendix Table 4.2 Standard Differences Before and After Inverse  
                Probability of Treatment Weighting (IPTW)………………………………………..139 
 
xi 
LIST OF FIGURES 
 
Figure 2.1 Conceptual Framework ………………………………………………………………30 
Figure 3.1 Study Design for Aim 1 ………………………………………………………………37 
Figure 3.2 Flow Diagram of Study Plan Selection for Aim 1……………………………………39 
Figure 3.3 Flow Diagram of Study Population Selection for Aim 2 …………………………….49 
Figure 3.4 Study Design for Aim 2………………………………………………………………50 
Figure 3.5 Flow Diagram of Study Population Selection for Aim 3 …………………………….61 
Figure 3.6 Study Design for Aim 3 ………………………………………………………………64 
Figure 4.1 Median Prices of Advanced Non-Small Cell Lung Cancer Drugs  
                 Covered under Part D (2017 USD)…………………………………………………...68 
Figure 4.2 Average Price of Advanced Non-Small Cell Lung Cancer Drugs  
                 Covered under Part D, by Therapeutic Class (2017 USD) …………………………...70 
Figure 4.3 Average Sales Prices for Advanced NSCLC Drugs Covered under  
                 Part B (2017 USD)……………………………………………………………………71 
Figure 4.4 Average Sale Prices of Advanced Non-Small Cell Lung Cancer  
                 Drugs Covered under Part B, by Therapeutic Class (2017 USD) ……………………72 
Figure 4.5 Part D Plan Coverage for Advanced Non-Small Cell Lung Cancer  
                 Care, by Plan Type, 2010Q1 to 2017Q1…………………………………………...…73 
Figure 4.6 Utilization Management Tools and Formulary Tiering in Advanced 
                 Non-Small Cell Lung Cancer Drugs, 2010Q1 vs. 2017Q1 …………………………..75 
Figure 4.7 Trend of Cost-Sharing Requirement for Erlotinib on Medicare  
                 Part D Formularies in the Initial Coverage Phase, 2010Q1 – 2016Q3…………….…76 
Figure 4.8 Estimated First-Month Out-of-Pocket Cost (OOP) of Advanced  
                 Non-Small Cell Lung Cancer Part D Drug Treatments in 2017 ……………………...77 
Figure 4.9 Flow chart of the study population selection…………………………………………79 
Figure 4.10A Utilization NSCLC Drugs on Medicare Part D within 12-month 
                 after Diagnosis of Advanced NSCLC, 2007-2014 ………………...…………………86 
 
xii 
Figure 4.10B First NSCLC Drugs on Medicare Part D within 12-month after  
                 Diagnosis of Advanced NSCLC, 2007-2014, by Drug Product ……………………...87 
Figure 4.11A. Utilization of NSCLC Drugs on Medicare Part B within 12-month 
                 after Diagnosis of Advanced NSCLC, 2007-2014 …………………………………...88 
Figure 4.11B. First NSCLC Drugs on Medicare Part B within 12-month  
                 after Diagnosis of Advanced NSCLC, 2007-2014, by Regimen ……………………..89 
Figure 4.12 Flow chart of the study population selection………………………………………100 
Figure 4.13 Product-Limit Failure Curves for Time-to-Initiate Part D 
                 Treatments by Low-Income Subsidy (LIS) Status……………..……………………104 
Figure 4.14 Product-Limit Failure Curves for Time-to-Initiate Part B  
                 Treatments by Low-Income Subsidy (LIS) Status……………………………..……106 
Appendix Figure 4.1A Composition of NSCLC Drugs Utilization on Medicare  
                 Part D within 12-month after Diagnosis of Advanced NSCLC, 2007-2014 …..……138 
Appendix Figure 4.1B. Composition of NSCLC Drugs Utilization on Medicare 
                 Part B within 12-month after Diagnosis of Advanced NSCLC, 2007-2014…….…..138 
 
xiii 
LIST OF ABBREVIATIONS 
 
ALK   Anaplastic lymphoma kinase 
DS   Disability Status 
EGFR   Epidermal growth factor receptor 
HR   Hazard Ratio 
IPTW   Inverse probability of treatment weighting 
LIS   Low-income subsidy 
NSCLC  Non-small cell lung cancer 
PA   Prior authorization 
PS   Propensity Score 
QL   Quantity limit 
RR   Risk ratio / relative risk 
SEER   Surveillance, Epidemiology, and End Results 




CHAPTER ONE: INTRODUCTION 
 
1.1 OVERVIEW 
Lung cancer is the leading cause of death from cancer and the second most common 
cancer among both men and women in the United States (U.S.).1,2 In 2017, an estimated 222,500 
new cases of lung cancer are expected to be diagnosed and 155,870 patients will die from the 
disease, representing 13% of all new cancers and more than one-fourth of all cancer death, 
respectively.1,2 Lung cancer is a disease mainly occurring among older populations with an 
average age of 70 at the time of diagnosis.3 More than 80% of patients are diagnosed at stages III 
and IV with 5-year survival of only 4.2% for those with stage IV disease.1–3 Due to the high 
mortality of the disease, there is a significant need for treatments that extend survival for these 
patients. 
Until recently, treatments available to lung cancer patients were limited. For late stage 
cancer, chemotherapy has been the main treatment. However, advances have been made in 
pharmaceutical discovery, research, and development in recent years. Since 2010, 14 cancer 
drugs (12 new drugs and 2 older drugs with new indications) have been approved by the United 
States Food and Drug Administration (FDA) for lung cancer, all of which are biological targeted 
therapies.4 These novel targeted therapies are increasing the number of treatment options for 
patients and are generally preferred over traditional anticancer therapies (chemotherapy) due to 
greater clinical efficacy, lower rate of severe adverse events, and improved outcomes in quality 
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of life and/or symptom assessments.5,6 According to a 2015 marketing report, there are currently 
661 lung cancer drugs under  development targeting 377 different gene mutations; 49 of these 
have entered phase III trials.7 Further, recent success in immunotherapy trials suggest that 
research and development focused on lung cancer is expected to increase.6 
A major concern regarding the use of targeted treatments is their high cost to both 
patients and society. On average, the monthly cost of these novel drugs for lung cancer in the 
U.S. is $9,945 (in 2014 US dollars) with a range from $2,069 (gefitinib, Iressa
○R
) to $14,837 
(atezolizumab Tecentriq
○R
)8, with prices doubling in the last decade.6,9 In addition, cancer 
regimens increasingly consist of multiple drugs (either sequential or combination therapies), 
which exacerbates the cost problem.10 Prior research has found that patients going through 
cancer treatments can be burdened with high out-of-pocket costs, termed “financial toxicity”.11–13 
The resulting financial distress, and even bankruptcy following cancer diagnosis 14–16, has been 
reported to impact patient’s choice of treatment and adherence to therapy, 17–19 leading to poorer 
patient outcomes,20,21 reduced quality of life,22,23 and even greater costs of care in the long 
term.20  
However, a major modifier of financial burden is health insurance. In the context of lung 
cancer treatment, Medicare is a primary payer – largely due to the age of patients needing 
treatment. Under the federal Medicare program, which provides health insurance coverage for 
individuals aged 65 years or older, the cost of drug treatments can be covered through either the 
outpatient medical benefit (Part B) or the outpatient pharmacy benefit (Part D).24 This distinction 
is important because coverage varies between Medicare Part B and Part D and affects the level of 




Medicare Part B, as part of traditional / fee-for-service Medicare (i.e., the Original 
Medicare), is administered directly through the federal government. It applies a standardized 
coverage structure for services included in the program, including injectable and infused drugs 
that are not usually self-administered and that are furnished and administered as part of a 
physician service. In 2017, for example, in addition to a standard monthly premium, patients 
with Part B pay a deductible (on average $183) and/or coinsurance when receiving health 
services (usually 20% of the Medicare-approved cost for outpatient care).25 Despite the above 
cost-sharing requirements under Part B, there are supplemental health insurance options 
available for beneficiaries to fully or partially pay those cost-sharing requirements, including 
deductibles, copayments, and coinsurance. According to Kaiser Family Foundation, more than 
80% of fee-for-service Medicare beneficiaries have some source of coverage that supplements 
Medicare, including Medigap, employer or union-sponsored retiree health plans, and Medicaid 
for individuals with low-incomes.26,27 This supplemental coverage results in more consistent and 
predictable expenses for patients using Part B services throughout the year.  
In contrast, Medicare Part D, the outpatient prescription drug benefit for most orally-
administered anticancer medications, is offered through private insurance companies. Because of 
this, the cost-sharing requirement for drug treatments varies across plans (although plans are 
required to be actuarially equivalent to a prescribed standard benefit package). According to the 
Centers for Medicare & Medicaid Services (CMS), the Part D base beneficiary premium in 2017 
is $35.63, with adjustment by income. In 2017, the Part D standard benefit has a $400 deductible 
and 25% coinsurance up to an initial coverage limit of $3,700 in total drug costs, followed by a 
coverage gap, in which a beneficiary pays 40% of their prescription costs (100% patient 
responsibility before 2011), until the cost reaches the catastrophic coverage threshold of $8,071 
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in drug costs.25 After entering the catastrophic coverage phase, Part D enrollees pay 5% of the 
drug price (or $3.30 for generics or $8.25 for brand-name drugs, whichever is greater) for 
covered drugs for the rest of the year.25 For medications offered on Part D there has been 
increasing use of coinsurance (where the patient pays a percentage of the drug’s price) over 
time.28–30 Given the high price of novel anticancer medications, patients obtaining these drugs 
through their Medicare Part D plans are expected to face significant out-of-pocket spending. 
In addition to standard cost-sharing structures, to limit the use of expensive therapies, 
Medicare Part D plan sponsors may also adopt restrictive formularies and engage utilization 
management tools. 28,30,31 Formulary structures consist of drug tier placement and cost-sharing 
amounts assigned to these tiers (through copayments or coinsurance arrangements). Typically, 
higher tier placement requires greater patient cost-sharing for the drug. Prescription drug benefits 
typically include at least three tiers: Tier 1 for generic drugs, Tier 2 for preferred brand-name 
drugs, and Tier 3 for non-preferred brand-name drugs. In recent years, there has been an increase 
in both plan use of tiering and the number of tiers in a formulary, specifically including a unique 
specialty drug tier.30,32 Specialty drug tiers often include high-priced treatments; those typically 
used for complex conditions including cancer.33,34 The growth of specialty tiering in outpatient 
drug formularies reflects plans’ attempts to contain costs.  
Although cancer drugs are required to be included on Part D plan formularies due to their 
status as a protected drugs, many are placed on specialty tiers that require patients to pay a 
percentage of the drug price (i.e., coinsurance) rather than a fixed dollar amount (i.e., 
copayment).35 As a result, a patient filling an anticancer drug on Medicare Part D can face 
thousands of dollars in annual out-of-pocket costs.36  
In addition to tiered cost sharing, utilization management tools may be employed to 
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enforce formulary adherence or to manage drug costs for Part D payers more generally.31 These 
measures include prior authorization (i.e., the plan must grant permission before a particular drug 
can be prescribed and qualified for coverage), quantity limits (i.e., restriction on the amount of 
drugs a plan will cover over a certain period of time) and step therapy (i.e., use less expensive 
drug options before “stepping up” to treatments that cost more). If utilization restrictions are not 
met, a patient would have to pay out-of-pocket for using the drug despite the fact that the drug is 
listed on the formulary by his/her plan. Drugs in higher tiers or specialty drugs are regularly 
subject to utilization management requirements.36 Although these interventions are effective 
cost-management tools for payers, they can affect appropriate access to care and thus treatment 
utilization for patients.31 
Affordability of and patient access to care are major issues in cancer care.37–41 Compared 
to traditional chemotherapies offered through Medicare Part B, patients might face greater 
barriers to accessing drugs offered under Part D due to the plan’s benefit structure and the 
relative lack of out-of-pocket cost protections that are typically available for drugs offered under 
Part B. For those who are newly diagnosed with cancer, initial access to treatment is particularly 
important as prompt treatment is often essential. However, for Medicare beneficiaries needing 
orally-administered anticancer therapies covered under their prescription drug benefit (Part D) to 
initiate the treatments, they may be responsible for very high out-of-pocket spending given 
plan’s benefit designs and limited support of out-of-pocket cost. This high up-front cost for 
initiating anticancer treatment could cause delay in obtaining appropriate care. One key 
exception to this exists for Medicare Part D enrollees who are eligible and enrolled in the Low-
Income Subsidy (LIS) program.42,43 This program provides patients with cost-sharing support for 
Part D prescription drugs but is only available to Medicare beneficiaries with limited income (≤ 
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150% federal poverty level) and resources (≤ $12,320 for individuals in 2017). 42,43 For a full-
subsidy qualified individual, he/she is exempt from the monthly premium, annual deductible, and 
has no cost-sharing during the coverage gap or above the annual out-of-pocket catastrophic 
coverage threshold. In addition, all Part D plans are required to charge full LIS beneficiaries the 
same fixed copayment amounts rather than coinsurance for drugs that they fill. For example, in 
2017, patients with full LIS are responsible for no more than $3.30 for each generic or $8.25 for 
each brand-name covered drug. In contrast, those without full LIS assistance could face 
coinsurance from 5-51% of the drug’s price depending on the coverage phase and the type of 
drug used. According to CMS, average patient out-of-pocket costs of using a Part D drug during 
a year could be more than a hundred times higher for beneficiaries without versus with a LIS.44 
In 2016, over 12 million beneficiaries (28.9% of Part D enrollees) are receiving drug coverage 
for little or no cost through LIS.45,46 In the context of anticancer therapies, having the subsidy 
could mean a difference of thousands of dollars out-of-pocket for patients using the same drug, 
even for just the first prescription fill.36,47  
Lung cancer is currently one of the top five most expensive cancers nationwide and 
accounts for the largest proportion (13%) of cancer-related expenditures in Medicare among all 
cancer types.48 It is estimated that approximately 13% of total Medicare expenditures for lung 
cancer care is paid directly out-of-pocket by patients.48 With a number of targeted therapies for 
lung cancer emerging on the market combined with high drug prices and the aging of the U.S. 
population, the economic burden of lung cancer will be considerable and will likely increase 
significantly in coming years. Given health plans’ efforts to contain costs, this may result in 
greater cost shifting from plans to patients over time.  
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To date, the extent of health insurance coverage for drug treatments has not been 
explored from a disease-specific perspective. This is particularly crucial for lung cancer as high-
priced novel drugs have been increasingly approved for the disease over time and are expected to 
grow in the near future. Understanding the scope of coverage provided for lung cancer drug 
treatment options and the effect of cost-sharing support on treatment uptake could provide 
insights into treatment affordability and accessibility among patients with NSCLC, improve 
clinical decision making, as well as inform policy movement towards affordable and equal 
access to high quality care for the cancer population. 
 
1.2 SPECIFIC AIMS AND HYPOTHESIS 
I propose to evaluate the accessibility and affordability of anticancer medications used to 
treat advanced non-small cell lung cancer (NSCLC), which accounts for more than 85% of lung 
cancer cases. I focus on drug-specific price and formulary structure and utilization management 
tools applied for advanced NSCLC medications covered by Medicare Part D (Aim#1), available 
treatment options for advanced NSCLC and their real-world utilization through Medicare Part B 
and Part D coverage (Aim#2), as well as the effect of Medicare Part D low-income subsidy on 
treatment uptake (Aim#3).  
To achieve these goals, Aim 1 was conducted using the Medicare Prescription Drug Plan 
Formulary, Pharmacy Network, and Pricing Information Files. Given the up-to-date availability 
of the data, the examination expands the number of treatments studied to include those approved 
by June 2017. Aims 2 and 3 both utilize the SEER-Medicare linked databases, with the latest 
available data, including patients diagnosed with cancer by the end of 2013 and their fee-for-
service Medicare claims through 2014. The specific aims are as follows: 
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Specific Aim 1: Examine changes in drug-specific prices, formulary structure, and the use of 
utilization management tools for Part D medications approved for advanced NSCLC from 2009 
to 2017. 
Hypothesis 1a: Over time Part D drug prices have increased over the study period in addition to 
inflation. 
Hypothesis 1b: Over time advanced NSCLC medications covered under Part D are more likely to 
be placed on the highest drug tier or specialty drug tier within the formulary.  
Hypothesis 1c: Over time advanced NSCLC medications covered under Part D are more likely to 
require coinsurance (rather than copayments) for calculating patient cost-sharing. 
Hypothesis 1d: Over time advanced NSCLC medications covered under Part D are more likely to 
be subject to utilization management (e.g., step therapy, prior authorization, 
quantity limits).   
Proposed Contribution to the Literature: Formulary structure and associated benefit design 
within Medicare Part D plans for anticancer medications have not been examined specifically in 
advanced NSCLC settings. This exploration is expected to provide insights into the level of 
coverage for novel advanced NSCLC treatments to inform the scope of patient responsibility for 
treatment cost (i.e., treatment affordability) in NSCLC care. 
 
Specific Aim 2: To examine trends in the utilization of advanced NSCLC medications by 
coverage source (i.e., Medicare Part B or Part D). In addition, to identify clinical, 
sociodemographic, and health system factors associated with the use of Part D treatments among 
patients diagnosed with advanced NSCLC from 2007 to 2014. 
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Hypothesis 2a: The use of advanced NSCLC medications covered under Part D has increased 
over the study period. 
Hypothesis 2b: The use of advanced NSCLC medications covered under Part B has decreased 
over the study period 
Proposed Contribution to the Literature: Real-world utilization of treatments for advanced 
NSCLC care remains largely unknown and may vary by coverage source. Particularly, how 
novel therapies have been adopted over recent years and the characteristics of patients receiving 
orally-administered therapies covered under Part D has not been previously explored. The 
examination will promote better understanding of differential patient access to treatment under 
the effects of price, plan benefit design, and reimbursement policies assigned to the drug 
treatments, which could be targets for policy intervention. 
 
Specific Aim 3: Evaluate the effect of low-income subsidies for Medicare Part D medications on 
treatment initiation among patients with advanced NSCLC from 2007 to 2014. 
Hypothesis 3a: For medications covered under Part D, due to the higher cost-sharing required for 
patients who do not receive low income subsidies, time to initiation is shorter 
among patients with (full or partial) low-income subsidies as compared to those 
without. 
Hypothesis 3b: For medications covered under Part B, due to the availability of supplemental 
insurance coverage for reducing or eliminating out-of-pocket costs for most 
Medicare enrollees, there is no difference in the time to initiation among patients 
with low-income subsidies as compared to those without. 
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Proposed Contribution to the Literature: There is limited evidence regarding the impact of high 
up-front cost sharing on patient access to drugs offered on Medicare Part D. By comparing time 
to initiation of orally-administered anticancer drugs for patients with and without a low-income 
subsidy, we will gain insight into cost-related barriers to treatment use in an advanced NSCLC 
population. This examination may inform policy movement towards affordable and equal access 
to high quality care for the cancer population. 
 
1.3 SIGNIFICANCE AND INNOVATION 
For understanding treatment access and affordability in the context of advanced NSCLC, 
we will examine changes in drug-specific price and formulary structures and utilization 
management tools applied by Medicare Part D plans, examine the trends in real-world 
medication use by coverage source (i.e., Medicare Part B or Part D), and estimate the effect of 
low-income subsidies for Medicare Part D medications on treatment initiation.   
The study is innovative in many aspects. First, distinct from general overview of drug 
coverage in the U.S., our examination applies a disease-specific perspective for understanding 
the scope of care affordability and accessibility in a population with significant unmet needs. 
Beyond focusing on drug prices alone, our planned approach also considers diverse angles of 
growing patient financial burden in cancer care, including the benefit structure of plans as well as 
financial assistance in prescription drug expenses through the Medicare part D low income 
subsidy program. In addition, we examine the role of cost-sharing subsidies on treatment 
initiation to identify possible gaps in treatment access – a crucial element to optimizing cancer 
care, particularly in advanced cancer settings. To our knowledge, this project is the first study to 
examine the drug coverage and resulting patient cost-sharing on high-priced novel anticancer 
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drugs as well as the corresponding effect on treatment uptake among the advanced NSCLC 
population. 
This study will contribute to an in-depth understanding of the Medicare beneficiary out-
of-pocket costs for currently available lung cancer treatment options and the effect of cost-
sharing support for out-of-pocket costs on access to treatment. This information could be used to 
improve physician-patient discussions around challenges to obtaining novel orally-administered 
cancer treatments and may inform policy decisions around increasing affordability and 
accessibility of cancer medications for the population. 
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Advanced Non-Small Cell Lung Cancer Overview 
2.1.1 Epidemiology 
Lung cancer is the leading cause of death from cancer and the second most common 
cancer among both men and women in the United States (U.S.). 1,2 In 2017, an estimated 222,500 
new cases of lung cancer are expected to be diagnosed and 155,870 patients will die from the 
disease, representing 13% of all new cancers and more than one-fourth of all cancer death, 
respectively.1,2 Among three main types of lung cancer, non-small cell lung cancer (NSCLC) is 
the most common type, accounting for about 85% of cases.1,3  The average patient age at 
diagnosis is around 70 years old.3 Due to lack of salient symptoms in its early stage, the disease 
is mostly diagnosed at late stages.1–3,49 More than 80% of patients present with stage III or IV 
disease at the time of diagnosis, and the five-year survival is usually poor at less than 5% for 
those with distant-stage diseases.1–3,49 
 Smoking is the main cause of lung cancer. Approximately 85-90% of cases are caused by 
voluntarily or involuntary (second-hand) cigarette smoking.1,50,51 While smokers are 15 to 30 
times more likely to develop lung cancer or die from lung cancer than nonsmokers,52 recent 
epidemiological data of increased rates of NSCLC among never smokers suggest specific 
molecular and genetic tumor characteristics could also be related.53 Other known risk factors also 
include sex, family history, previous cancer history, occupational exposure, other lung disease, 
exposure to infectious agents, exposure to chemicals, or history suggestive of infection.1,50–52
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 Patients with NSCLC experience high symptom burden and reduced quality of life 
throughout the course of NSCLC diagnosis and treatment.54,55 The most common symptoms 
associated with NSCLC are dyspnea, pain, fatigue, and coughing, which are especially prevalent 
in advanced disease and adversely impact patient health-related quality of life (HRQoL).1,54 For 
example, the mean utility score of quality of life ranged from 0.62 to 0.75 for advanced NSCLC 
(the value assigned represents a year of healthy life expectancy, with ranges from 0.0 for being 
dead up to 1.0 for living in perfect health).54–59 A U.S.-based multicenter study on advanced at 11 
tumor sites showed the lowest HRQoL score in lung cancer and that it is significantly associated 
with pain/discomfort and difficulty in performing usual activities for patients.60 Even with 
treatment, disease progression and severe adverse events were reported to have a considerable 
negative impact on HRQoL, scores low at 0.46 and 0.52, respectively.54–59 This stresses the 
importance of developing treatments that improve survival as well as reduce disease progression 
and severe toxicities for advanced NSCLC. 
 
2.1.2 Treatment options 
 Prior to 2010, treatments available to advanced NSCLC patients were limited. For locally 
advanced or metastatic disease (stage IIIB/stage IV) drug regimens were typically limited to 
chemotherapy, depending on the patient’s overall health.50,51 Platinum-based chemotherapy has 
been considered the standard-of-care, particularly for patients with unknown genetic 
status.50,51,61It has been shown to prolong survival, improve symptom control, and it yields 
superior quality of life compared to best supportive care.62 Data from randomized controlled 
trials suggest that combinations of platinum-based chemotherapy with newer agents (e.g., 
cisplatin/gemcitabine and cisplatin/pemetrexed) have generated a plateau in overall response 
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rates (25%–35%), time to progression (4–6 months), median survival time (8–10 months), 1-year 
survival rate (30%–40%), and 2-year survival rate (10%–15%) in fit patients (e.g., at least being 
capable of all selfcare or performance status score 0-2).51 The suboptimal efficacy and 
considerable toxicity of chemotherapy underscored the unmet patient needs in advanced NSCLC 
care, as only a small impact on survival was observed. 
 Advances have been made in pharmaceutical discovery, research, and development in 
recent years. Histology and gene mutation have been found to be of importance in the 
management of NSCLC.51,61 Particularly, the discovery of actionable molecular abnormalities 
from the early 2000s, such as epidermal growth factor receptor (EGFR) and anaplastic 
lymphoma kinase (ALK), have led to a major shift in the treatment paradigm.61,63–65 Until 
recently, immunotherapy for lung cancer has become a burgeoning revolutionized therapeutic 
modality.6,66–69 Randomized trial data have shown that immunotherapy can greatly improve 
median survival (9-17 months), overall response rate (17-30%), 1-year survival rate (42-56%), 
and 2-year survival (24-40%) as compared to traditional chemotherapy in fit patients.66 These 
novel targeted therapies are expected to be less toxic than traditional chemotherapies because 
they can make distinctions between cancerous and normal cells, targeting the cancer cells 
directly or through stimulating a patient's own immune system to recognize cancer cells more 
effectively without damaging normal healthy cells, which pushes the boundary to significantly 
improve patient outcomes and quality of life.5 Therefore, these novel targeted therapies are 
generally preferred over traditional chemotherapy.6 Not only do the targeted therapies increase 
the number of treatment options for patients, it also allows for a more tailored selection of 
treatment in advanced NSCLC care.6,51 
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Since 2010, 14 cancer drugs (12 new drugs and 2 older drugs with new indications) have 
been approved by the United States Food and Drug Administration (FDA) for lung cancer, all of 
which are biological targeted therapies.4 To date, types of targeted drugs available include 
1) Monoclonal antibodies targeting tumor blood vessel growth (e.g., bevacizumab 
(Avastin
○R ), ramucirumab (Cyramza
○R )) (IV therapies) 
2) Monoclonal antibody targeting EGFR (e.g., necitumumab (Portrazza
○R )) (IV therapies) 
3) EGFR tyrosine kinase inhibitors (e.g., erlotinib (Tarceva
○R ), afatinib (Gilotrif
○R ), gefitinib 
(Iressa
○R ), osimertinib (Tagrisso
○R )) (oral therapies) 
4) ALK tyrosine kinase inhibitors (e.g., crizotinib (Xalkori
○R ), ceritinib (Zykadia
○R ), alectinib 
(Alecensa
○R ), brigatinib (Alunbrig
○R )) (oral therapies) 
5) Immunotherapy with PD-1/PD-L1 inhibitors (i.e., nivolumab (Opdivo
○R ), pembrolizumab 
(Keytruda
○R ), atezolizumab (Tecentriq
○R ) (IV therapies) 
 Recent success in immunotherapy trials suggest that research and development focused 
on lung cancer is expected to increase in the near future for both monotherapy and combination 
treatments.6,70 
 
2.2 Treatment Burden of Medicare Beneficiaries with Advanced NSCLC 
2.2.1 High cost of novel treatments  
A major concern regarding the use of novel treatments is their high cost to both patients 
and society.71 In 2015, U.S. national health expenditure increased 5.8% to reach $3.2 trillion, or 
$9,990 per person. Among different types health spending, prescription drug spending outpaced 
all other services in 2015 and has grown to account for 10.1% of all health spending.72 The 
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strong spending growth for prescription drugs is attributed to the increased spending on new 
medicines, price growth for existing brand name drugs, increased spending on generics, and 
fewer expensive blockbuster drugs going off-patent.72,73 For Medicare specifically, spending on 
Part B drugs (usually injectable or infused drugs) — a category dominated by drugs used to treat 
cancer — doubled from $13 billion in 2009 and to $26 billion in 2015.74 Similarly, spending on 
Part D drugs increased from $46 billion in 2007 to over $80 billion in 2015 (an average annual 
growth rate of more than 7%).74  
The strong upward rise in specialty drug prices and availability, including cancer drugs, 
has contributed to Medicare’s spending growth.72–74  According to a National Institutes of Health 
analysis, the national costs of cancer care is expected to increase by 40 percent, from $125 
billion in 2010 to $175 billion (in 2010 dollars) in 2020.75 The number could reach as high as 
$207 billion if high prices continue to be charged for new developments in oncology.75 Currently 
in the U.S., the average price of a novel anticancer drug routinely exceeds US$100,000 per 
year76; a novel anti-cancer drug can now cost close to $200,000 a year or more than $16,000 a 
month of treatment, up $80,000 in just a few years.77 For lung cancer specifically, the average 
monthly cost of these novel drugs in the U.S. is $9,945 (adjusted from the original US price in 
the FDA approval year to 2014), ranging from $2,069 (gefitinib, Iressa
○R
) to $14,837 
(atezolizumab Tecentriq
○R
)8, with prices doubling in the last decade.6,9  
In addition, cancer regimens increasingly consist of multiple drugs (either sequential or 
combination therapies), which exacerbates the cost problem.10 Combination among these 
different types of drugs are increasingly under evaluation (e.g., Keytruda plus chemotherapy78, 
Opdivo plus Yervoy79, durvalumab plus tremelimumab80). Although these novel treatments 
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present more options for patients, the high costs may create access and affordability challenges 
for patients. 
 
2.2.2 Financial toxicity among patients with cancer 
Patients undergoing cancer treatments can be burdened with high out-of-pocket costs, 
often described as “financial toxicity”.11–13 The resulting financial distress and even bankruptcy 
following cancer diagnosis14–16 has been reported to impact patient’s choice of treatment and 
adherence to therapy, 17–19 leading to poorer patient outcomes,20,21 reduced quality of life,22,23 and 
even greater costs of care in the long term.20  
Lung cancer is currently one of the top five most expensive cancers nationwide and 
accounts for the largest proportion (13%) of cancer-related expenditures in Medicare.48 For lung 
cancer patients, a 2010 report shows that the mean monthly net costs were greater than $5,000 in 
the initial phase of care, and among patients who died of lung cancer, mean monthly net costs 
were at least $7,700 in their last year of life.75 The above estimates are likely to be understated 
since the study did not consider the Medicare Part D coverage under which most orally-
administered anticancer and anti-nausea drugs are covered.24 It is estimated that approximately 
13% of the total Medicare expenditures for lung cancer care are paid directly out-of-pocket by 
patients.48 As payers pursue cost containment strategies in response to rising drug prices, it is 
likely that patients will continue to experience high out-of-pocket spending.13,81  
 
2.3 Drug Coverage under Medicare 
Original Medicare is the traditional fee-for-service program offered directly through the 
federal government. It includes Part A (inpatient hospital coverage) and Part B (outpatient 
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medical benefit) to provide health insurance coverage for individuals aged 65 years or older. 
Enrollees may additionally choose to purchase a separate Part D plan (outpatient pharmacy 
benefit) from a private insurance provider. Under the federal Medicare program, the cost of drug 
treatments can be covered through either the outpatient medical benefit (Part B) or the outpatient 
pharmacy benefit (Part D).24 The distinction is important because coverage varies between 
Medicare Part B and Part D and affects the level of expected out-of-pocket spending required for 
patients needing different types of anticancer drugs. 
 
2.3.1 Medicare Part B 
Medicare Part B, designed in the 1960s, is part of traditional fee-for-service Medicare 
(i.e., the Original Medicare) to provide outpatient medical benefits. Before implementation of 
Medicare’s Part D prescription drug benefit in 2006, Medicare Part B was the main source of 
outpatient prescription drugs coverage for beneficiaries. However, drug coverage under Part B is 
limited within narrowly defined conditions. It generally includes injectable and infused drugs 
that are not usually self-administered and that are furnished and administered as part of a 
physician service (e.g., chemotherapies, biologics, vaccines) as well as a small number of orally-
administered anticancer drugs and oral anti-emetic drugs when specific contexts apply. 
Medicare Part B is administered directly through the federal government. It applies a 
standardized coverage structure for services included in the program; common annual deductible 
and coinsurance percentages for all Medicare Part B beneficiaries with standard monthly 
premium adjusted by income or the “hold-harmless” provision. In 2017, for example, the 
standard monthly premium averages $109 for 70% of beneficiaries protected under the “hold-
harmless” provision, and $134 or higher depending on income for the remaining 30% of 
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beneficiaries. Under a standard benefit, patients with Part B also pay a deductible ($183) and/or 
coinsurance when receiving health services (usually 20% of the Medicare-approved cost for 
outpatient care).25 
 
2.3.2 Medicare Part D 
2.3.2.1 Overview of Medicare Part D  
 Before Medicare Part D went into effect, one-third of Medicare’s forty-three million 
elderly beneficiaries had no prescription drug coverage, and, according to surveys, often 
restricted their medication use because of high costs.82 Since 2006, Medicare Part D has 
expanded access to outpatient prescription drugs to seniors. Drugs not administered by 
physicians and in additional formulations, including oral and self-injectibles, are typically 
included.  
Medicare Part D is voluntary prescription drug benefit that is offered through private 
insurance plans approved by the federal government. Beneficiaries can choose to enroll in either 
stand-alone prescription drug plans (PDPs) to supplement traditional Medicare or Medicare 
Advantage prescription drug plans (MA-PDs) (mainly coordinated care plans such as Health 
Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs)) that integrate 
prescription drug coverage into all Medicare benefits under Medicare Part C. In 2017, more than 
42 million of all Medicare beneficiaries (73%) were enrolled in Part D: about 6 in 10 were in 
PDPs and the rest in MA-PD plans.74 
Drug coverage on Part D is determined by individual insurance companies and the 
designated cost-sharing requirements vary across plans. The basic benefit structure requires 
beneficiaries enrolling in Part D to be responsible for, in addition to monthly premiums and 
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annual deductible, varying cost-sharing amounts depending on the coverage phase. During the 
coverage gap patients pay a substantial proportion of drug costs; 100% patient responsibility 
before the passage of the Affordable Care Act with gradual decreases since 2011. In 2017, the 
Part D base beneficiary premium is $35.63, with adjustment by income. The Part D standard 
benefit has a $400 deductible and 25% coinsurance up to an initial coverage limit of $3,700 in 
total drug costs, followed by a coverage gap.25 Although the Affordable Care Act is closing the 
gap over time, a patient falling into the hole still has to pay 40% of their prescription costs until 
the cost reaches the catastrophic coverage threshold of $8,071 in drug costs.25 In addition, most 
PDPs (72%) will not offer additional gap coverage in 2017 beyond what is required under the 
CMS’s standard benefit. Even when additional gap coverage is offered, the benefit has been 
typically limited to generic drugs only but not brand name drugs.83 After entering the 
catastrophic coverage phase, Part D enrollees pay 5% of the price (or $3.30 for generics or $8.25 
for brand-name drugs, whichever is greater) for covered drugs for the rest of the year.25 The 
standard benefit amounts are indexed to change annually based on the growth rate of Part D per 
capita spending, and, with the exception of 2014, have increased each year since 2006.83 
 
2.3.2.2 Cost management strategies 
On top of the basic benefits, Part D payers may also adopt restrictive formulary structure 
and utilization management tools to reduce use of expensive products in the context of the steep 
upward trajectory of cancer-related expenditures. 28,30,31,84 
 
2.3.2.2.1 Formularies and drug tiering  
Formularies have become a universal tool in the management of drug benefits.31 The  
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scope of formulary coverage varies widely across plans as each plan may determine the drugs 
covered based on the CMS program guidance and the drug reference file.85 A plan’s formulary 
must be reviewed and granted approval under the condition that it meets the CMS’s 
nondiscrimination requirement. That is, the plan cannot be designed in a way that substantially 
discourages enrollment of beneficiaries with certain health conditions. One of the key rules is a 
requirement that formularies must include “all or substantially all" drugs in the six protected 
therapeutic classes, including the anti-neoplastics class.24  
Formulary structure consists of drug tier placement and cost-sharing amounts assigned to 
the tiers (through copayments or coinsurance arrangements). Typically, higher tier placement 
requires greater patient cost-sharing for the drug, which aims to provide financial incentives (i.e., 
lower cost share) to use preferred drugs over non-preferred drugs.84,86 On average, the percentage 
of covered drugs facing coinsurance has greatly increased from 35% in 2014 to 58% in 2016 
among PDPs.29 Prescription drug benefits typically include at least three tiers: Tier 1 for generic 
drugs, Tier 2 for preferred brand-name drugs, and Tier 3 for non-preferred brand-name drugs.84 
In recent years, there has been an increase in both the number of plans using tiering and the 
number of tiers offered within a formulary, including use of “specialty” drug tiers29,30,32 that 
often include high-priced treatments; those typically used for complex conditions including 
cancer.33,34 In 2016, the vast majority of Part D enrollees (98% PDP enrollees and 96% MA-PD 
enrollees) enrolled in plan with five cost-sharing tiers for their formularies including a specialty 
drug tier (i.e., tiers for preferred and non-preferred generic drugs, preferred and non-preferred 
brand drugs, and specialty drugs).30 
The growth of specialty tiering in outpatient drug formularies reflects plans’ attempts to 
contain costs. Use of drugs placed on specialty tiers typically require patients to pay a percentage 
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of the drug price (i.e., coinsurance) rather than a fixed dollar amount (i.e., copayment), which 
often leads to patients paying more out of pocket.35 In 2016, nearly all Part D enrollees are in 
plans that charge coinsurance of 25% to 33% for specialty drugs while nearly half of them (49% 
PDP and 43% MA-PD) are at the maximum 33% coinsurance rate.29,30 Although cancer drugs 
are required to be included on Part D plan formularies due to their status as a protected drugs, 
coinsurance requirements assigned to the tier can result in thousands of dollars in annual out-of-
pocket costs.36 It is worth noting that while most PDPs have been applying coinsurance to high-
cost drugs on the specialty tier, plans have extended coinsurance to drugs on lower tiers in recent 
years, including those covered on preferred and non-preferred brand tiers. 28–30 Enrollment in 
PDP plans with at least 2 coinsurance tiers has drastically grown from 39% in 2014 to 96% in 
2016.29 Given the high price of novel anticancer medications, patients obtaining these drugs 
through their Medicare Part D plans are expected to face significant out-of-pocket spending.  
 
2.3.2.2.2 Utilization management tools 
In addition to tiered cost sharing, utilization management tools may be employed to 
enforce formulary adherence or to manage drug costs for Part D payers more generally.31,87 
Briefly, these measures include prior authorization, quantity limits, and step therapy. According 
to Kaiser Family Foundation, since 2007, PDPs have applied utilization management restrictions 
to an increasing share of on-formulary drugs, from 18% in 2007 to 35% in 2014.88  Drugs in 
higher tiers or specialty drugs are regularly subject to utilization management requirements.36 
Although these interventions are effective cost-management tools for payers, they can affect 





Prior authorization is an administrative tool used by a health plan or pharmacy benefit 
manager that requires the prescriber receive pre-approval for prescribing a drug to qualify for 
that drug to be covered by the plan.89 The prescriber must justify the clinical appropriateness and 
medically necessity regarding the intended use of the drug. The process takes additional time for 
patients to obtain a covered prescription. If the request is disapproved, the prescriber could 
prescribe an alternate drug covered by the patient’s benefit, if available, or the patient may still 
have the prescription filled but by paying the entire drug cost. 
 Prior authorization has been one major approach applied by payers to direct coverage of 
high-cost or newer drugs to only those patients who demonstrate a medical need for the drug or 
are at increased risk of developing an adverse event without the drug. Literature consistently 
shows that prior authorization is significantly associated with reductions in pharmacy utilization 
and spending.31 There has been an increase in the share of covered drugs assigned prior 
authorization across PDPs, from 8% in 2007 to 21% in 2016, while application of other 
utilization management tools remains stable over time.74,88 A study, which specifically analyzes 
differences in coverage and cost sharing for cancer drugs within Medicare Part D showed that 8-
10% of cancer drugs required prior authorization in 2006.90 However, there is limited research 
evaluating the longitudinal trend in prior authorization and its use for the growing number of 
novel and high-cost drugs approved in recent years.  
 
Quantity limit 
Quantity limits may be applied to drugs based on the approved dosage allowed over a 
specified period established during the FDA approval, including drugs used in cancer 
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treatment.31 For example, plans may set limits on the number of pills per prescription or cap the 
number of prescriptions filled in a month for the covered drug. Only prescriptions within the 
quantity limit will be covered by the plan or the patient will be responsible for the full cost of the 
drugs prescribed. 
 Quantity limits have been used for both drug safety and cost containment. Through 
careful application, plans may protect their plan members from drug overuse or misuse. 
Meanwhile, it may help plans manage drug costs on specific medications without eliminating 
coverage. Over the past few years, quantity limits have been applied for more than 20% of all 
covered drugs among PDPs.74 However, there is paucity of evidence evaluating the effect of 
quantity limits on patient care.91,92 The limited evidence shows mixed results on patient 
outcomes, including reduction in the costs and utilization of disease-related services.91,92 
Moreover, quantity limits can be related to reduced use of appropriate medications93,94 and 
increased long-term care admissions (e.g., nursing home95).31,91,92 One study on Medicare Part D 
coverage and cost sharing for cancer drugs showed 3-4% of the cancer drugs covered were 
subject to quantity limits in the first year of Medicare.90  
 
Step therapy 
Step therapy protocols limit coverage to specific drugs (typically more expensive 
therapies) only when certain other, therapeutically-equivalent (often less expensive) drug 
therapies have been tried first.31 For example, a patient is required to use generics drugs before 
moving to brand-name alternatives. Step therapy is often used in conjunction with prior 
authorization for effective pharmacy benefit management by plans. 
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Step therapy is one of the most popular utilization management tools in both private and 
public sectors, and is used 1% to 3% of covered drugs among PDPs.74,88 Research demonstrates 
that step therapy can effectively encourage the utilization of first-step drugs.31,92,96 The effect of 
step therapy on healthcare utilization and costs varies by clinical area. It can provide significant 
drug savings through the greater use of lower-cost alternatives without increasing use of other 
related medical services.96 However, two studies on depression showed increases in overall and 
mental health-specific medical utilization and costs.97,98 To date, only five therapy classes, 
including antidepressants, antihypertensives, antipsychotics, nonsteroidal anti-inflammatory 
drugs (NSAIDs), and proton pump inhibitors (PPIs), have been evaluated in previous 
literature.31,92,96 The adoption of step therapy has been outpacing the understanding of its clinical, 
humanistic, and economic outcomes.96 A recent review finds that no published studies have 
specifically examined step therapy in the context of Medicare Part D and that existing evidence 
regarding its effect on medication quality in non-Part D plans remains inconclusive.96 Further 
research on step therapy is needed for numerous therapy classes where step therapy is common 
and for the Medicare Part D population. 
 
2.3.3 Cost sharing support for prescription drugs 
2.3.3.1 Supplemental insurance for Medicare Part B 
Despite the standard cost-sharing requirements under Part B, there are supplemental 
health insurance options available for beneficiaries to fully or partially pay those cost-sharing 
requirements, including deductibles, copayments, and coinsurance. According to the Kaiser 
Family Foundation, more than 80% of fee-for-service Medicare beneficiaries have some source 
of coverage that supplements Medicare, including Medigap, employer or union-sponsored retiree 
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health plans, and Medicaid for individuals with low-incomes.26,27 First-dollar coverage Medigap 
plans are popular options among these options.99,100 With first-dollar coverage, deductibles are 
waived and the plan provides extensive coverage for other Medicare out-of-pocket costs 
including 100% co-insurance and co-payments.101 By 2015, more than 70 percent of the 
Medigap policyholders had plans with no cost-sharing.99 This supplemental coverage results in 
more consistent and predictable spending for patients using Part B services throughout the year.  
 
2.3.3.2 Low-Income Subsidy (LIS) for Medicare Part D 
Compared to Part B, patients may face greater barriers to accessing drugs offered under 
Part D due to the plan’s benefit structure and the lack of out-of-pocket cost protections that are 
typically available for drugs offered under Part B. One key exception to this lack of out-of-
pocket cost protections in Medicare Part D is the Low-Income Subsidy (LIS) program.42,43  
LIS is available to Medicare beneficiaries with limited income and resources (Table 2.1). 42,43 An 
individual is deemed eligible for a full subsidy when his/her annual income is at or below 135% 
of the federal poverty level (FPL) and when their resources are at or below the annually updated 
lower limit (e.g., $7,390 for individuals in 2017).42,43 Beneficiaries are eligible for partial 
subsidies when their annual incomes are between 135-150% FPL or at or below 135% FPL with 
resource between the lower and higher limits (e.g., $7,390 to $12,320 for individuals in 
2017).42,43 In 2016, over 12 million (28.9% of Part D enrollees) beneficiaries are receiving drug 




Table 2.1 Summary of Eligibility and Cost-Sharing for Medicare Part D Benefit for Low-

















Full LIS • Full-benefit dual 
eligiblesa 
• Medicare Savings 
Programb 
• SSI recipientsc  
• Income ≤ 135% FPL 
with resources not exceed 
lower SSA limitations 
$0 $0 Copay: $3.30 generics 




• Income ≤ 135% FPL 
with resources between 
lower and higher SSA 
limitations 
• Income level between 
135-150% FPL 
25-100% $82 Coinsurance: 15% Copay: $3.30 generics 
             $8.25 brand 
Non-
LIS 






$400 Coinsurance: 25-51% 
depending on coverage 
phase 
 
Coinsurance: 5% or 
$3.30 for generics / 
$8.25 for brand-name 
drugs, whichever is 
greater 
Abbreviation: FPL, Federal Poverty Level; LIS, low-income subsidy; SSA, Social Security Administration; SSI, 
Supplemental Security Income. 
Data Source: The Centers for Medicare & Medicaid Services (CMS): Full & partial LIS: 2017 Resource and Cost-
Sharing Limits for Low-Income Subsidy;42 Non-LIS: Medicare 2017 costs at a glance. 2017.25  
a People eligible for both Medicare and full Medicaid benefits 
b Supplemental Security Income (SSI) recipients, including SSI recipients who do not qualify for Medicaid, and 
individuals deemed to be SSI recipients. 
c Medicare beneficiaries who are participants in the Medicare Saving Programs (MSP), which are Qualified 
Medicare Beneficiary Program (QMB), Specified Low-Income Medicare Beneficiary Program (SLMB), and 
Qualified Individual Program (QI). 
 
The level of cost-sharing support varies between beneficiaries with full and partial 
subsidies (Table 2.1). For a full-subsidy qualified individual, he/she is exempt from the monthly 
premium, annual deductible, and has no cost-sharing above the annual out-of-pocket threshold. 
Only a fixed copayment amounts rather than coinsurance is required for drugs that they fill 
before the out-of-pocket threshold (no more than $3.30 for each generic or $8.25 for each brand-
name covered drug). In 2017, a partial-subsidy qualified individual receives 25% to 100% 
subsidy for the monthly premium, a reduction in their deductible. This group is still responsible 
for 15% coinsurance before reaching the out-of-pocket threshold; however, they pay no more 
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than $3.30 for each generic or $8.25 for each brand-name covered drug after the annual out-of-
pocket threshold is met. Neither group is subject to the coverage gap where non-LIS 
beneficiaries are responsible for substantial proportion of the drug cost (100% before 2011) in 
addition to the cost sharing required for other coverage phases.  
The coverage gap in Part D design has been a major concern for Medicare beneficiaries, 
particularly for seniors with multiple health conditions or those who need multiple medications 
for certain disease.102  Research has shown that reaching the coverage gap decreases medication 
adherence for essential drugs, and increases drug discontinuation in many chronic illnesses, 
including diabetes, cardiovascular diseases, and depression, 103–108 particularly among patients 
taking brand-name drugs.106,109,110 Given these effects, patients might even have higher risk of 
poor health outcomes in the long-term, such as hospitalizations and medical spending.111,112 
Compared to those with supplemental coverage after reaching the coverage gap, those lacking of 
financial assistance are more likely to experience higher out-of-pocket spending105,113, worse 
adherence105,106, as well as a doubling in discontinuing essential medications but not switching 
drugs111.  
Through coverage gap elimination and additional subsidies, LIS provides valuable 
assistance with patients’ drug expenses. On average, out-of-pocket cost may account for 36-40% 
of total drug spending for a beneficiary without LIS and only 2-5% for those with LIS.109 For 
Part D drugs specifically, the associated out-of-pocket cost of a pill could be more than a 
hundred times difference 44 ; the average annual out-of-pocket spending could be more than 20 
times difference among high-cost enrollees.74 In the context of anticancer therapies, this could 




2.3.4 Cost sharing support for access to cancer care 
Novel cancer drugs are usually unique and under patent protection with no cheaper 
generic substitutes or therapeutically equivalent options available. For beneficiaries without cost-
sharing subsidies, costs for initiating a novel targeted therapy on Part D can be substantial.114 For 
example, a targeted therapy for advanced NSCLC, crizotinib, is priced at $14,364.38 for a 30-
day supply on a Part D plan in 2017.115 The expected out-of-pocket cost to a Medicare 
beneficiary filling the first single month of drug therapy would be almost $3,000.115 However, 
for those with full subsidy support, the cost would be only $8.25 for the month of the treatment. 
With cancer regimens increasingly consisting of multiple drugs (either sequential or combination 
therapies), the cost problem is expected to be exacerbated in the near future.10 This is particularly 
important for those in need of treatment but without appropriate resources to access the care. 
It has been reported that cancer survivors are delaying or avoiding necessary care due to 
costs, including cost-related nonadherence109,116–118 and treatment delays or discontinuation119. 
However, few studies consider LIS as a factor influencing treatment utilization in the cancer 
setting. One study on tyrosine kinase inhibitors (TKIs) among Medicare beneficiaries with 
chronic myeloid leukemia (CML) found that no having LIS was associated with reduced or 
delayed initiation of TKIs.114 The other study on a similar population examined the factors 
associated with TKI initiation and adherence in CML. They found that cost-sharing subsidies, 
younger age, lower comorbidity, and later year of diagnosis were significantly associated with 
TKI initiation.47 None of the above studies consider the difference in subsidy level by LIS status 
(i.e., partial vs. full subsidy).  
Further research is warranted for other cancers where affordability of and patient access 
to care are major issues in the care.34,37–41 Lung cancer, a cancer with many novel high-cost 
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treatments or specialty drugs approved in the past decade for the significant unmet patient needs, 
is an area that needs in-depth exploration. 
 
2.4 Conceptual Framework 
The Andersen’s Behavioral Model of Health Services Use forms the basis for the 
consideration of appropriate variables for this study.120 The model contains three main 
components: external environment, population characteristics, and health behavior. Together, it 
posits that the use of healthcare services is a function of a set of dynamic population 
characteristics in the context of the healthcare environment. Specifically, these characteristics are 
divided in to three groups: 
 
Figure 2.1 Conceptual Framework 
 
 
1) Predisposing factors, suggesting patient predisposition to use services; these factors could 
be demographics (e.g., age, gender), genetic factors, and health beliefs. 
2) Enabling factors, suggesting the resources that enable persons to act on their 
predispositions (e.g., socioeconomic status, financial assistance). 
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3) Need factors, representing both perceived and actual need for health care services patient 
need for care (e.g., cancer-related characteristics, comorbid conditions). 
The proposed conceptual framework for our study, as depicted in Figure 2.1, is an 
adaptation based on the Andersen’s Behavioral Model of Health Services Use. 
 
2.4.1 Predisposing factors 
Predisposing characteristics of the proposed framework include the demographic factors 
of age, sex, and marital status along with the social determinants of race and education level. 
Older age has been consistently shown to be associated with lower use of treatment in the 
advanced NSCLC setting.121–125 Female patients are found to be more likely to receive biomarker 
testing as well as timely and appropriate treatment.121,126–129 Although women appear to have 
higher risk of adverse effect from treatments130–133, they tend to have improved survival 
compared with men.126,134–137 Marital status suggests the presence of social support for a 
patient.138,139 A recent meta-analysis suggests that, among a cancer population, marital status 
would have effects on health behaviors (e.g., treatment-seeking, treatment compliance), access to 
the health care systems and assistance with navigating its complexities, the likelihood of 
receiving vigorous and aggressive, active cancer treatment.139 All of these could have either 
direct or indirect effect on treatment uptake and survival. These observations have also been 
supported by several studies in lung cancer populations in the literature; married patients are 
more likely to receive treatment, including surgery, radiation, and systemic therapy, and have 
better prognosis than unmarried patients.121,140–144  
A growing base of evidence has demonstrated disparities by race/ethnicity with respect to 
receipt of appropriate care in NSCLC population.121,127,145–156 Minority groups experienced 
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inequalities throughout all areas of the cancer spectrum, spanning screening, diagnosis, and 
treatment, as well as survivorship and end-of-life care. Another social determinant, education 
level, has also been associated in patients with lung cancer with greater care intensity (e.g., 
diagnostic procedures and multidisciplinary care) and longer survival experienced among 
patients with high education as compared to low education.157–160 Because socioeconomic data 
are not collected at the individual level within the SEER-Medicare database, we measure 
education at the census tract level to serve as a proxy measure of education at the individual 
level. 
Genetic susceptibility could potentially influence need and response to treatment for 
NSCLC.51,161 However, information on genetic mutations and test results are not regularly 
collected in population-level registry-linked claim databases to date. In addition, health beliefs, 
consisting of patient personal attitudes, values, and knowledge related to health and health 
services, may affect the perception of whether they need health services or not but this 
information cannot be obtained within the SEER-Medicare databases. 
 
2.4.2 Enabling factors 
Enabling characteristics of the proposed framework include socioeconomic status (e.g., 
income), area of residence at diagnosis (e.g., state/region, urban residence), financial assistance 
(e.g., low-income subsidy, supplemental insurance options), financial navigation, and time at 
diagnosis (e.g., year of diagnosis, diagnosed month). Disparity by socioeconomic status, 
including income and poverty level, in cancer outcomes has been well documented, suggesting 
that potential association between lower socioeconomic status and poorer access to treatment as 
well as greater risk of mortality.121,159,160,162 Given that the SEER-Medicare program does not 
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collect individual measures of socioeconomic status for patients, census tract level median 
household income and poverty information are used as proxy measures for individual level data. 
Area of residence may play a role in treatment access as local policy could be influential to 
availability of financial assistance, insurance plan design, as well as pharmaceutical prescribing 
or treatment modality across geographic regions.83,163–166 Furthermore, individuals residing in 
rural areas may be more likely to live in poorer areas with a limited supply of health care 
providers. 163,164 
Low-income subsidy and supplemental insurance are resource to alleviate patient out-of-
pocket burden for prescription drugs and thus improve affordability of care. Without the 
financial assistance, significant out-of-pocket costs would be incurred following a diagnosis of 
cancer.40,167,168 High out-of-pocket cost have been shown association with suboptimal utilization 
of essential treatments in cancer care, including decreasing adherence17,34,169, 
persistence/discontinuation17,34,119, delay initiation34,114,119,170, and treatment abandonment34,170. 
High out-of-pocket costs for patients who do not receive a low-income subsidy could be related 
to treatment delay and discontinuation.114,119 These observations are especially true for expensive 
orally-administered cancer drugs covered under Medicare Part D.  
Although Part B supplemental insurance information is not directly measured in 
Medicare data, we expected there to be a limited effect of supplemental Part B coverage at the 
population level as most of fee-for-service Medicare beneficiaries have some source of 
supplemental coverage.171 
Financial navigation is a financial counseling program that educates patients about their 
financial responsibility, optimizes patient coverage, and maximizes external cost-sharing 
assistance in oncology setting.172,173 The ultimate goals of financial navigation are to address 
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access barriers to health services, decrease the financial burden of cancer care and thus to reduce 
delays in delivering timely care and poor health outcomes for cancer patients.172,173 However, the 
service is usually provided for patients receiving care at hospitals or cancer centers. While 
financial navigation cannot be directly measured in the Medicare data, we can explore the use of 
proxies for access to financial navigation services by including a measure of whether a patient 
was treated at an NCI-designated comprehensive cancer center.  
Finally, time of diagnosis is expected to affect treatment utilization in two ways. First, 
year of diagnosis is associated with greater variety and availability of treatments for patients as 
more treatments are approved and diffuse into clinical practice over time.174–176 Second, patients 
needing an expensive therapy may decide to delay treatment initiation if diagnosed late in the 
benefit year to avoid facing very high out-of-pocket costs in back-to-back fills when the benefit 
year resets.1099,40 
 
2.4.3 Need factors 
Need factors of the proposed framework include perceived needs and evaluated needs 
(e.g., tumor stage, comorbidity). Perceived need for health care services is how people view and 
experience their own general health, functional state and illness/symptoms. Patient perceptions 
about the importance and magnitude of a health problem would lead to a decision to seek 
medical care or not. In other words, people tend to take action to manage illness if they (a) 
believe that they are susceptible to that illness, especially if they view the illness as potentially 
having serious consequences to them; (b) believe that by following a recommended health action 
(e.g., treatment initiation), they would reduce their susceptibility to or the severity of the illness; 
(c) believe that the benefits of taking the recommended action outweigh the perceived barriers or 
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costs for doing; (d) are aware of the illness and have information or resource regarding the 
approaches to manage the illness; and (e) are confident of their ability to manage the illness.177 
Overall, perceived need can be determined health beliefs.178–183 The information on perceived 
need is not available in the SEER-Medicare databases.  
Nevertheless, we are able to estimate evaluated need. Evaluated need represents 
professional assessments and objective measurements of patients’ health status and need for 
medical care. This more measurable and unprejudiced need include in our proposed framework 
include tumor status (e.g., stage, grade, histology), other comorbid conditions, and medical 
procedures performed besides pharmaceutical treatments (e.g., receipt of radiation). Patient 
tumor and comorbid characteristics may significantly influence the need for and expected benefit 
from treatment.51,184,185 As a result, they would affect the treatment modalities recommended and 
received as well as the timing of treatment uptake among patients with NSCLC. 
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CHAPTER THREE: RESEARCH METHODS 
 
3.1 AIM 1 – Examine changes in drug-specific price, formulary structure, and the use of 
utilization management tools for Part D medications approved for advanced NSCLC from 
2009 to 2017. 
 
3.1.1 Data Source 
The Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files 
from the Centers for Medicare & Medicaid Services (CMS) contain formulary, pharmacy 
network, and pricing data for Stand-alone Medicare Prescription Drug Plans (PDPs) and 
Medicare Advantage Prescription Drug Plans (MA-PDs). These public use files are comprised of 
non-identifiable data tables, including Plan Information, Geographic Locator, Formulary, 
Beneficiary Cost, Pharmacy Network, and Drug Pricing. The Plan Information file contains 
contract ID, plan ID, and segment ID, which together allow data linkage across tables to retrieve 
detailed plan-level (or formulary-level) data, including plan service area, plan type, plan benefit 
design, plan pharmacy networks, National Drug Codes (NDCs), cost share tier level, indicators 
for utilization management, and cost-sharing arrangement for drugs. The data are available in 
quarterly files, which are first available in quarter 1, 2009. Therefore, we are able to use the 
dataset to identify coverage for a specific drug on each of the available plans/formularies as well 
as changes in coverage over time. 
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For this aim, we used the first quarter of data for each year from 2010 to 2017 to evaluate 
the change in drug price and coverage for Part D advanced NSCLC drugs during 2010 to 2017 
(number of years studied for each drug depended on its year of FDA approval); the most updated 
quarter data available (Q12017 as of 06/2017) was also used for an overall evaluation across all 
advanced NSCLC drugs available by that time. Figure 3.1 summarizes the design for both the 
horizontal comparison (same product across time) and vertical comparison (same time point 
across products). We used plan/formulary as the unit of analysis to understand the coverage 
provided for each advanced NSCLC drug across all Medicare Part D plans in the United States. 
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To provide a more comprehensive assessment of drug affordability, we also presented 
information on Part B drug pricing for products available in 2017 using the Average Sales Price 
(ASP) data provided by CMS. 
 
3.1.2 Study Design 
3.1.2.1 Sample selection 
The sample consisted of health plans which provide prescription drug coverage, including 
Stand-alone Medicare Part D prescription drug plans (PDPs) and Medicare Advantage 
Prescription Drug Plan (MA-PDs) during 2010 to 2017; plans available during the first quarter of 
each year from 2010 to 2017 for across time examination and during the first quarter of 2017 
(most updated data as of June 2017) for a most up-to-date comparison across product.  Each 
plan/formulary serves as the unit of analysis for the examination. Please note that if a plan 
sponsor (e.g., United Healthcare) provides a national plan and a state plan, it would be counted 
as two plan/formularies.  
We identified Part D plan/formularies’ coverage design and formulary structure for Part D 
anti-cancer medications with FDA approved indications for treating advanced NSCLC as of June 
2017 (Table 3.1). Plans were excluded if the information on state or plan/formulary structural 
features is unknown. We also excluded Special Needs Plans, which accounted for 10% of the 
Part D plans, since they target subgroups of beneficiaries (e.g., institutionalized individuals) and 
may have specialized formularies.186,187 Figure 3.2 summarizes the inclusion and exclusion 




Figure 3.2 Flow Diagram of Study Plan Selection for Aim 1  
 
a if a plan sponsor (e.g., United Healthcare) provides a national plan and a state plan, it would be counted as two 
plan/formularies. 
 
3.1.2.2 Drugs of Interest 
Table 3.1 Advanced Non-Small Cell Lung Cancer Drugs covered under Part D and 
approved by U.S. FDA by June 2017a  
Aim Drug Name Brand Name 

















Gefitinib Iressa  2003 Targeted therapy – EGFR Tyrosine kinase inhibitor   
   Erlotinib  Tarceva  2004 Targeted therapy – EGFR Tyrosine kinase inhibitor 
   Crizotinib Xalkori  2011 Targeted therapy – ALK Tyrosine kinase inhibitor 
   Afatinib  Gilotrif  2013 Targeted therapy - EGFR Tyrosine kinase inhibitor 
   Ceritinib  Zykadia  2014 Targeted therapy – ALK Tyrosine kinase inhibitor 
   Alectinib  Alecensa 2015 Targeted therapy – ALK Tyrosine kinase inhibitor 
   osimertinib Tagrisso 2015 
Targeted therapy – EGFR T790M Tyrosine kinase 
inhibitor 
 
a See Appendix Table 3.1 for more detailed drug information of the Part D drugs of interest; see Appendix Table 
3.3 for the NDC codes used for identifying each drug of interest. 
Abbreviation: ALK: Anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; mTOR: mammalian 






Table 3.2 Advanced Non-Small Cell Lung Cancer Drugs covered under Part B and 
approved by U.S. FDA by June 2017a  
Aim Drug Name 
Brand 
Name 

















Cisplatin Platinol  
1994b 
Traditional Chemo – Platinum-based agent 







Traditional Chemo – DNA topoisomerase inhibitor 
   Carboplatin Paraplatin   1999c Traditional Chemo – Platinum-based agent 





Traditional Chemo – Taxane 
   Vinorelbine Navelbine  1994 Traditional Chemo – Vinca alkaloid and analog 
   Docetaxel Taxotere  1999 Traditional Chemo – Taxane 
   Gemcitabine Gemzar  1996 Traditional Chemo – Pyrimidine analog 
   Pemetrexed Alimta  2008 
Traditional Chemo – Folate analog metabolic inhibitor 
(i.e., antifolate) 
   Bevacizumab  Avastin  2006 Targeted therapy – Monoclonal antibody on VEGF 
   Ramucirumab Cyramza  2014 Targeted therapy – Monoclonal antibody on VEGF 
   Nivolumab  Opdivo  2015 Targeted therapy/immunotherapy – PD-1 Inhibitor 
   
Pembrolizuma
b   
Keytruda  2015 Targeted therapy/immunotherapy – PD-1 Inhibitor 
   Necitumumab Portrazza 2015 Targeted therapy– monoclonal antibody on EGFR 
 
a See Appendix Table 3.2 for more detailed drug information of the Part B drugs of interest; see Appendix Table 
3.4 for the HCPCS codes used for identifying each drug of interest. 
b Indication for NSCLC is not specified in the cisplatin’s labeling. However, within the approval of vinorelbine in 
1994, cisplatin was used as combination treatment for advanced NSCLC. 
c Indication for NSCLC is not specified in the etoposide’s labeling. However, etoposide has long been recommended 
in combination use with platinum-based agent by the NCCN Guidelines. 
d Indication for NSCLC is not specified in the carboplatin’s labeling. However, within the approval of decetaxel in 
1999, carboplatin was used as combination treatment for advanced NSCLC. 
Abbreviation: EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; PD-1: programmed 
cell death protein 1; PD-L1: programmed death-ligand 1; VEGF: Vascular endothelial growth factor. 
 
Drugs of interests were Part D anti-cancer medications with FDA approved indications 
for treating advanced NSCLC as of June 2017 (Table 3.1). Drugs were excluded from the 
analysis if the drug was not yet available (e.g., brigatinib) at the time of data release. 
Advanced NSCLC drugs covered under Part B were additionally considered in the 
examination of prices (Table 3.2) in order to complement the overview regarding the pricing of 




Please note that for all the analysis in this aim, since we used data from the first quarter 
of each year, drugs approved later in the calendar year would be included in estimates from the 
next calendar year. 
 
3.1.2.3 Outcome Measurement 
Drug Price  
Drug prices for Part D drugs were retrieved from the Pricing file; representing the plan 
level average cost of a drug for specified days supply at in-area retail pharmacies. The price for a 
30-day supply of the most commonly covered dose of each drug was identified. Median costs 
were then calculated among plans with corresponding ranges (minimum and maximum) 
reported.  
In the examination of drug prices, we additionally presented the prices of advanced 
NSCLC drugs covered under Part B (Table 3.2). This additional examination aimed to 
complement the overview regarding the pricing of all drug treatments available, despite of 
coverage source, over the past decade. For that, we excluded Part B drugs that were removed 
from the NCCN Clinical Practice Guidelines™ Non-Small Cell Lung Cancer 9th version 2017 
(e.g., vinblastine, mitomycin, ifosfamide) for its rare use in clinical practice or those with no 
recommended regimen specified in the Guideline (e.g., irinotecan). Drugs that had no specific J 
code effective (e.g., atezolizumab) at the time of data release were also not considered for this 
examination.   
Drug prices for Part B drugs available in 2017 (approved as of June 2017, Table 3.2) 
were obtained from the average sales price (ASP) data provided by CMS. Estimation of monthly 
price was based on previously published methodology.9 Because infused drugs are often billed 
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per unit based on patient size, we calculated the price for a 12-week dosing regimen for an 
average adult who weighs 70 kg or has a body-surface area of 1.7 m2. This value was then 
divided by 2.77 (to obtain a 1-month price) and further multiplied by 106% (to reflect the 
standard reimbursement from Medicare Part B for physician-administered drugs of ASP+6%).9 
This estimated price would reflect the total price of the Part B drug in 2017, including the 
amount from Medicare reimbursement and the amount paid by the patient or by a third-party 
payer. The lowest total dosing regimen9 for advanced NSCLC recommended by the NCCN 
Guideline was used for the calculation for each drug. Median monthly prices were reported for 
individual drugs. 
We measured overall changes in price paid by Medicare for each product covered during 
2010 to 2017. For the longitudinal evaluations, prices were inflated to 2017 based on the 
Consumer Price Index (CPI)188 for prescription drugs.  
 
Coverage Design and Formulary Structure 
Medicare Part D formulary structures provide a view of how individual drugs are covered 
under each available health plan, utilization management tools in place to restrict treatment 
access, and the extent of cost sharing required by patients needing the drug of interest. We 
evaluated three structural plan/formulary features applied to each included Part D drug product 
by each Medicare Part D plan available during the study period: formulary drug tier, patient cost-
sharing arrangement (i.e., use of copayments versus co-insurance), and the application of 
utilization management tools (including prior authorization (i.e., the plan must grant permission 
before a particular drug can be prescribed and qualified for coverage), quantity limit (i.e., 
restriction on the amount of drugs a plan will cover over a certain period of time), and step 
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therapy (i.e., use less expensive drug options before “stepping up” to treatments that cost 
more)).. To understand how benefits coverage has changed over time, we measured overall 
changes in the benefit design and formulary structure for each product covered during 2010 to 
2017. Two types of prescription drug plans, PDPs and MA-PDs, were treated separately. For 
drugs approved on or before 12/31/2009 we assessed changes for each year from 2010 to 2017; 
for drugs approved after 12/31/2009 we assessed changes from the year of FDA approval to 
2017. An evaluation encompassing all available drugs was performed in the most recent quarter-
year (i.e., Q12017).  
 We first reported the proportion of plan/formularies covering individual drugs of interest 
in each year as well as the proportion of plan/formularies covering at least one medication from 
each therapeutic class in each year. 
For understanding formulary tier placement for each Part D anticancer drug available in 
each year, we used the Beneficiary Cost File to identify the product’s tier placement in each 
Medicare Part D formulary, the total number of tiers designed in the associated plan, and whether 
the designated tier of the drug is a specialty tier. We calculated the percentage of plan/formularies 
placing the drug on the top tier and the percentage of plans placing the drug on the specialty tier.  
 Next, cost-sharing arrangements were defined based on three features of the benefit 
design, including the type of cost sharing designated for the tier, the associated coverage phase, 
and type of dispensing pharmacy. The three components were provided by the Beneficiary Cost 
File. There were two types of cost-sharing approaches: copayment or coinsurance; three 
coverage phases: initial coverage, coverage gap, and catastrophic phases; three types of 
pharmacies: preferred, non-preferred, and mail order. For this study, we focused on cost-sharing 
requirement for preferred pharmacy. That is, the type of cost sharing designated for the tier of the 
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drug at preferred pharmacies during the associated coverage phases. We reported the proportion 
of plans applying copayments (a flat fee per fill) versus coinsurance (a percentage of the drug 
price) as well as the median cost-sharing amount (absolute dollars if copay was used; percentage 
if co-insurance was used). 
 Application of utilization management tools was determined by whether the drug was 
subject to quantity limit, prior authorization, and step therapy. Information is available in the 
Basic Drugs Formulary File, Excluded Drugs Formulary File, or Beneficiary Cost File. We 
measured the percentage of plan/formularies requiring each of the three tools for a specific drug.  
All the abovementioned measurements for plan/formulary features were reported in a 
drug-specific and annual fashion. 
 
Expected Patient Out-of-Pocket Cost 
To understand the actual financial burden on patient for starting a Part D treatment, 
particularly those without subsidy support,we also identified corresponding amounts of patient 
cost-sharing for the initial month of drug use during a calendar year for a non-LIS patient 
enrolled in a standard Part D plan in 2017 for . We calculated the median out-of-pocket costs for 
a 30-day supply with the assumption that the patient did not have any other Part D costs prior to 
this initial fill of advanced NSCLC treatment.  
 
3.1.2.4 Analysis   
Descriptive statistics were used to characterize the changes in drug price, formulary 





Table 3.3 Summary of Unit of Analysis, Covariates, and Outcomes for Aim 1  
 Type Definition Source File 
Unit of analysis    
Plan/formulary Unique ID A unique ID assigned to each 
plan/formulary 
Formulary Files 
Time    
Year Categorical 2007, 2008, 2009, 2010, 2011, 
2012, 2013, 2014 
Basic Drugs Formulary 
File 
Outcomes    
Median advanced NSCLC 
drug price 
Continuous  Median price with interquartile 
range for a 30-day supply of the 
most commonly covered dose 
of each advanced NSCLC drug 
(in 2017 dollar). 
Pricing File, ASP File 
Top tier placement  Binary  Whether the formulary tier 
associated with the advanced 
NSCLC drug is the top tier 
within the plan (Yes; No) 
Beneficiary Cost File 
Application of specialty 
tier  
Binary Whether the designated tier of 
the advanced NSCLC drug is a 
specialty tier (Yes; No)  
Beneficiary Cost File 
Cost-sharing arrangement Categorical Use of copayment or co-
insurance at different coverage 
phase for the advanced NSCLC 
drug  
Beneficiary Cost File 
Application of utilization 
management tools 
Binary 1) Whether the drug was 
subject to quantity limit 
(Yes; No) 
2) Whether the drug was 
subject to prior 
authorization (Yes; No) 
3) Whether the drug was 
subject to step therapy 
(Yes; No) 
Basic Drugs Formulary 
File, Excluded Drugs 
Formulary File, 
Beneficiary Cost File. 
Median drug cost in the 
initial month of use 
Continuous Median patient OOP on an 
advanced NSCLC drug cost in 
the first month of use within a 
calendar year 
Beneficiary Cost File, 
Pricing file 





3.2 AIM 2 – Examine trends in the utilization of advanced NSCLC medications by coverage 
source (i.e., Medicare Part B or Part D). In addition, to identify clinical, sociodemographic, 
and health system factors associated with the use of Part D treatments among patients 
diagnosed with advanced NSCLC from 2007 to 2014. 
 
3.2.1 Data Source  
 The SEER–Medicare database represents a linkage of two population-based data sources 
– the SEER cancer registry and fee-for-service Medicare claims data – that provides detailed 
health information about Medicare beneficiaries with cancer. Since 1973, the SEER program of 
the National Cancer Institute has been collecting data from 18 population-based cancer registries 
of all incident cancer cases in diverse geographic areas, which covers approximately 30 % of the 
US population. It is a primary source of nationally representative data on cancer incidence and 
survival in the U.S., and contains information on patient demographics, tumor characteristics, 
and first course of treatment.  
 Medicare is the federal funded health insurance program for older people aged 65 or 
older, individuals with disabilities, as well as those with end-stage renal disease. In particular, it 
is the primary insurer for 97% of the older population in the U.S. Medicare program and 
provides 4 parts of coverage for specific services: Part A for inpatient hospital services; Part B 
for supplemental medical services provided mostly on outpatient basis (Part A and Part B 
together are known as the traditional fee-for-service Medicare); Part C (also known as Medicare 
Advantage), a managed care options for additional services excluded from Parts A and B; Part D, 
implemented since 2006, for prescription drug benefit. According to Kaiser Family Foundation, 
around 70% of the Medicare enrollees were in traditional fee-for-service Medicare and the rest in 
Medicare Advantage. For the project, we focused on traditional fee-for-service Medicare as the 
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claims databases provide comprehensive longitudinal information on inpatient, outpatient as well 
as pharmacy services used by individuals enrolled in fee-for-service Medicare Parts A, B and D. 
 The SEER-Medicare linked databases includes the Patient Entitlement and Diagnosis 
Summary File (PEDSF), which contains basic patient demographics, cancer-related 
characteristics, Medicare entitlement and enrollment, and health service utilization. In addition, 
census tract and zip code-level census data including socioeconomic information from the 1990 
and 2000 Censuses and the 2008 – 2012 American Community Survey are included.  
 The fee-for-service Medicare files includes Part A inpatient service (MEDPAR, Medicare 
Provider Analysis and Review), Part B institutional outpatient services (Outpatient Claims), Part 
B non-institutional outpatient services (NCH, National Claims History), home health services 
(HHA, Home Health Agency), hospice care, and durable medical equipment services (DME, 
Durable Medical Equipment). Prescription drug coverage and utilization through Medicare Part 
D is also available (PDE, Prescription Drug Event file) since 2007.  
 The population-based linked database serves as the foundation for epidemiological and 
health services research in cancer populations. Currently, the linkage is updated biennially 
through the concerted efforts among the National Cancer Institute, the SEER registries, and the 
Centers for Medicare and Medicaid Services (CMS). As of the most recent update in 2016, the 
data include all Medicare eligible persons appearing in the SEER data who were diagnosed with 
cancer through December 31, 2013, and their Medicare claims through December 31, 2014. 
 
3.2.2 Study Design 
3.2.2.1 Cohort Selection  
The study population consisted of a retrospective cohort of patients aged 65 or older and 
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diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC), stages 
IIIB/IV (based on American Joint Committee on Cancer Stage Group (AJCC), 6th edition 
staging) between July 1, 2007, and December 31, 2013. We refined the cohort to include only 
patients with NSCLC as their first or only primary cancer during the study period. We excluded 
patients whose Medicare eligibility was based on end-stage renal disease (ESRD) or disability as 
these patients likely have different health-care related needs than patients qualifying for 
Medicare due to age. To minimize misclassification of outcomes, we required patients to have 
continuous enrollment in 1) Medicare Parts A and B for 6 months prior to NSCLC diagnosis and 
2) Medicare Parts A, B, and D from the month of NSCLC diagnosis through death, 
disenrollment, 12 months since diagnosis, or the end of data (December 31, 2014), whichever 
occurred first. Patients enrolled in Medicare Advantage plan (health maintenance organization) 
for the same period were excluded since their claims are not available in the SEER-Medicare 
database. In addition, we excluded patients who had missing information regarding diagnosis or 
inconsistent death records between SEER and Medicare, whose diagnosis were made by death 
certificate or autopsy, or who died within 30 days after diagnosis. We further excluded patients 
enrolled in hospice before or at the time of diagnosis because patients in hospice care are 
certified by their doctor as being terminally ill and would no longer receive curative treatment 





Figure 3.3 Flow Diagram of Study Population Selection for Aim 2 
 
Abbreviation: NSCLC, non-small cell lung cancer; ESRD, end-stage renal disease 
 
The study design includes a six-month period prior to the diagnosis of NSCLC to 
measure the baseline patient characteristics (see 3.2.2.3 for the covariates considered). We 
followed patient from the diagnosis until death, disenrollment, the 12th month since diagnosis, or 
the end of data (December 31, 2014), whichever occurred first. This post-diagnosis period was 





Figure 3.4 Study Design for Aim 2  
 
 
3.2.2.2 Outcome Measurement 
Utilization of anticancer therapies reflects both the clinical practice of oncology as well 
as patient access to care. In this aim we examined changes in both Part D and Part B covered 
anticancer medication use over time for patients with NCSLC. Drugs of interest included those 
with United States FDA approvals for advanced NSCLC by the end of 2014 (Table 3.1 and 
Table 3.2). The primary outcome of interest was whether a patient ever filled an anti-cancer drug 
on Medicare Part D from diagnosis through the end of follow-up, up to one-year post diagnosis. 
The use of studied drugs was identified between 2007 and 2014 while the annual utilization rates 
were presented based on patients’ year of advanced diagnosis (i.e., 2007-2013). The rate was 
calculated as the number of advanced NSCLC patients on a specific drug divided by total 
number of advanced NSCLC patients during a year. In addition to examination of each specific 
drug, we also assess the overall utilization of Part B and Part D drugs, respectively.  
In addition, we explored the effect of clinical, sociodemographic, and health system 
factors on the use of Part D drugs among patients diagnosed with advanced NSCLC from 2007 
to 2014. The use studied was “ever use a Part D anti-cancer drug within 12 months since the 
diagnosis of NSCLC.” That is, a patient would be counted a Part D drug user if he/she had ever 
used a Part D anti-cancer drug for advanced NSCLC from diagnosis through end of follow-up. 
Detailed information on the covariates included please see section 3.2.2.3. Table 3.4 
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summarized the outcome for Aim 2. 
Table 3.4 Summary of Outcomes for Aim 2 
Variable  Type Definition Source File 
Outcomes    
Annual rates of people on 
specific drug(s) 
Dichotomous Number of advanced NSCLC 
patients on a specific drug 
divided by total number of 
advanced NSCLC patients 
during a year. 
PDE 
Ever use a Part D anti-
cancer drug within 12 
months of diagnosis 
Dichotomous A patient was counted as an 
ever user of Part D drug if 
he/she had ever used a Part D 
anti-cancer drug for advanced 
NSCLC from the diagnosis 
through end of follow-up. 
PDE 
Abbreviation: PDD, Prescription Drug Event file. 
 
3.2.2.3 Covariates 
The six-month period prior to the diagnosis of NSCLC (Figure 3.3) was used to measure 
the baseline characteristics of the study population (Table 3.5), including: 
❖ Demographic characteristics 
 Age: Age was calculated as difference between the month and year of birth and the 
month and year of diagnosis in the PEDSF file. It was further measured in both 
continuous and categorical approaches. For continuous measurement, we calculated 
mean and standard deviation. For categorical measurement, we classified patients into 
3 age groups: 65-69, 70-74, 75-79, 80 and older.  
 Sex: Sex is a categorical variable based on the information provided in the PEDSF file; 
1 as ‘male’ and 2 as ‘female’. 
 Race/ethnicity: Race and Hispanic ethnicity information was combined using the 
SEER variable and was further categorized into Non-Hispanic White, Non-Hispanic 
Black, Hispanic, and Others based on the established algorithm. 
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 Marital status: Marital status at diagnosis was divided into following groups: Single 
(including those in separated, divorced, widowed, or unmarried status, and those 
having domestic partner (same sex or opposite sex or unregistered)), Married 
(including common law), Unknown. 
❖ Institution affiliation***: Institution affiliation was provided in the SEER-Medicare Provider 
file, including affiliation with the Eastern Cooperative Oncology Group (ECOG), NCI cancer 
center designation, teaching hospital designation, and level of affiliation with a medical 
school. The provider file can be linked to MEDPAR and Outpatient files. Therefore, we used 
the linkage to identify patients receiving care (i.e., any chemotherapy/radiation) for their 
advanced NSCLC in the aforementioned institutions during follow-up period defined above. 
Indicator variables were created for each type of institution affiliation for every patient. 
❖ Geographic characteristic 
 SEER registry region: SEER registries were grouped into 5 regions based on the state 
and region where a patient was diagnosed in PEDSF. There are Northeast 
(Connecticut, New Jersey), South (Kentucky, Louisiana, Atlanta, Rural Georgia, 
Greater Georgia), North Central (Iowa, Detroit), West (Hawaii, New Mexico, Utah, 
San Francisco, San Jose, Los Angeles, Greater California, Seattle), and 
Other/Unknown. 
 Urban residence: The coding definition provided in PEDSF, Rural/Urban Continuum 
Codes, is based on the classification scheme developed by Economic Research Service 
of the Department of Agriculture. The classification considers population size, degree 
of urbanization, and adjacency to a metro area. We applied this definition to classify 
patients into 6 groups: Big metro (Counties of metropolitan areas of 1 million 
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population or more), Metro (counties in metropolitan areas of less than 1 million 
population), Urban (non-metropolitan counties with urban population of 20,000 or 
more), Less Urban (non-metropolitan counties with urban population of 2,500-19,999), 
Rural (non-metropolitan counties which are completely rural or with less than 2,500 
urban population), and Unknown. 
❖ Socioeconomic characteristics: In SEER-Medicare linked data, there is no individual-level 
information available for socioeconomic variables such as household income and education. 
Thus, the related information used in the analysis will be based on aggregate measures from 
the US Census Bureau as a basis for inference about individuals. The information can be 
obtained from the Census Tract and Zip Code files. For this study, census tract-based data is 
preferred over the zip code-based ones. This is because the former covers relatively 
homogeneous units with respect to population characteristics, provides richer and more 
reliable geographically-based socioeconomic data, and provides static geography information 
from census to census. Data collected from the American Community Survey (ACS) in the 
Census Tract file was used to create census-tract-based socioeconomic characteristics for the 
study population.  
 Education: Education attainment at the census tract level in the Census Tract File was 
measured as the percentage of persons aged 25 and older with less than high school 
degree within the same census tract as the patient. We used this variable and further 
divide our population into four groups: <5%, 5%–<10%, 10%–<20%, and ≥20% of the 
residents without high school degrees. 
 Income: Median household income measured at the census tract level in the Census 
Tract File was used to represent the median income for all individuals in the same 
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census tract as the patient. We further divided the study population into four groups 
based on the quartile values of this income variable. 
 Census Tract Poverty Indicator: According to census-tract poverty level, the percentage 
of residents in a census-tract below the official poverty threshold, census-tract poverty 
was grouped into four categories: <5%, 5%–<10%, 10%–<20%, and ≥20% under the 
variable of Census Tract Poverty Indicator in the PEDSF file. We used this variable as 
one of the measure of area-based socioeconomic status 
❖ Low-income subsidy status (Also see section 3.3.2.3 for more details): Whether an 
individual had received LIS will be based on the combined consideration of two variables in 
the Part D enrollment file: Cost Share Group (i.e., monthly indicators for beneficiary’s LIS 
status) and State Reported Dual Eligible Status Code (i.e., monthly indicators for the dual 
Medicaid eligibility status, if any, for the beneficiary). Patients were defined as having a LIS 
if they received full or partial subsidy or were dually eligible for both Medicare and 
Medicaid (full or partial eligibility) at the month of their index date (i.e., date of NSCLC 
diagnosis). Three exposure groups were then created for the examination, including full LIS, 
partial LIS, and non-LIS. The definition of subsidy status is based on an established 
algorithm provided by the Research Data Assistance Center (ResDAC).189,190 
❖ Health Status 
 Charlson Comorbidity Index (CCI): Health status was measured using the Klabunde 
adaptation191 of the CCI as approved by the National Cancer Institute. The adapted 
version contains the following main changes: First, the adapted version also considers 
diagnoses from the Medicare physician claims (Part B) to identify comorbid 
conditions, which aims to maximize the possibility of capturing important patient 
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comorbidities recorded on outpatient claims while more patients receive outpatient 
care than hospitalization. Second, a rule-out algorithm is applied to require any code in 
the physician claims should appear more than once and the code should appear again 
in either physician or inpatient claims after more than 30 days. This requirement aims 
to prevent overestimation of comorbidity. Last, the adapted version excludes cancer 
from the comorbidity index because cancer is the disease of interest, resulting 18 non-
cancer conditions to be weighted for the adapted CCI. The refined measurement 
mentioned above helps enhance the measurement accuracy of comorbidities in claims 
data in cancer population. For this project, CCI was measured during the 6 months 
before the diagnosis date to capture baseline non-cancer comorbidities.  
 Disability Status (DS)192: Predicted disability status (DS) was calculated based on a 
validated claims-based algorithm developed by Davidoff AJ et al. The estimation used 
physician, hospice, and durable medical equipment claims to include healthcare service 
use indicators (such as use of home oxygen, mobility aids, nursing home admission, or 
use of preventive services and elective surgical procedures) that are clinically relevant 
and prevalent among cancer population. This could serve as a proxy measure of 
performance status (PS), among older cancer population. 
❖ Tumor characteristics 
 Year and quarter of year: Although time at diagnosis does not directly impact patient 
outcomes, our study might be subject to the effect of longer-term observations from 
2007-2013. These effects include advances in diagnosis and treatments, changes in 
treatment patterns, and natural disease progression (or care maturation). Thus, year of 
diagnosis, provided in the PEDSF file, will be categorized into 2007, 2008, 2009, 
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2010, 2011, 2012, or 2013 for each patient; quarter of the diagnosed year will be 
categorized into Q1 (January to March), Q2 (April to June), Q3 (July to September), or 
Q4 (October to December) based on the month of diagnosed made for the patient. 
 Stage: Tumor stage in the PEDSF file is provided based on the 6th American Joint 
Committee on Cancer (AJCC) staging criteria. Our project focuses on locally advanced 
or metastatic cases. That is, stage IIIB and stage IV cases. Thus, we created a 
categorical variable to indicate a patient’s cancer stage.  
 Histology: Tumor histology was categorized according to ICD-O-3 histologic subtype 
codes in PEDSF file. We will include four categories: adenocarcinoma (8140-8147, 
8250-8255, 8260, 8310, 8320, 8323, 8480-8481, 8490, 8510, 8550-8551, 8570-8576), 
squamous cell (8051-8078, 8083), large cell (8012-8015), and other/ not otherwise 
specified (NOS) (8003, 8004, 8020-8022, 8030-8035, 8046, and 8050, 8200-8201, 
8230-8231, 8240-8246, 8249, 8980-8982, 8120-8124, 8430, 8560, 8562, 9050-9053). 
Other histological codes not representative of the NSCLC subtypes above was 
excluded from this study. 
❖ Procedures 
For this set of variables, the identification period would be from the diagnosis of NSCLC to 
the use of first anti-cancer medications for their advanced NSCLC. Due to concerns about 
possible sample size issues, we would not investigate into the distinct types of radiation or 
surgery procedures that may have been performed. Detailed information regarding the 
procedure codes are listed in Appendix Table 3.5 and Appendix Table 3.6. 
 Radiation: An indicator variable was created based on the Medicare claims files, to 
denote whether the patient received radiation as part of the first course treatment.  
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 Cancer-directed Surgery: An indicator variable was created based on the Medicare 
claims files, to identify whether the patient received surgery as part of the first course 
treatment. Surgery of interest will include biopsy, local excision, and resection. 
Table 3.5 Summary of Covariates at Baseline for Aim 2 
Variable  Type Definition Source File 
Demographic 
characteristics 
   
Age Continuous & 
Categorical 
Categorized as: 66-69; 70-79; 
80+ 
PEDSF 
Sex Categorical Male; Female PEDSF 




Marital status Categorical Single (never married), Married 
(including common law), 
Separated, Divorced, Widowed, 
Unmarried or domestic partner 





   
Region Categorical Northeast, South, North Central, 
West, Other/Unknown. 
PEDSF 
Urban residence Categorical Big metro (Counties of 
metropolitan areas of 1 million 
population or more), Metro 
(counties in metropolitan areas 
of less than 1 million 
population), Urban (non-
metropolitan counties with 
urban population of 20,000 or 
more), Less Urban (non-
metropolitan counties with 
urban population of 2,500-
19,999), Rural (non-
metropolitan counties which are 
completely rural or with less 





   
Institutional Affiliation Binary Ever received care from 
providers with affiliations, 
including the Eastern 
Cooperative Oncology Group 
(ECOG) (Yes/No), NCI cancer 
center designation, teaching 
hospital designation (Yes/No), 
or each level of affiliation with 
a medical school (Yes/No). 
Provider file and 




Socioeconomic status    
Income – Median 
household income 
Categorical Aggregate census tract level 
measure of median household 
income 
Census Tract file  
Education – Percent 25 
and older with < high 
school education 
Categorical Aggregate census tract level 
measure of education attainment 
Census Tract file  
Census Tract Poverty 
Indicator 
Categorical 1= 0%-<5% poverty 
2 = 5% to <10% poverty 
3 = 10% to <20% poverty 





   
Low-income subsidy 
(LIS) 
Categorical Receipt of full LIS, partial LIS, 










0; 1; 2+ MEDPAR, NCH, 
Outpatient 
Disability Status (DS) Categorical Good (0-2); Poor (3-4) NCH, DME, Hospice 
Tumor-related 
characteristics 
   
Year of diagnosis Categorical 2007; 2008; 2009; 2010; 2011; 
2012; 2013 
PEDSF 
Quarter of the diagnosed 
year 
Categorical Q1 (January to March); Q2 
(April to June); Q3 (July to 
September); Q4 (October to 
December) 
PEDSF 
Stage Categorical Stage IIIB; Stage IV PEDSF 
Histology Categorical Lung and bronchus cancer 
(International Classification of 
Diseases for Oncology, 3rd 
Edition, ICD-O-3, C34.0–
C34.9) with ICD-O-3 histology: 
adenocarcinoma (8140-8147, 
8250-8255, 8260, 8310, 8320, 
8323, 8480-8481, 8490, 8510, 
8550-8551, 8570-8576); 
squamous cell (8051-8078, 
8083); large cell (8012-8015); 
other/ not otherwise specified 
(NOS) (8003, 8004, 8020-8022, 
8030-8035, 8046, and 8050, 
8200-8201, 8230-8231, 8240-
8246, 8249, 8980-8982, 8120-
8124, 8430, 8560, 8562, 9050-
9053). 
PEDSF 
Procedures    
Radiation therapy Dichotomous Radiation as part of the first 
course treatment (Yes; No) (See 
Appendix Table 3.5 for specific 
procedure codes) 
PEDSF; MEDPAR, NCH 
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Cancer-directed surgery Dichotomous Surgery as part of the first 
course treatment (Yes; No) (See 
Appendix Table 3.6 for specific 
procedure codes) 
PEDSF; MEDPAR, NCH 
Abbreviation: PEDSF, Patient Entitlement and Diagnosis Summary File; MEDPAR, Medicare Provider Analysis 
and Review File (i.e., Part A inpatient service); Outpatient, Part B institutional outpatient services; NCH, National 
Claims History File (i.e., Part B non-institutional outpatient services), HHA, Home Health Agency File (i.e., home 
health services), DME, Durable Medical Equipment File (i.e., durable medical equipment services) PDE, 
Prescription Drug Event file (i.e., Part D prescription drug dispensing). 
 
3.2.2.4 Analysis 
Descriptive statistics were first used to characterize both Part B and Part D treatment 
utilization and no treatment in the advanced NSCLC population. Changes in treatment patterns 
over time were assessed using the Chi-square test. Please note that, according to CMS, we are 
not allowed to show cell size less than 11. Therefore, the grouping in the results tables were 
changed accordingly. 
Next, modified Poisson regressions were used to estimate the effect of each factor on the 
use of Part D drugs following 12 months of the advanced NSCLC diagnosis. Outcome of the 
model was the use of Part D drugs, a dichotomous variable defined as “ever use a Part D anti-
cancer drug within 12 months after the diagnosis of advanced NSCLC” (versus never using a 
Part D drug). Because patients without any treatment within 12 months after diagnosis could be 
different from treated patients, we have another examination excluding these non-treated 
patients, comparing patients ever using a Part D anti-cancer drug with those only using Part B 
drugs within the 12 months since diagnosis. Bivariate examination was performed to understand 
the relationship between each independent variable and Part D drug use (i.e., crude estimates). 
Multivariate examination was then performed to include variables that are clinically and/or 
statistically important to Part D drug use (i.e., adjusted estimates). Risk ratios (RR) and 
corresponding 95% confidence intervals for each considered factors would be reported to 
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indicate the association between Part D medication use and the variable of interest (i.e., the 
relative risk of Part D drug use given exposure to the variable of interest). 
All statistical tests are 2-sided, with a threshold of α=0.05 for statistical significance. All 
analyses will be performed in SAS 9.3 (SAS Institute, Cary NC). 
 
3.3 AIM 3 – Evaluate the effect of low-income subsidies for Medicare Part D medications 
on treatment initiation among patients with advanced non-small cell lung cancer (NSCLC) 
from 2007 to 2014. 
 
3.3.1 Data Source 
 The SEER–Medicare database is used for this aim. Detailed description please see 
section 3.2.1. 
 
3.3.2 Study Design 
3.3.2.1 Cohort selection  
Inclusion and exclusion criteria of study population were the same as Aim 2. Detailed 
description please see section 3.2.2.1. We further grouped the eligible cohort into 3 subgroups, 
including Full-LIS, Partial-LIS, and non-LIS groups (Figure 3.5). Detailed definition of LIS was 




Figure 3.5 Flow Diagram of Study Population Selection for Aim 3  
 
Abbreviation: ESRD, end-stage renal disease; LIS, low-income subsidy; NSCLC, non-small cell lung cancer;  
 
3.3.2.2 Exposure 
To understand the effect of financial assistance on treatment uptake, our primary 
exposure is patients’ low-income subsidy status (LIS) at the month of cancer diagnosis. Whether 
an individual had received LIS will be based on the combined consideration of two variables in 
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the Part D enrollment file: Cost Share Group (i.e., monthly indicators for beneficiary’s LIS 
status) and State Reported Dual Eligible Status Code (i.e., monthly indicators for the dual 
eligibility status, if any, for the beneficiary). Dual Eligible Status is considered because with 
concurrent enrollment in Medicaid or Medicare Savings Programs (e.g., Qualified Medicare 
Beneficiary Program (QMB), Specified Low-Income Medicare Beneficiary Program (SLMB), or 
Qualified Individual Program) (QI)), where state programs pay Medicare Part B premiums, one 
will automatically qualify to get help paying for Medicare prescription drug coverage. Therefore, 
patients were defined as having a LIS if they received full or partial subsidy or were dually 
eligible for both Medicare and Medicaid (full or partial eligibility) at the month of their index 
date (i.e., date of NSCLC diagnosis). Three exposure groups were then created for the 
examination, including full LIS, partial LIS, and non-LIS. That is, a patient would be assigned to 
full LIS group if either one of the two indicators at the month of diagnosis is shown as full. The 
rest of the patient would then be grouped into partial LIS group if either one of the two indicators 
at the month of diagnosis is shown as partial. Lastly, the rest of the patients would fall into non-
LIS group. The definition of subsidy status is based on an established algorithm provided by the 
Research Data Assistance Center (ResDAC).189,190  
We categorized people into three LIS groups based on the following rules: a patient 
would be assigned to Full LIS group if either one of the two indicators at the month of diagnosis 
is shown as Full. The rest of the patient would then be grouped into Partial LIS group if either 
one of the two indicators at the month of diagnosis is shown as Partial. Lastly, the rest of the 
patients will fall into non-LIS group. 
Please also see Table 2.1 for the eligibility and cost-sharing for Medicare Part D benefit 
for each low-income subsidy groups. 
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3.3.2.3 Outcome Measurement 
Initial access to treatment is particularly important for those who are newly diagnosed 
with cancer, where prompt treatment is often essential. This aim examines uptake and timing of 
anticancer medications (separately for Medicare Part B and Medicare Part D). The key outcome 
of interest was the timing of anticancer medications initiation.  
 Drugs of interest were Part D and Part B drugs with United States Food and Drug 
Administration approval for advanced NSCLC by the end of 2014 (Table 3.1 and Table 3.2). 
Part D drugs were the primary focus for the examination. In addition, Part B drugs would serve 
as a negative control for a robustness check, in which no effect of LIS status is expected on the 
time to initiation, since most Medicare beneficiaries have supplemental coverage for Part B 
treatments.  
To identify the use, patients were followed starting from the date of being diagnosed with 
advanced NSCLC until they initiated a Part D NSCLC treatment, or being censored (i.e., through 
the date of death from any cause, disenrollment, the 12th month, or the end of data since 
diagnosis). Outcome of interest is the time to receive first Part D drug treatment since diagnosis, 
counted as the period of days between the date of advanced NSCLC diagnosis and first receiving 




Figure 3.6 Study Design for Aim 3 
 
a The study design includes a six-month period prior to the diagnosis of NSCLC to measure the baseline patient 
characteristics. We followed patient from the diagnosis until death, disenrollment, the 12th month since diagnosis, or 
the end of data (December 31, 2014), whichever occurred first. This post-diagnosis period was used to identify the 
outcomes of interest. 
 
3.3.2.4 Covariates 
Covariates considered are the same as Aim 2, except that Low-income subsidy status 
serves as the exposure of interest for Aim 3. A six-month period prior to the diagnosis of NSCLC 




We first described baseline characteristics of the study population, with respect to their 
demographic, geographic, clinical, and institutional characteristics, stratified by LIS status at the 
month of NSCLC diagnosis. Chi-square tests and t-tests were used to compare group difference 
in categorical and continuous variables considered, respectively. This step aims to understand 
potential underlying differences between those who received LIS and those who did not. 
Second, Kaplan-Meier curves were generated to compare the unadjusted timing of Part D 
medication use among full LIS, partial LIS, and non- LIS populations. In addition, Cox 
proportional hazards model were applied for covariate adjustment in the comparison of the 
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treatment timing of initiation among the three LIS groups.  
 
Inverse Probability of Treatment Weight193 
Given the differences among those who received LIS and those who did not, we 
additionally applied inverse probability of treatment weight (IPTW) in the models to adjust for 
the imbalance of patient characteristics among LIS groups. To calculate the IPTW, we first used 
a logistic regression to estimate the propensity score by predicting LIS status as a function of the 
following covariates: patient demographic (age, sex, marital status, race/ethnicity), geographic 
characteristics (SEER region, urban residence), institutional characteristics (whether the patient 
ever receive care from providers in affiliations with: the Eastern Cooperative Oncology Group 
(ECOG), NCI cancer center designation, teaching hospital designation, or level of affiliation 
with a medical school), socioeconomic status (census tract level of education, poverty, and 
median household income), health status (Klabunde's adaptation of the Charlson comorbidity 
index, predictd Disability Status), tumor-related characteristics (stage, histology, time of 
diagnosis), and receipt radiation or surgery as part of the first course treatment (See Table 3.5 for 
complete list of variables considered).  
Next, we created IPTW for each patient using the inverse of the propensity score. These 
were equal to 1/p (where p is the propensity score). We further stabilized the propensity score 
weights by multiplying the IPTW weights by the marginal prevalence of the treatment they 
received. The resulting IPTW were used to reduce selection bias and better clarify the effect of 
LIS status.  
 
66 
Hazard Ratios and corresponding 95% confidence intervals were provided to indicate the 
relative likelihood of initiating Part D medication in three LIS groups (i.e., non-LIS, partial LIS, 
and full LIS as reference). 
All statistical tests are 2-sided, with a threshold of α=0.05 for statistical significance. All 
analyses will be performed in SAS 9.3 (SAS Institute, Cary NC). 
 
3.3.3.6 Sensitivity Analysis 
In our primary analysis, we want to isolate the effect of high out-of-pocket spending on 
treatment uptake using LIS as a marker for treatment affordability. However, patients who 
qualify for LIS are financially disadvantaged relative to their non-LIS peers and may face 
additional challenges starting and managing their medication use. To better understand the 
relationship between out-of-pocket costs and treatment uptake we selected a negative control 
scenario to explore the relationship between LIS and treatment initiation when out-of-pocket 
spending is expected to be low for both LIS and non-LIS groups. We used Part B medication 
uptake as our negative control scenario because supplemental health insurance options are 
available for beneficiaries to pay the cost-sharing requirements for the services under Part B, 
including deductibles, copayments, and coinsurance. This supplemental coverage results in 
lower, more consistent and predictable expenses for patients using Part B services throughout the 
year. According to Kaiser Family Foundation, more than 80% of fee-for-service Medicare 
beneficiaries have some source of supplemental coverage.7
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CHAPTER FOUR: RESULTS 
 
4.1 AIM 1– Examine changes in drug-specific price, formulary structure, and the use of 
utilization management tools for Part D medications approved for advanced NSCLC from 
2009 to 2017. 
In this aim, we hypothesized that 1) over time Part D drug prices have increased over the study 
period in addition to inflation; 2) over time advanced NSCLC medications covered under Part D 
are more likely to be placed on the highest drug tier or specialty drug tier within the formulary; 
3) over time advanced NSCLC medications covered under Part D are more likely to require 
coinsurance (rather than copayments) for calculating patient cost-sharing; and 4) Over time 
advanced NSCLC medications covered under Part D are more likely to be subject to utilization 
management (e.g., step therapy, prior authorization, quantity limits). 
 
Drug Prices for Products Covered Under Medicare Part D 
Prices for all advanced NSCLC drugs covered under Part D have increased over the study 
period (Figure 4.1). Over time, prices have increased from an average of 3,851/month in 
2010Q1 to $9,996/month in 2017Q1. For individual products, prices in the most recent quarter 
ranged from $5,109/month (for erlotinib) to $15,384/month (for ceritinib) (Figure 4.1, 
Appendix Table 4.1).  
Over time we observe higher initial prices for approved treatments and growing prices for 
existing products. For example, the most recently approved drug, alectinib, was priced at around 
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$14,000/month at approval (Figure 4.1, Appendix Table 4.1). Whereas, the prices asked for 
older drugs (e.g., erlotinib) were below $5,000/month. Given the fact, its price has still increased 
by almost 50% during the study period.  
Gefitinib, the oldest tyrosine kinase inhibitor approved for advanced NSCLC, had limited 
use in the U.S. since 2005 because of disappointing trial results194 and was not covered under any 
Part D plans between 2013Q1 and 2015Q1 due to withdrawal195 (Figure 4.1, Appendix Table 
4.1). Since 2015, gefitinib coverage has improved based on new evidence of its role in the 
treatment for individuals with EGFR mutations. In 2010Q1 this drug was priced at $2,296/month 
but more recently the price has increased to $7,898/month. 
 
Figure 4.1 Median Prices of Advanced Non-Small Cell Lung Cancer Drugs Covered under 
Part D (2017 USD)a,b 
 
a Only one dosage form within each drug were presented in the figure. Dosage form were selected if the dose per pill 
matches the dose per uptake recommended in the NCCN guideline.  




When we consider drug prices at the therapeutic class level, we see somewhat different 
trends. There are two primary drug classes among drugs used for NCSLC and covered under 
Medicare Part D in our study period, including ALK-targeted drugs and EGFR-targeted drugs. 
We observed that ALK targeted drugs were priced much higher at the time of FDA approval 
(over $12,000/month) as compared to EGFR-targeted drugs (below $5,000/month) (Figure 4.2). 
This might be because ALK targeted agents are a relatively newer therapeutic class at the time 
and the prevalence of ALK is small (less than 10%). On average, the price asked for ALK-
targeted agents had been 1.5 to 3 times higher than the price for EGFR-targeted agents ($11,843 
vs. $4,135/month in 2012Q1 and $14,769 vs. $9550/month in 2017Q1) (Figure 4.2, Appendix 
Table 4.1). However, osimertinib, the newest EGFR-targeted drug which was approved in 2015, 
was priced at comparable price for ALK-targeted agents for more than $14,000/month (Figure 
4.1, Appendix Table 4.1). 
Interestingly, we observed that different dosage forms of a drug were priced at similar 
level or with minimal difference (Appendix Table 4.1). For example, there is less than $60 
difference in the price (both mean and median) between afatinib 20mg and 40mg over time. An 
identical price, over $14,000/month, was even set for osimertinib in both 40mg and 80mg 
formulations since its approval. 
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Figure 4.2 Average Price of Advanced Non-Small Cell Lung Cancer Drugs Covered under 
Part D, by Therapeutic Class (2017 USD)a 
 
a Only one dosage form within each drug were selected (if the dose per pill matches the dose per uptake 
recommended in the NCCN guideline) for the average price calculation.  
 
Drug Prices for Products Covered Under Medicare Part B 
In contrast to trends observed among drugs covered under the Medicare Part D benefit, 
Part B drug prices have been stable over the past 8 years (Figure 4.3, Appendix Table 4.2). 
Most of the traditional chemotherapies were off patent and have generics available during the 
study period; the prices were consistently low at below $100/month (e.g., platinum-based agents) 
or dropped considerably by up to 80% in the year when generic versions were approved (e.g., 
docetaxel, gemcitabine). Traditional agents in new formulations were still under patent 
protection with prices consistently high above $8,000/month (e.g., albumin-bound paclitaxel) 
and even increasing by 88% over the period examined, from $2,513 in 2010 to $4,728 in 2017 
(e.g., oral etoposide). A relatively newer infused chemotherapy, pemetrexed, had also been 
priced above $8,000/month since 2010. 
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Figure 4.3 Average Sales Prices for Advanced NSCLC Drugs Covered under Part B (2017 
USD)a 
Drugs with Prices above $500b Drugs with Prices below $500 
 
   
a Please see Appendix Table 4.2 for more details in Average Sales Prices for Part B drugs. 
b The Average Sales Prices of docetaxel 1mg IV and gemcitabine 200mg IV declined to below $500/month since 2017 
and 2013, respectively. In 2017, the price of docetaxel 1mg IV was $499.0/month and the price of gemcitabine 200mg 




Novel targeted therapies covered under Part B were priced above $10,000 for a month of 
treatment at the time of first FDA approval for advanced NSCLC. Even the drug with the earliest 
indication for NSCLC, bevacizumab, which was approved in 2006, was priced at almost 
$12,000/month in 2010 and at similar level afterwards. The price for the most recent approved 
immunotherapies could be more than $14,000/month (e.g., nivolumab). On average, the price of 
novel targeted treatments was 5.6 times higher than the price of traditional chemotherapies; 
among novel treatments, immunotherapies were priced more than $400 higher compared to the 
prices for monoclonal antibodies. (Figure 4.4).  
Figure 4.4 Average Sale Prices of Advanced Non-Small Cell Lung Cancer Drugs Covered 
under Part B, by Therapeutic Class (2017 USD)a,b 
 
a Blue-shaded colors represent traditional chemotherapies; orange-shaded colors represent targeted therapies and its 
subgroups. 
b Targeted therapy (overall) include both monoclonal antibodies treatments and immunotherapies. 
 
Coverage Design and Formulary Structure 
Across years, the overall number of Medicare prescription drug plans available to seniors 
has decreased (Figure 4.5, Appendix Table 4.3). Decreases have occurred mainly in the 
category of stand-alone prescription drug plans (PDPs) rather than in the Medicare Advantage 
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prescription drug plans (MA-PDs). Stand-alone plans are typically offered to enrollees in 
traditional Medicare (about 70% of all Medicare enrollees) and Medicare Advantage plans are 
offered in private plans (about 30% of all Medicare enrollees).6 The number of PDPs declined by 
53% from 1,594 to 757 plans between 2010Q1 and 2017 Q1. A considerable drop in number of 
plans (14% in MA-PDs and 29% in PDPs) was observed in 2011Q1.  
Among the available plans in each year (except 2011Q1), more than 90% of them 
covered at least 1 advanced NSCLC drug in each therapeutic class. Since 2013Q1, more than 
90% of the plans covered all advanced NSCLC drugs available at the time. In 2017Q1, 98% of 
the MA-PDs and 91% of the PDPs provide coverage for all advanced NSCLC drugs on the 
market. 
Figure 4.5 Part D Plan Coverage for Advanced Non-Small Cell Lung Cancer Care, by Plan 
Type, 2010Q1 to 2017Q1 
 
 
In terms of the application of utilization management tools, MA-PDs were less likely 
than PDPs to apply prior authorization and quantity limits to advanced NSCLC drugs across 
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years. An increase was observed in the use of both tools, particularly for older drugs that have 
been available since mid-2000s (e.g., erlotinib, gefitinib) (Figure 4.6, Appendix Table 4.4). On 
the other hand, step therapy requirements were rarely used by plans. In 2017, utilization 
management tools were applied in a similar manner across available drug treatments (prior 
authorization use: 85-95% MA-PDs and 92-100% PDPs; quantity limits: 59-72% MA-PDs and 
55-79% PDPs; step therapy: 0% in both MA-PDs and PDPs). 
In terms of the drug tiering, PDPs were more likely to assign top tiers or specialty tiers to 
advanced NSCLC drugs as compared to MA-PDs across years although more than 80% of both 
types of plan applied the tiering (Figure 4.6). Particularly in 2017Q1, 5 out of the 7 drugs 




Figure 4.6 Utilization Management Tools and Formulary Tiering in Advanced Non-Small 
Cell Lung Cancer Drugs, 2010Q1 vs. 2017Q1a 
 
a Each bar in the figure represents proportion of plans applying the measures among all plans that covering the drug. 
 
Cost-sharing requirement for approved NSCLC treatments have changed only slightly 
over the study period. Almost all plans required coinsurance for using each advanced NSCLC 
drug treatment in the initial coverage phase of the Part D benefit across each year. Between 
2010Q1 and 2016Q3 (the most recently available complete data) the median coinsurance applied 
to drugs was 33% (IQR: 25-33% for both MA-PDs and PDPs). Similarly, in catastrophic phase, 
most of the plans applied co-insurance (in 2017Q1, 98.2% in MAs and 100% in PDPs), at 
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consistent 5% amount, for each drug treatment across each year. Figure 4.7 shows the cost-
sharing requirement for erlotinib as an example. 
Figure 4.7 Trend of Cost-Sharing Requirement for Erlotinib on Medicare Part D 




a Due to missing data on cost-sharing in initial coverage phase in 2016Q4 and 2017Q1, we used the most recent and 
complete data for this examination. 
b The left axis denotes the total number of plans each year; the right axis denotes the median amount of coinsurance 




Out-of-Pocket Spending Estimates for Medicare Part D Covered Drugs  
Given the high prices and cost-sharing requirement by Part D plans, patient out-of-pocket 
cost (OOP) could be several thousand dollars for initiating a Part D drug treatment for advanced 
NSCLC. For a non-LIS patient enrolled in a plan with standard Part D benefits in 2017, the OOP 
could be more than $2,500/month for drugs with the most commonly used dosage (Figure 4.8). 
For the most recently approved drugs, the initiating cost of using could be $3,300/month (e.g., 
osimertinib of EGFR-targeted agents and alectibnib of ALK-targeted agents).   
Figure 4.8 Estimated First-Month Out-of-Pocket Cost (OOP) of Advanced Non-Small Cell 
Lung Cancer Part D Drug Treatments in 2017 a 
 
a This estimation was based on each drug’s median cost per month in 2017. We calculated the out-of-pocket costs 
(OOP) for a non-LIS patient enrolled in a plan with standard Part D benefits in 2017 with the assumption that the 




4.2 AIM 2– Examine trends in the utilization of advanced NSCLC medications by coverage 
source (i.e., Medicare Part B or Part D). In addition, to identify clinical, sociodemographic, 
and health system factors associated with the use of Part D treatments among patients 
diagnosed with advanced NSCLC from 2007 to 2014. 
In this aim, we hypothesized that: 1) the use of advanced NSCLC medications covered 
under Part D has increased over the study period; and 2) the use of advanced NSCLC 
medications covered under Part B has decreased over the study period. 
 
To derive a NSCLC cohort (Figure 4.9), all patients in the SEER database with a primary 
cancer of the lung and bronchus diagnosed between July 1, 2007 and December 31, 2013 were 
initially selected (N=205,060). Subsequently, we excluded patients for whom lung cancer was 
not their first primary cancer and patients without valid NSCLC histology codes, those died at 
diagnosis, and those aged equal or older than 65, which resulted in an initial eligible cohort of 
112,661 NSCLC patients. After further applying additional selection criteria for continuous 
enrollment in Medicare, health status (e.g., hospice enrollment, death within 30 days of 
diagnosis, chronic ESRD or not), and the completeness of data we obtained the final eligible 




Figure 4.9 Flow chart of the study population selection 
 
Abbreviation: ESRD, end-stage renal disease; NSCLC, non-small cell lung cancer. 
 
The final advanced NSCLC cohort diagnosed between July of 2007 and December of 
2013 were on average 75.1 years old (SD: 6.8) (Figure 4.9, Table 4.1). Mean comorbidity 
scores were 1.2 (SD 1.5; 70.0% with scores 0-1) and more than 90% of the patients had good 
predicted Disability Status (DS, a claim-based proxy measure of performance status192 at 
baseline). Among them, 49% were male and more than 75% were non-Hispanic Whites. 
Adenocarcinoma and squamous subtypes consisted of 51.7% and 26.5% of the patient tumor 
histology, respectively. In respect of socioeconomic status, more than 80% of the patients lived 
in metro areas of 1 million or more population (i.e., Big Metro or Metro areas). When 
considering census tract level characteristics, 30.7% of the patients lived in areas with more than 
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20% of the population without high school diploma. In addition, more than a quarter (28.7%) of 
the patients lived in areas with more than 20% of the residents living below poverty and 40.3% 
of the patients received partial or full low-income subsidy for Medicare Part D prescription drug 
coverage. 
Based on the drug use within 365 days of diagnosis of advanced NSCLC, we observe 
four treatment groups, use of both Part B & D drugs, only Part D drug use, only Part B drug use, 
and never use of Part B or Part D drugs (Table 4.1A). Patients who did not receive treatment 
within 365 days of diagnosis accounted for 49.7% of the total advanced NSCLC population. 
Compared to other treated groups, they were less likely to be married (33.7%), appeared to live 
in poorer areas (63.1% living in census tract with more than 20% residents below poverty level) 
or areas with lower education level (64.1% living in census tracts with more than 10% residents 
without High School Degree). Among this group, 41.8% received full LIS (vs 35.3% of all 
NCSLC patients). In terms of health status, these patients appeared to have the highest levels of 
comorbidity (34.3% with Comorbidity Score of 2 or more) and were more likely to have a poor 
Disability Score (14% with score of 3-4), in comparison to other treated groups. In addition, 
these patients were also much less likely to receive care from hospitals designed as NCI centers, 
teaching hospital, or with major affiliation with medical school. 
Patients who used only Part D drugs (versus other patients receiving any drug-based 
therapy) were older (more patients aged 80 or over: 45.4% for Part D drug only vs. 19.2% for 
both Parts D &B drugs vs. 14.8% for Part B drug only), most likely to be women (66.8% vs. 
55.6% vs. 47.4%), and had more than a quarter of the patients in “Other” race/ethnicity group 
(28.9% vs. 17.0% vs. 5.6%). In addition, more than half of the Part D only group lived in the 
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West region (56.8% vs. 49.5% vs. 36.0%) and almost 90% lived in Metro or Big Metro areas 
(88.7% vs. 82.2% vs. 79.2%).  
Socioeconomic status was similar across treated groups; about 57% of the patients lived 
in census tracts where more than 10% of residents had no High School Degrees and about 25% 
residing in census tracts with more than 20% of residents living below poverty level. Patients 
treated with only Part D drugs were most likely to receive full LIS (45.8% vs. 32.4% vs. 26.7%) 
while those treated with only Part B drugs were least likely to receive any level of LIS.  
In terms of health status, patients receiving Part D drugs only were most likely to have 
poor Disability Scores (8.6% vs. 2.5% vs. 3.8%) while the Part B drug only group was most 
likely to have Comorbidity Score of 1 or more (51.8% vs. 50.2% vs. 55.3%). Compared to Part B 
drug only group, those who ever received a Part D drug were more like to be diagnosed with 
stage IV cancers (76.2% vs. 69.8%) and more likely to have adenocarcinoma histology (71.5% 
vs. 49.7%). In terms of the other treatments, Part B drug only groups were most likely to receive 







Table 4.1A Patient Characteristics at Baseline (N=19,746) 
  Grand Total 
Use both Part B & 
D drugs use within 
365 days 
Use only Part D 
drugs within 365 
days 
Use only Part B 
drugs within 365 
days 
No Part B or D 
drugs use within 
365 days 
 
  N=19746 N=1017 N=1019 N=7906 N=9804  
  N % N % N % N % N % p-value 
Age                        <.0001 
  65-69 4733 24.0% 301 29.6% 143 14.0% 2413 30.5% 1876 19.1% 
 
  70-74 5375 27.2% 284 27.9% 189 18.5% 2558 32.4% 2344 23.9% 
 
  75-79 4433 22.5% 237 23.3% 224 22.0% 1766 22.3% 2206 22.5% 
 
  80+ 5205 26.4% 195 19.2% 463 45.4% 1169 14.8% 3378 34.5% 
 
Sex                       <.0001 
  Male 9745 49.4% 452 44.4% 338 33.2% 4162 52.6% 4793 48.9% 
 
  Female 10001 50.6% 565 55.6% 681 66.8% 3744 47.4% 5011 51.1% 
 
Race/Ethnicity                     <.0001 
  Non-Hispanic White 14929 75.6% 705 69.3% 591 58.0% 6350 80.3% 7283 74.3% 
 
  Non-Hispanic Black 2025 10.3% 73 7.2% 62 6.1% 702 8.9% 1188 12.1% 
 
  Hispanic 1151 5.8% 66 6.5% 71 7.0% 409 5.2% 605 6.2% 
 
  Others 1641 8.3% 173 17.0% 295 28.9% 445 5.6% 728 7.4% 
 
Marital Status                     <.0001 
  Married 8903 45.1% 581 57.1% 475 46.6% 4191 53.0% 3656 37.3% 
 
  Single 10092 51.1% 405 39.8% 510 50.0% 3445 43.6% 5732 58.5% 
 
  Unknown 751 3.8% 31 3.0% 34 3.3% 270 3.4% 416 4.2% 
 
Region                     <.0001 
  North East 3765 19.1% 174 17.1% 183 18.0% 1599 20.2% 1809 18.5% 
 
  South 5746 29.1% 247 24.3% 189 18.5% 2353 29.8% 2957 30.2% 
 
  North Central 2571 13.0% 93 9.1% 68 6.7% 1106 14.0% 1304 13.3% 
 
  West 7664 38.8% 503 49.5% 579 56.8% 2848 36.0% 3734 38.1% 
 
Urban/Rural Residence                     <.0001 
  Big Metro 10188 51.6% 557 54.8% 653 64.1% 4000 50.6% 4978 50.8% 
 
  Metro 5694 28.8% 278 27.3% 251 24.6% 2279 28.8% 2886 29.4% 
 
  Urban 1227 6.2% 70 6.9% 46 4.5% 523 6.6% 588 6.0% 
 
  Less Urban 2125 10.8% 93 9.1% 64 6.3% 869 11.0% 1099 11.2% 
 
  Rural 512 2.6% 19 1.9% 5 0.5% 235 3.0% 253 2.6% 
 
Census Tract % of without High 
School Degree 
                    <.0001 
  00-05% 3114 15.8% 209 20.6% 213 20.9% 1337 16.9% 1355 13.8% 
 








  10-20% 5953 30.1% 262 25.8% 266 26.1% 2370 30.0% 3055 31.2% 
 
  20-100% 6058 30.7% 305 30.0% 310 30.4% 2215 28.0% 3228 32.9% 
 
Census Tract % below poverty                     <.0001 
  00-05% 3303 16.7% 211 20.7% 205 20.1% 1471 18.6% 1416 14.4% 
 
  05-10% 4672 23.7% 258 25.4% 253 24.8% 1957 24.8% 2204 22.5% 
 
  10-20% 6109 30.9% 293 28.8% 308 30.2% 2439 30.8% 3069 31.3% 
 
  20-100% 5662 28.7% 255 25.1% 253 24.8% 2039 25.8% 3115 31.8% 
 
Census Tract Household Median 
Income 
                    <.0001 
  1st Quartile 4936 25.0% 222 21.8% 185 18.2% 1749 22.1% 2780 28.4% 
 
  2nd Quartile 4937 25.0% 220 21.6% 224 22.0% 2008 25.4% 2485 25.3% 
 
  3rd Quartile 4936 25.0% 252 24.8% 261 25.6% 2025 25.6% 2398 24.5% 
 
  4th Quartile 4937 25.0% 323 31.8% 349 34.2% 2124 26.9% 2141 21.8% 
 
Receipt of Low Income Subsidy 
(LIS) 
                    <.0001 
  Full LIS 6979 35.3% 329 32.4% 467 45.8% 2112 26.7% 4071 41.5% 
 
  No LIS 11778 59.6% 654 64.3% 513 50.3% 5427 68.6% 5184 52.9% 
 
  Partial LIS 989 5.0% 34 3.3% 39 3.8% 367 4.6% 549 5.6% 
 
Comorbidity Indexa                     <.0001 
  0 8194 41.5% 507 49.9% 491 48.2% 3530 44.6% 3666 37.4% 
 
  1 5832 29.5% 304 29.9% 286 28.1% 2469 31.2% 2773 28.3% 
 
  2+ 5720 29.0% 206 20.3% 242 23.7% 1907 24.1% 3365 34.3% 
 









 Good 0-2 17964 91.0% 992 97.5% 931 91.4% 7606 96.2% 8435 86.0% 
 
 Poor 3-4 1782 9.0% 25 2.5% 88 8.6% 300 3.8% 1369 14.0% 
 
Year of Diagnosis            
  2007 1465 7.4% 103 10.1% 82 8.0% 529 6.7% 751 7.7% 0.0002 
  2008 2938 14.9% 161 15.8% 141 13.8% 1145 14.5% 1491 15.2% 
 
  2009 2976 15.1% 176 17.3% 147 14.4% 1169 14.8% 1484 15.1% 
 
  2010 2900 14.7% 139 13.7% 139 13.6% 1141 14.4% 1481 15.1% 
 
  2011 2835 14.4% 142 14.0% 138 13.5% 1166 14.7% 1389 14.2% 
 
  2012 3198 16.2% 132 13.0% 165 16.2% 1337 16.9% 1564 16.0% 
 
  2013 3434 17.4% 164 16.1% 207 20.3% 1419 17.9% 1644 16.8% 
 
Quarter of Year of Diagnosis                     0.229 
  Q1 4682 23.7% 233 22.9% 219 21.5% 1834 23.2% 2396 24.4% 
 
  Q2 4511 22.8% 219 21.5% 227 22.3% 1843 23.3% 2222 22.7% 
 
  Q3 5363 27.2% 283 27.8% 297 29.1% 2175 27.5% 2608 26.6% 
 
  Q4 5190 26.3% 282 27.7% 276 27.1% 2054 26.0% 2578 26.3% 
 







  Stage IIIB 5499 27.8% 249 24.5% 236 23.2% 2390 30.2% 2624 26.8% 
 
  Stage IV 14247 72.2% 768 75.5% 783 76.8% 5516 69.8% 7180 73.2% 
 
Cancer Histology                     <.0001 
 Adenocarcinoma  10207 51.7% 664 65.3% 792 77.7% 3929 49.7% 4822 49.2% 
 
 Squamous  5241 26.5% 186 18.3% 90 8.8% 2252 28.5% 2713 27.7% 
 
 Large cell 499 2.5% 23 2.3% 13 1.3% 215 2.7% 248 2.5% 
 
 Others  3799 19.2% 144 14.2% 124 12.2% 1510 19.1% 2021 20.6% 
 
Radiation as First Course of 
Therapy 
8116 41.1% 408 40.1% 347 34.1% 4011 50.7% 3350 34.2% <.0001 
Surgery as First Course of 
Therapy 
1264 6.4% 31 3.0% 35 3.4% 560 7.1% 638 6.5% <.0001 
Receipt of Care from Hospital 
Affiliation with 
           
 NCI Designation 3195 16.2% 270 26.5% 234 23.0% 1572 19.9% 1119 11.4% <.0001 
 ECOG 4997 25.3% 297 29.2% 235 23.1% 2300 29.1% 2165 22.1% <.0001 
 Teaching Hospital 13134 66.5% 768 75.5% 727 71.3% 5570 70.5% 6069 61.9% <.0001 
 
Major Affiliation with 
Medical School 
7504 38.0% 473 46.5% 452 44.4% 3288 41.6% 3291 33.6% <.0001 
a Klabunde's adaptation of the Charlson comorbidity index191 was used to assess cancer-specific Comorbidity Index with Charlson comorbidity index included 
comorbidities other than cancer.  
b Predicted disability status (DS)192 was calculated based on a validated claims-based algorithm developed by Davidoff AJ et al. This could serve as a proxy 
measure of performance status (PS), among older cancer population.  
Abbreviation: 95% CI, 95% Confidence Interval; aRR: adjusted Relative risk; cRR: crude Relative Risk; DS, Disability Status; ECOG: the Eastern Cooperative 




During the observation period, about 10% of the advanced NSCLC population ever used 
a Part D drug within 12 months of diagnosis, including 1,019 patients using only Part D drugs 
and 1,017 patients using both Part B and Part D drugs within the period (Figure 4.10A). Rates of 
Part D drug use decreased slightly over time, from 12.6% for patients diagnosed in 2007 to 
10.8% for patients diagnosed in 2013. Specifically, 3 out of 5 Part D drugs approved during the 
study period were used as first Part D treatment by the patients (Figure 4.10B), including 
erlotinib, crizotinib, and afatinib (gefitinib and ceritinib were not observed possible because of 
FDA announcement of restrictive use of geftinitb in previously treated patients and ceritinib’s 
late approval in the study period). Of these, erlotinib accounted for more than 90% of all use.
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Figure 4.10A Utilization NSCLC Drugs on Medicare Part D within 12-month after 
Diagnosis of Advanced NSCLC, 2007-2014a,b  
 
 
a The percentage of Part D drug users (green) was calculated as the number of people ever using a Part D drug 
within 365 days of advanced NSCLC diagnosis (blue) divided by the total number of advanced NSCLC patients of 
the year (red). Utilization is presented by patients’ year of advanced NSCLC diagnosis.  
b Among the ever Part D users, about 50% has used both Part B and Part D drugs during the 12 months of diagnosis. 
Please see Appendix Figure 4.1A for detailed composition on the utilization of Part D drugs. 
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Figure 4.10B First NSCLC Drugs on Medicare Part D within 12-month after Diagnosis of 
Advanced NSCLC, 2007-2014, by Drug Producta 
 
 
a The yellow line indicated the annual number of advanced NSCLC patients ever receiving Part D drug within 365 
days of the diagnosis, presented by patients’ year of advanced NSCLC diagnosis. Each bar of a year was composed 
of percentage of patients using specific Part D drug (represented by different color) within the year and summed to 
100%. Drugs not shown were those not observed with any use by the patients during the study period. 
 
On the other hand, the utilization of Part B drugs within 12-month of diagnosis was much 
higher than the utilization of Part D drugs, accounting for around 45% of the advanced NSCLC 
population, including 7,906 patients using only Part B drugs and 1,017 patients using both Part B 
and Part D drugs within the period. Overall, a slight increase was observed, from 43.1% for 
patients diagnosed in 2007 to 46.1% for patients diagnosed in 2013 (Figure 4.11A).   
Among the Part B drugs, platinum-based regimens consisting of all traditional 
chemotherapies were the most common first-line treatments. Specifically, carboplatin-based 
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regimens and cisplatin-based regimens accounted for 65-70% or 8-10% of all use over time, 
respectively (Figure 4.11B).  Regimens with targeted therapy (e.g., bevacizumab), however, 
accounted for only 10-14% of all use over the same period. Since ramucirumab was approved in 
the end of our study period, December 2014, there had not been any observation of ramucirumab 
use during the time.   
Figure 4.11A.  Utilization of NSCLC Drugs on Medicare Part B within 12-month after 
Diagnosis of Advanced NSCLC, 2007-2014a,b  
 
 
a The percentage of Part D drug users (green) was calculated as the number of people ever using a Part D drug 
within 365 days of advanced NSCLC diagnosis (blue) divided by the total number of advanced NSCLC patients of 
the year (red). Utilization is presented by patients’ year of advanced NSCLC diagnosis. In addition, among the ever 
Part D users, about 50% has used both Part B and Part D drugs during the 12 months of diagnosis. Please see 
Appendix Figure 4.1A for detailed composition on the utilization of Part D drugs.  
b Among mong the ever Part B users, more than 10% has used both Part B and Part D drugs during the 12 months of 
diagnosis. Please see Appendix Figure 4.1B for detailed composition on the utilization of Part D drugs. 
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Figure 4.11B. First NSCLC Drugs on Medicare Part B within 12-month after Diagnosis of 
Advanced NSCLC, 2007-2014, by Regimena 
 
 
a Utilization of Part B drugs were presented in terms of regimen rather than specific products because these drugs 
are mainly used in combination. 
a The brown line indicated the annual number of advanced NSCLC patients ever receiving Part B drug within 365 
days of the diagnosis, presented by patients’ year of advanced NSCLC diagnosis. Each bar of a year was composed 











 A secondary goal for Aim 2 is to understand the factors associated with receipt of any 
Part D treatment (versus no Part D treatment). Characteristics of the cohort once categorized into 
this binary treatment assignment are provided in Table 4.1B below and difference between Part 
D treated and untreated patients are discussed below.  
Table 4.1B Patient Characteristics at Baseline, Part D treated vs. No Part D treated 
(N=19,746)   
  Grand Total 
Part D drug use 
within 365 days 
No Part D drug 
use within 365 
days 
 
    N=19746 N=2036 N=17710  
  N % N % N % p-value 
Age          <.0001 
  65-69 4733 24.0% 444 21.8% 4289 24.2%  
  70-74 5375 27.2% 473 23.2% 4902 27.7%  
  75-79 4433 22.5% 461 22.6% 3972 22.4%  
  80+ 5205 26.4% 658 32.3% 4547 25.7%  
Sex               <.0001 
  Male 9745 49.4% 790 38.8% 8955 50.6%  
  Female 10001 50.6% 1246 61.2% 8755 49.4%  
Race/Ethnicity            <.0001 
  Non-Hispanic White 14929 75.6% 1296 63.7% 13633 77.0%  
  Non-Hispanic Black 2025 10.3% 135 6.6% 1890 10.7%  
  Hispanic 1151 5.8% 137 6.7% 1014 5.7%  
  Others 1641 8.3% 468 23.0% 1173 6.6%  
Marital Status            <.0001 
  Married 8903 45.1% 1056 51.9% 7847 44.3%  
  Single 10092 51.1% 915 44.9% 9177 51.8%  
  Unknown 751 3.8% 65 3.2% 686 3.9%  
Region               <.0001 
  North East 3765 19.1% 357 17.5% 3408 19.2%  
  South 5746 29.1% 436 21.4% 5310 30.0%  
  North Central 2571 13.0% 161 7.9% 2410 13.6%  
  West 7664 38.8% 1082 53.1% 6582 37.2%  
Urban/Rural Residence            <.0001 
  Big Metro 10188 51.6% 1210 59.4% 8978 50.7%  
  Metro 5694 28.8% 529 26.0% 5165 29.2%  
  Urban 1227 6.2% 116 5.7% 1111 6.3%  
  Less Urban 2125 10.8% 157 7.7% 1968 11.1%  
  Rural 512 2.6% 24 1.2% 488 2.8%  
Census Tract % of without High School 
Degree 
 
          <.0001 
  00-05% 3114 15.8% 422 20.7% 2692 15.2%  
  05-10% 4621 23.4% 471 23.1% 4150 23.4%  
  10-20% 5953 30.1% 528 25.9% 5425 30.6%  
  20-100% 6058 30.7% 615 30.2% 5443 30.7%  
Census Tract % below poverty            <.0001 
  00-05% 3303 16.7% 416 20.4% 2887 16.3%  
  05-10% 4672 23.7% 511 25.1% 4161 23.5%  
  10-20% 6109 30.9% 601 29.5% 5508 31.1%  
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  20-100% 5662 28.7% 508 25.0% 5154 29.1%  
Census Tract Household Median Income            <.0001 
  1st Quartile 4936 25.0% 407 20.0% 4529 25.6%  
  2nd Quartile 4937 25.0% 444 21.8% 4493 25.4%  
  3rd Quartile 4936 25.0% 513 25.2% 4423 25.0%  
  4th Quartile 4937 25.0% 672 33.0% 4265 24.1%  
Receipt of Low Income Subsidy (LIS)            <.0001 
  Full LIS 6979 35.3% 796 39.1% 6183 34.9%  
  No LIS 11778 59.6% 1167 57.3% 10611 59.9%  
  Partial LIS 989 5.0% 73 3.6% 916 5.2%  
Comorbidity Indexa            <.0001 
  0 8194 41.5% 998 49.0% 7196 40.6%  
  1 5832 29.5% 590 29.0% 5242 29.6%  
  2+ 5720 29.0% 448 22.0% 5272 29.8%  
Predicted DSb           <.0001  
Good 0-2 17964 91.0% 1923 94.4% 16041 90.6%   
Poor 3-4 1782 9.0% 113 5.6% 1669 9.4%  
Year of Diagnosis        
  2007 1465 7.4% 185 9.1% 1280 7.2% 0.0127 
  2008 2938 14.9% 302 14.8% 2636 14.9%  
  2009 2976 15.1% 323 15.9% 2653 15.0%  
  2010 2900 14.7% 278 13.7% 2622 14.8%  
  2011 2835 14.4% 280 13.8% 2555 14.4%  
  2012 3198 16.2% 297 14.6% 2901 16.4%  
  2013 3434 17.4% 371 18.2% 3063 17.3%  
Quarter of Year of Diagnosis            0.1314 
  Q1 4682 23.7% 452 22.2% 4230 23.9%  
  Q2 4511 22.8% 446 21.9% 4065 23.0%  
  Q3 5363 27.2% 580 28.5% 4783 27.0%  
  Q4 5190 26.3% 558 27.4% 4632 26.2%  
Cancer Stage            <.0001 
  Stage IIIB 5499 27.8% 485 23.8% 5014 28.3%  
  Stage IV 14247 72.2% 1551 76.2% 12696 71.7%  
Cancer Histology            <.0001 
 Adenocarcinoma  10207 51.7% 1456 71.5% 8751 49.4%  
 Squamous  5241 26.5% 276 13.6% 4965 28.0%  
 Large cell 499 2.5% 36 1.8% 463 2.6%  
 Others  3799 19.2% 268 13.2% 3531 19.9%  
Radiation as First Course of Therapy 8116 41.1% 755 37.1% 7361 41.6% <.0001 
Surgery as First Course of Therapy 1264 6.4% 66 3.2% 1198 6.8% <.0001 
Receipt of Care from Hospital Affiliation 
with 
 
          
 NCI Designation 3195 16.2% 504 24.8% 2691 15.2% <.0001 
 ECOG 4997 25.3% 532 26.1% 4465 25.2% 0.3669 
 Teaching Hospital 13134 66.5% 1495 73.4% 11639 65.7% <.0001 
 
Major Affiliation with Medical 
School 7504 38.0% 925 45.4% 6579 37.1% 
<.0001 
a Klabunde's adaptation of the Charlson comorbidity index191 was used to assess cancer-specific Comorbidity Index 
with Charlson comorbidity index included comorbidities other than cancer.  
b Predicted disability status (DS)192 was calculated based on a validated claims-based algorithm developed by 
Davidoff AJ et al. This could serve as a proxy measure of performance status (PS), among older cancer population.  
Abbreviation: 95% CI, 95% Confidence Interval; aRR: adjusted Relative risk; cRR: crude Relative Risk; DS, 
Disability Status; ECOG: the Eastern Cooperative Oncology Group; LIS: Low Income Subsidy; NSCLC: Non-




Overall, among the advanced NSCLC population, 10.3% ever received a Part D drug 
treatment within the year of diagnosis and 89.7% did not (Table 4.1B). When comparing those 
who received a Part D drug treatment to those who did not, Part D drug users were older (Age 
75+: 54.9% vs. 48.1%, p<0.0001), had a higher proportion of female users (61.2% vs. 49.4%, 
p<0.0001), and were more likely to be married (51.9% vs. 41.3%, p<0.0001). In addition, users 
consisted of a much higher proportion of “Other” racial groups, which includes Asian, than non-
users, 23.0% vs 6.6%, respectively (p<0.0001).  
In terms of socioeconomic status, patients who received Part D drug treatments had 
higher education measured at the census tract level (56.1% vs. 61.3% living in areas with ≥10% 
residents with no High School Degree, p<0.0001) and higher household income at census tract 
level (residents with income above the 4th quartile, $73,391: 33.0% vs. 24.1%, p<0.0001). 
Although more than one third of both groups received full low-income subsidies (LIS) to offset 
out-of-pocket costs for drugs obtained through Medicare Part D, more Part D drug users received 
full cost-sharing assistance within the year of diagnosis (39.1% vs. 34.9%).  
Health status measured through either comorbidity or disability scores was generally 
better among Part D drug users than that among non-users (comorbidity 0-1: 78.0% vs. 70.2%, 
p<0.0001; good predicted disability status: 94.4% vs. 90.6%, p<0.0001) although more patients 
who used Part D drugs were diagnosed with stage IV cancers as compared with non-users 
(76.2% vs. 71.7%, p<0.0001). Adenocarcinoma accounts for the largest proportion among both 
groups (71.5% and 49.4% of tumor types, respectively), particularly among those receiving Part 
D drug treatments within the year of diagnosis. Among all adenocarcinomas, 14% ever received 
Part D drugs within the year of diagnosis. 
 
93 
In model examinations to further consider factors associated with filling Part D drug 
prescriptions (Table 4.2), we first compared patients ever using Part D drugs within the year of 
diagnosis with those never using any Part D drugs within the year of diagnosis. We found that 
patients aged over 80 years at diagnosis (adjusted Risk Ratio (aRR): 1.35 [95% CI: 1.19-1.50], 
female (aRR: 1.53 [95% CI: 1.40-1.66], and married (aRR: 1.30 [95% CI: 1.19-1.43] were 
significantly more likely to receive Part D drug treatments in the 12-month post-diagnosis 
period. Race/ethnicity were also important factors in use of Part D treatments. Especially for the 
“Other” group, which includes Asian, the probability of using Part D treatments was more than 2 
times that of non-Hispanic Whites (aRR: 2.26 [95% CI: 2.00-2.53].  
Socioeconomic status was generally not associated with the use of Part D drug treatment 
after adjustment for other characteristics. In the bivariate analysis, we found that patients 
residing in census tract areas with lower education status (aRR from 0.65 to 0.75), greater 
poverty level (aRR from 0.71 to 0.87), or lower income (aRR from 0.61 to 0.76) were less likely 
receive Part D drug treatments. However, the effects were no longer significant when 
considering the effects of other factors in the multivariate examinations. For low income 
subsidies (LIS), on the other hand, in bivariate analysis patients who did not receive a full LIS 
were significantly less likely to receive Part D treatments, particularly among those with partial 
LIS (crude Risk Ratio (cRR)partial LIS: 0.65 [95% CI:0.51-0.81]; cRRno LIS: 0.87 [95% CI:0.79-
0.94]). After adjustment for other clinical and socio-demographic factors, this association was 
attenuated (aRRpartial LIS: 0.83 [95% CI: 0.65-1.03;] aRRno LIS: 0.81 [95% CI: 0.81-1.00]).  
In terms of tumor characteristics, stage IV cancers (compared to stage IIIB cancers) or 
adenocarcinoma subtype (compared to other cancer histology) were associated with 26-82% 
higher probability of Part D treatment use. Patients with poor predicted disability status or higher 
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comorbidity burden were less likely to receive Part D treatments (aRRpoor DS: 0.67 [95% CI: 0.55-
0.79]; aRRCCI(2+): 0.83 [95% CI: 0.74-0.92]). Having surgery or radiation as part of first course of 
therapy was associated with lower possibility of Part D drug use (aRRsurgery: 0.32 [95% CI: 0.24-
0.40]; aRRradiation: 0.88 [95% CI: 0.81-0.96]). Hospital affiliation was also significantly related to 
the use of Part D drug treatments; except NCI designation, patients ever receiving care from 
hospitals affiliated with the Eastern Cooperative Oncology Group (ECOG), a teaching hospital, 
or a medical school remain 12-25% more likely to receive Part D drug treatments after 
adjustment as compared to those never receiving care from these hospitals.   
Table 4.2A Association between Key Factors and Part D Drug Treatment Use for 
Advanced Non-Small Cell Lung Cancer, among All Patients.  (N=19,746)a 
    cRRa 95% CI aRRa 95% CI 
Demographic Characteristics         
Age           
  65-69 Reference  Reference   
  70-74 0.94 (0.82, 1.06) 0.95 (0.84, 1.06) 
  75-79 1.11 (0.97, 1.25) 1.10 (0.97, 1.23) 
  80+ 1.35 (1.20, 1.50) 1.34 (1.19, 1.50) 
Sex          
  Male Reference  Reference   
  Female 1.54 (1.41, 1.67) 1.53 (1.40, 1.66) 
Race/Ethnicity          
  Non-Hispanic White Reference  Reference   
  Non-Hispanic Black 0.77 (0.64, 0.91) 0.90 (0.74, 1.07) 
  Hispanic 1.37 (1.16, 1.61) 1.24 (1.04, 1.47) 
  Others 3.29 (2.99, 3.60) 2.26 (2.00, 2.53) 
Marital Status          
  Married Reference  Reference   
  Single 0.76 (0.70, 0.83) 0.77 (0.70, 0.84) 
Geographic Characteristics         
Region          
  North East Reference  Reference   
  South 0.80 (0.70, 0.91) 1.21 (1.04, 1.41) 
  North Central 0.66 (0.55, 0.79) 0.75 (0.62, 0.89) 
  West 1.49 (1.32, 1.66) 1.34 (1.17, 1.52) 
Urban/Rural 
Residence  
       
  Big Metro Reference  Reference   
  Metro 0.78 (0.71, 0.86) 0.95 (0.86, 1.05) 
  Urban 0.80 (0.66, 0.95) 1.14 (0.94, 1.36) 
  Less Urban 0.62 (0.53, 0.72) 1.02 (0.85, 1.21) 
  Rural 0.39 (0.26, 0.58) 0.68 (0.44, 1.01) 
Socioeconomic Status         
Census Tract % of Non-High School Degree        
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  00-05% Reference  Reference   
  05-10% 0.75 (0.66, 0.85) 0.85 (0.75, 0.96) 
  10-20% 0.65 (0.58, 0.73) 0.84 (0.72, 0.96) 
  20-100% 0.75 (0.66, 0.84) 0.94 (0.79, 1.10) 
Census Tract % below poverty        
  00-05% Reference  Reference   
  05-10% 0.87 (0.76, 0.98) 0.95 (0.83, 1.07) 
  10-20% 0.78 (0.69, 0.87) 0.96 (0.82, 1.11) 
  20-100% 0.71 (0.63, 0.80) 1.00 (0.81, 1.21) 
Census Tract Household Median Income        
  4th Quartile Reference  Reference   
  3rd Quartile 0.76 (0.69, 0.85) 0.95 (0.84, 1.07) 
  2nd Quartile 0.66 (0.59, 0.74) 0.93 (0.79, 1.09) 
  1st Quartile 0.61 (0.54, 0.68) 0.87 (0.71, 1.06) 
Cost-Sharing Support Status         
Receipt of Low Income Subsidy (LIS)        
  Full LIS Reference  Reference   
  No LIS 0.87 (0.79, 0.94) 0.90 (0.81, 1.00) 
  Partial LIS 0.65 (0.51, 0.81) 0.83 (0.65, 1.03) 
Health Status         
Klabunde adapted Comorbidity Indexb        
  0 Reference  Reference   
  1 0.83 (0.75, 0.91) 0.94 (0.85, 1.02) 
  2+ 0.64 (0.57, 0.71) 0.83 (0.74, 0.92) 
Predicted DSc         
  Good 0-2 Reference  Reference   
  Poor 3-4 0.59 (0.49, 0.71) 0.67 (0.55, 0.79) 
Tumor-Related Characteristics         
Year of Diagnosis        
  2007 Reference  Reference   
  2008 0.81 (0.68, 0.96) 0.82 (0.68, 0.97) 
  2009 0.86 (0.72, 1.01) 0.86 (0.72, 1.02) 
  2010 0.76 (0.63, 0.90) 0.76 (0.63, 0.90) 
  2011 0.78 (0.65, 0.93) 0.75 (0.63, 0.89) 
  2012 0.74 (0.61, 0.87) 0.72 (0.60, 0.86) 
  2013 0.86 (0.72, 1.00) 0.87 (0.73, 1.02) 
Quarter of Year of Diagnosis        
  Q1 Reference  Reference   
  Q2 1.02 (0.90, 1.15) 1.00 (0.88, 1.12) 
  Q3 1.12 (0.99, 1.25) 1.06 (0.94, 1.18) 
  Q4 1.11 (0.99, 1.25) 1.06 (0.94, 1.18) 
Cancer Stage          
  Stage IIIB Reference  Reference   
  Stage IV 1.23 (1.12, 1.36) 1.26 (1.14, 1.39) 
Cancer Histology        
  Adenocarcinoma 2.35 (2.13, 2.57) 1.82 (1.61, 2.06) 
  Squamous 0.43 (0.38, 0.49) 0.88 (0.74, 1.03) 
  Large Cell 0.69 (0.50, 0.95) 1.15 (0.82, 1.60) 
Radiation as First Course of Therapy         
  No Reference  Reference   
  Yes 0.83 (0.76, 0.90) 0.88 (0.81, 0.96) 
Surgery as First Course of Therapy        
  No Reference  Reference   
  Yes 0.49 (0.38, 0.62) 0.32 (0.24, 0.40) 
Institutional Affiliation         
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Receipt of Care from Hospital Affiliation with        
  NCI Designation 1.70 (1.55, 1.87) 1.08 (0.96, 1.20) 
  ECOG 1.04 (0.95, 1.14) 1.12 (1.01, 1.24) 
  Teaching Hospital 1.39 (1.26, 1.52) 1.25 (1.12, 1.39) 
  Major Affiliation with Medical School 1.36 (1.25, 1.47) 1.14 (1.02, 1.26) 
a Modified Poisson Regression196 were applied to estimate the crude and adjusted effects of key sociodemographic, 
and health system factors. Bivariate analysis was used to evaluate the unadjusted effect of a single independent 
variable on the outcome. multivariate models were used to estimate adjusted while controlling for all key variables 
listed in the table.  
b Klabunde's adaptation of the Charlson comorbidity index191 was used to assess cancer-specific Comorbidity Index 
with Charlson comorbidity index included comorbidities other than cancer.  
c Predicted disability status (DS)192 was calculated based on a validated claims-based algorithm developed by 
Davidoff AJ et al. This could serve as a proxy measure of performance status (PS), among older cancer population.  
Abbreviation: 95% CI, 95% Confidence Interval; aRR: adjusted Relative risk; cRR: crude Relative Risk; DS, 
Disability Status; ECOG: the Eastern Cooperative Oncology Group; LIS: Low Income Subsidy; NSCLC: Non-
Small Cell Lung Cancer. 
 
In another examination of key factors associated with Part D use, we excluded those did 
not receive any drug-based treatment within the year of diagnosis (i.e., restricting to treated 
population) (Table 4.2B) because the never-treated group differed from other treated groups, 
particularly in their health and socioeconomic status. Specifically, in this analysis, we compared 
patients using Part D drugs with those only using Part B drugs within the year of diagnosis.  
We found the results were consistent between models including and excluding patients 
who did not receive drug-based treatment. However, comorbidity and hospital affiliations were 
no longer statistically when excluding patients who did not receive treatment. Importantly, the 
association with receipt of Part D treatments in the 12 months since diagnosis became stronger 
among patients aged over 80 years at diagnosis (aRR: 1.91 [95% CI: 1.72-2.12]) and among LIS 
groups (aRRpartial LIS: 0.82 [95% CI: 0.66-1.00]; aRRno LIS: 0.78 [95% CI: 0.71-0.86]) in models 
that excluded untreated patients. One thing worth noting was the predicted disability status; the 
direction of association appeared to change. In other words, among treated population, patients 
with poor predicted disability status appeared to be more likely to receive Part D treatment for 
the advanced NSCLC. However, the effect became not significant after controlling other factors 
(aRR: 1.10 [95% CI: 0.95-1.27]). 
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Table 4.2B Association between Key Factors and Part D Drug Treatment Use for 
Advanced Non-Small Cell Lung Cancer, among Drug Treated Patients. (N=9,942)a 
    cRRa 95% CI aRRa 95% CI 
Demographic Characteristics         
Age           
  65-69 Reference  Reference   
  70-74 1.00 (0.89, 1.13) 0.98 (0.87, 1.09) 
  75-79 1.11 (1.18, 1.50) 1.24 (1.11, 1.39) 
  80+ 2.32 (2.09, 2.57) 1.91 (1.72, 2.12) 
Sex          
  Male Reference  Reference   
  Female 1.57 (1.44, 1.70) 1.46 (1.35, 1.59) 
Race/Ethnicity          
  Non-Hispanic White Reference  Reference   
  Non-Hispanic Black 0.95 (0.81, 1.12) 0.97 (0.74, 1.07) 
  Hispanic 1.48 (1.27, 1.73) 1.22 (1.04, 1.47) 
  Others 3.02 (2.79, 3.28) 1.95 (1.75, 2.16) 
Marital Status          
  Married Reference  Reference   
  Single 1.04 (0.96, 1.12) 0.92 (0.85, 1.00) 
Geographic Characteristics         
Region          
  North East Reference  Reference   
  South 0.86 (0.75, 0.97) 1.19 (1.03, 1.37) 
  North Central 0.70 (0.59, 0.83) 0.83 (0.70, 0.98) 
  West 1.51 (1.36, 1.68) 1.30 (1.15, 1.47) 
Urban/Rural 
Residence  
       
  Big Metro Reference  Reference   
  Metro 0.81 (0.74, 0.89) 0.99 (0.91, 1.08) 
  Urban 0.78 (0.66, 0.93) 1.06 (0.89, 1.26) 
  Less Urban 0.66 (0.57, 0.77) 1.06 (0.90, 1.25) 
  Rural 0.40 (0.27, 0.56) 0.65 (0.44, 0.96) 
Socioeconomic Status         
Census Tract % of Non-High School Degree        
  00-05% Reference  Reference   
  05-10% 0.80 (0.71, 0.90) 0.86 (0.77, 0.97) 
  10-20% 0.76 (0.68, 0.85) 0.84 (0.74, 0.96) 
  20-100% 0.91 (0.81, 1.01) 0.90 (0.77, 1.04) 
Census Tract % below poverty        
  00-05% Reference  Reference   
  05-10% 0.94 (0.84, 1.05) 0.97 (0.87, 1.09) 
  10-20% 0.90 (0.80, 1.00) 0.98 (0.85, 1.21) 
  20-100% 0.90 (0.81, 1.01) 0.97 (0.81, 1.16) 
Census Tract Household Median Income        
  4th Quartile Reference  Reference   
  3rd Quartile 0.84 (0.76, 0.93) 0.98 (0.87, 1.10) 
  2nd Quartile 0.75 (0.68, 0.84) 0.97 (0.84, 1.13) 
  1st Quartile 0.79 (0.70, 0.88) 1.01 (0.83, 1.21) 
Cost-Sharing Support Status         
Receipt of Low Income Subsidy (LIS)        
  Full LIS Reference  Reference   
  No LIS 0.65 (0.60, 0.70) 0.78 (0.71, 0.86) 
  Partial LIS 0.61 (0.49, 0.75) 0.82 (0.66, 1.00) 
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Health Status         
Klabunde adapted Comorbidity Indexb        
  0 Reference  Reference   
  1 0.88 (0.80, 0.96) 0.94 (0.86, 1.02) 
  2+ 0.86 (0.78, 0.95) 0.92 (0.84, 1.02) 
Predicted DSc         
  Good 0-2 Reference  Reference   
  Poor 3-4 1.36 (1.15, 1.59) 1.10 (0.95, 1.27) 
Tumor-Related Characteristics         
Year of Diagnosis        
  2007 Reference  Reference   
  2008 0.81 (0.69, 0.94) 0.84 (0.72, 0.98) 
  2009 0.84 (0.71, 0.98) 0.82 (0.70, 0.95) 
  2010 0.76 (0.64, 0.89) 0.73 (0.62, 0.86) 
  2011 0.75 (0.64, 0.88) 0.70 (0.60, 0.82) 
  2012 0.70 (0.60, 0.82) 0.65 (0.56, 0.76) 
  2013 0.80 (0.69, 0.93) 0.75 (0.64, 0.87) 
Quarter of Year of Diagnosis        
  Q1 Reference  Reference   
  Q2 0.99 (0.88, 1.11) 0.97 (0.87, 1.08) 
  Q3 1.06 (0.95, 1.19) 0.99 (0.90, 1.10) 
  Q4 1.08 (0.97, 1.21) 1.02 (0.92, 1.13) 
Cancer Stage          
  Stage IIIB Reference  Reference   
  Stage IV 1.30 (1.19, 1.43) 1.23 (1.14, 1.35) 
Cancer Histology        
  Adenocarcinoma 2.12 (1.95, 2.32) 1.69 (1.50, 1.90) 
  Squamous 0.46 (0.41, 0.52) 0.86 (0.74, 1.01) 
  Large Cell 0.69 (0.51, 0.94) 1.07 (0.79, 1.46) 
Radiation as First Course of Therapy         
  No Reference  Reference   
  Yes 0.63 (0.58, 0.68) 0.79 (0.73, 0.85) 
Surgery as First Course of Therapy        
  No Reference  Reference   
  Yes 0.50 (0.40, 0.63) 0.51 (0.41, 0.65) 
Institutional Affiliation         
Receipt of Care from Hospital Affiliation with        
  NCI Designation 1.25 (1.14, 1.36) 1.03 (0.93, 1.14) 
  ECOG 0.89 (0.81, 0.97) 1.03 (0.93, 1.13) 
  Teaching Hospital 1.12 (1.03, 1.23) 1.09 (0.99, 1.20) 
  Major Affiliation with Medical School 1.13 (1.05, 1.22) 1.14 (1.04, 1.26) 
a Modified Poisson Regression196 were applied to estimate the crude and adjusted effects of key sociodemographic, 
and health system factors. Bivariate analysis was used to evaluate the unadjusted effect of a single independent 
variable on the outcome. multivariate models were used to estimate adjusted while controlling for all key variables 
listed in the table.  
b Klabunde's adaptation of the Charlson comorbidity index191 was used to assess cancer-specific Comorbidity Index 
with Charlson comorbidity index included comorbidities other than cancer.  
c Predicted disability status (DS)192 was calculated based on a validated claims-based algorithm developed by 
Davidoff AJ et al. This could serve as a proxy measure of performance status (PS), among older cancer population.  
Abbreviation: 95% CI, 95% Confidence Interval; aRR: adjusted Relative risk; cRR: crude Relative Risk; DS, 
Disability Status; ECOG: the Eastern Cooperative Oncology Group; LIS: Low Income Subsidy; NSCLC: Non-





4.3 AIM 3 – Evaluate the effect of low-income subsidies for Medicare Part D medications on 
treatment initiation among patients with advanced non-small cell lung cancer (NSCLC) 
from 2007 to 2014. 
In this aim, we hypothesized that: 1) for medications covered under Part D, due to the 
higher cost-sharing required for patients who do not receive low income subsidies, time to 
initiation is shorter among patients with (full or partial) low-income subsidies as compared to 
those without; 2) for medications covered under Part B, due to the availability of supplemental 
insurance coverage for reducing or eliminating out-of-pocket costs for most Medicare enrollees, 
there is no difference in the time to initiation among patients with low-income subsidies as 
compared to those without. 
 
Derived from the final eligible cohort of advanced NSCLC patients from Aim 2 
(N=19,746), we further grouped the patients into three subsidy groups based on their low-income 
subsidy status at time of diagnosis. As a result, we identified 6,989 patients with Full subsidy, 
11,778 with no subsidy, and 989 with partial subsidy (Figure 4.12). 
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Figure 4.12 Flow chart of the study population selection 
 
Abbreviation: ESRD, end-stage renal disease; LIS, low-income subsidy; NSCLC, non-small cell lung cancer. 
 
In the examination of patient baseline characteristics (Table 4.3, Pre-IPTW) we found 
that patients without any LIS (i.e., non-LIS) were older than those with partial or full LIS (aged 
80 or over: 23.1% for full LIS vs. 28.7% for non-LIS vs. 21.1% for partial LIS, p<0.0001) 
Compared to those with full subsidy, patients without full subsidy (i.e., non-LIS or partial LIS) 
consisted of more women (49.4% for full LIS vs. 51.4% for non-LIS vs. 50.4% for partial LIS, 
p<0.0001) and Non-Hispanic Whites (52.7% for full LIS vs. 89.4% for non-LIS vs. 73.2% for 
partial LIS, p<0.0001). Most of the population lived in the West or South regions (79.5% for full 
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LIS vs. 61.1% for non-LIS vs. 67.0% for partial LIS, p<0.0001) and Big Metro/Metro areas 
(80.4% for full LIS vs. 81.1% for non-LIS vs. 73.2% for partial LIS, p<0.0001). In terms of 
socioeconomic status, patients with any subsidy (i.e., full or partial LIS groups) were more likely 
to live in an area with lower median incomes (Census Tract Household Median Income at first 
two quartiles: 65.7% for full LIS, 73.4% for partial LIS vs. 39.6% for non-LIS, p<0.0001) and 
with lower education level at Census Tract level (Census Tract of more than 20% without high 
school degree: 50.1% for full LIS, 38.7% for partial LIS vs. 18.5% for non-LIS, p<0.0001), as 
compared to those without any subsidy. In terms of health status, more patients with full subsidy 
were in poorer status based on comorbidity index (2+: 35.6% for full LIS vs. 30.7% for partial 
LIS vs. 24.9% for non-LIS, p<0.0001) and predicted disability status (Poor 3-4: 17.1% for full 
LIS vs. 4.5% for non-LIS vs. 5.7% for partial LIS p<0.0001). Across groups, around 70% were 








Table 4.3 Baseline Patient Characteristics before and after Inverse Probability Treatment Weight (IPTW)  
  Pre-IPTW Post-IPTWc 




Partial LIS at 
diagnosis 




Partial LIS at 
diagnosis 
 
  6979  11778  989   6911  12046  948   
  N % N % N % p-value N % N % N % p-value 
Age        <.0001             0.2707 
  65-69 1855 26.6% 2583 21.9% 295 29.8%  1599 23.1% 2890 24.0% 240 25.3%   
  70-74 1960 28.1% 3149 26.7% 266 26.9%  1878 27.2% 3355 27.9% 265 28.0%   
  75-79 1552 22.2% 2662 22.6% 219 22.1%  1545 22.4% 2678 22.2% 209 22.0%   
  80+ 1612 23.1% 3384 28.7% 209 21.1%  1889 27.3% 3124 25.9% 234 24.7%   
Sex         0.0291             0.8979 
  Male 3531 50.6% 5723 48.6% 491 49.6%  3413 49.4% 5977 49.6% 464 48.9%   
  Female 3448 49.4% 6055 51.4% 498 50.4%  3498 50.6% 6070 50.4% 484 51.1%   
Race/Ethnicity       <.0001             0.0035*** 
  Non-Hispanic White 3677 52.7% 10528 89.4% 724 73.2%  5183 75.0% 8857 73.5% 705 74.4%   
  Non-Hispanic Black 1339 19.2% 518 4.4% 168 17.0%  723 10.5% 1243 10.3% 91 9.6%   
  Hispanic 795 11.4% 312 2.6% 44 4.4%  410 5.9% 683 5.7% 62 6.5%   
  Others 1168 16.7% 420 3.6% 53 5.4%  595 8.6% 1264 10.5% 90 9.5%   
Marital Status       <.0001             0.5321 
  Married 2126 30.5% 6440 54.7% 337 34.1%  3019 43.7% 5193 43.1% 386 40.7%   
  Single 4578 65.6% 4905 41.6% 609 61.6%  3625 52.5% 6393 53.1% 523 55.2%   
  Unknown 275 3.9% 433 3.7% 43 4.3%  267 3.9% 461 3.8% 39 4.1%   
Region        <.0001             0.0007*** 
  North East 821 11.8% 2763 23.5% 181 18.3%  1492 21.6% 2336 19.4% 169 17.8%   
  South 2230 32.0% 3054 25.9% 462 46.7%  1947 28.2% 3369 28.0% 302 31.9%   
  North Central 610 8.7% 1816 15.4% 145 14.7%  855 12.4% 1604 13.3% 121 12.8%   
  West 3318 47.5% 4145 35.2% 201 20.3%  2618 37.9% 4737 39.3% 356 37.6%   
Urban/Rural Residence       <.0001            0.7708 
 Big Metro 3717 53.3% 6018 51.1% 453 45.8%  3439 49.8% 6119 50.8% 463 48.8%   
 Metro 1889 27.1% 3534 30.0% 271 27.4%  2077 30.1% 3539 29.4% 284 30.0%   
 Urban 387 5.5% 777 6.6% 63 6.4%  473 6.8% 781 6.5% 71 7.5%   
 Less Urban 794 11.4% 1168 9.9% 163 16.5%  749 10.8% 1292 10.7% 101 10.7%   
 Rural 192 2.8% 281 2.4% 39 3.9%  173 2.5% 315 2.6% 28 3.0%   
Census Tract % of Non-High School Degree       <.0001       0.4100 
 00-05% 454 6.5% 2579 21.9% 81 8.2%  1031 14.9% 1856 15.4% 122 12.9%  
 05-10% 975 14.0% 3475 29.5% 171 17.3%  1655 23.9% 2792 23.2% 226 23.8%  
 10-20% 2054 29.4% 3545 30.1% 354 35.8%  2099 30.4% 3665 30.4% 303 32.0%  
 20-100% 3496 50.1% 2179 18.5% 383 38.7%  2126 30.8% 3734 31.0% 297 31.3%  
Census Tract % below poverty       <.0001       0.2980 
 00-05% 562 8.1% 2645 22.5% 96 9.7%  1186 17.2% 1968 16.3% 145 15.3%  
 05-10% 1033 14.8% 3442 29.2% 197 19.9%  1586 22.9% 2833 23.5% 208 21.9%  
 10-20% 2171 31.1% 3582 30.4% 356 36.0%  2152 31.1% 3789 31.5% 294 31.0%  
 20-100% 3213 46.0% 2109 17.9% 340 34.4%  1988 28.8% 3456 28.7% 301 31.8%  
Census Tract Household Median Income       <.0001       0.2441 
 1st quartile 2791 40.0% 1811 15.4% 334 33.8%  1729 25.0% 3004 24.9% 254 26.8%  
 2nd quartile 1793 25.7% 2851 24.2% 293 29.6%  1763 25.5% 3094 25.7% 254 26.8%  








 4th quartile 1002 14.4% 3794 32.2% 141 14.3%  1755 25.4% 2971 24.7% 203 21.4%  
Comorbidity Indexa       <.0001             0.5093 
 0 2470 35.4% 5320 45.2% 404 40.8%  2811 40.7% 4894 40.6% 397 41.9%  
 1 2025 29.0% 3526 29.9% 281 28.4%  2022 29.3% 3538 29.4% 292 30.8%  
 2+ 2484 35.6% 2932 24.9% 304 30.7%  2079 30.1% 3614 30.0% 259 27.3%  
Predicted DSb             <.0001          0.6185 
 Good 0-2 5788 82.9% 11243 95.5% 933 94.3%  6280 90.9% 10929 90.7% 869 91.7%  
 Poor 3-4 1191 17.1% 535 4.5% 56 5.7%  631 9.1% 1117 9.3% 79 8.3%  
Year of Diagnosis       <.0001       0.9829 
 2007 537 7.7% 837 7.1% 91 9.2%  487 7.0% 879 7.3% 69 7.3%  
 2008 1048 15.0% 1711 14.5% 179 18.1%  994 14.4% 1772 14.7% 145 15.3%  
 2009 1069 15.3% 1745 14.8% 162 16.4%  1033 14.9% 1843 15.3% 137 14.5%  
 2010 1088 15.6% 1656 14.1% 156 15.8%  1019 14.7% 1760 14.6% 145 15.3%  
 2011 1061 15.2% 1620 13.8% 154 15.6%  985 14.3% 1712 14.2% 141 14.9%  
 2012 1089 15.6% 1974 16.8% 135 13.7%  1139 16.5% 1965 16.3% 155 16.4%  
 2013 1087 15.6% 2235 19.0% 112 11.3%  1254 18.1% 2116 17.6% 156 16.5%  
Quarter of Year of Diagnosis       0.8197       0.8999 
 Q1 1644 23.6% 2793 23.7% 245 24.8%  1643 23.8% 2889 24.0% 236 24.9%  
 Q2 1585 22.7% 2692 22.9% 234 23.7%  1576 22.8% 2716 22.5% 221 23.3%  
 Q3 1933 27.7% 3175 27.0% 255 25.8%  1917 27.7% 3311 27.5% 243 25.6%  
 Q4 1817 26.0% 3118 26.5% 255 25.8%  1776 25.7% 3130 26.0% 248 26.2%  
Cancer Stage       0.0063       0.2537 
 Stage IIIB 2033 29.1% 3182 27.0% 284 28.7%  1966 28.4% 3293 27.3% 266 28.1%  
 Stage IV 4946 70.9% 8596 73.0% 705 71.3%  4945 71.6% 8754 72.7% 682 71.9%  
Cancer Histology               
 Adenocarcinoma 3361 48.2% 6390 54.3% 456 46.1% <.0001 3510 50.8% 6166 51.2% 487 51.4% 0.8533 
 Squamous 2100 30.1% 2840 24.1% 301 30.4% <.0001 1843 26.7% 3206 26.6% 257 27.1% 0.9505 
 Large cell 170 2.4% 304 2.6% 25 2.5% 0.8290 174 2.5% 298 2.5% 24 2.5% 0.9788 
 Others 1348 19.3% 2244 19.1% 207 20.9% 0.3481 1384 20.0% 2377 19.7% 180 19.0% 0.7361 
Radiation as First Course of Therapy 2534 36.3% 5168 43.9% 414 41.9% <.0001 2898 41.9% 4953 41.1% 375 39.6% 0.4520 
Surgery as First Course of Therapy 339 4.9% 871 7.4% 54 5.5% <.0001 439 6.4% 762 6.3% 64 6.8% 0.6238 
Receipt of Care from Hospital Affiliation with                     
 NCI Designation 910 13.0% 2173 18.4% 112 11.3% <.0001 1205 17.4% 2035 16.9% 153 16.1% 0.4586 
 ECOG 1266 18.1% 3471 29.5% 260 26.3% <.0001 1819 26.3% 3125 25.9% 215 22.7% 0.0571 
 Teaching Hospital 4441 63.6% 8052 68.4% 641 64.8% <.0001 4617 66.8% 8076 67.0% 616 65.0% 0.4183 
 Major Affiliation with Medical 
School 
2291 32.8% 4820 40.9% 393 39.7% <.0001 2679 38.8% 4648 38.6% 350 36.9% 0.5390 
a Klabunde's adaptation of the Charlson comorbidity index191 was used to assess cancer-specific Comorbidity Index with Charlson comorbidity index included 
comorbidities other than cancer.  
b Predicted disability status (DS)192 was calculated based on a validated claims-based algorithm developed by Davidoff AJ et al. This could serve as a proxy 
measure of performance status (PS), among older cancer population.  
c The standardized mean differences197 post IPTW were all below 0.10 between groups (Non-LIS vs Full LIS; Partial LIS vs LIS), suggesting negligible 
imbalance in patient baseline characteristics between groups for the analysis. (Appendix Table 4.5).  
Abbreviation: DS, Disability Status; ECOG: the Eastern Cooperative Oncology Group; LIS: Low Income Subsidy; NCI, the National Cancer Institute; NSCLC: 
Non-Small Cell Lung Cancer. 
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During the 12-month period after being diagnosed with advanced NSCLC, around 10% 
of patients initiated Part D treatments (11.4% for full LIS, 9.9% for non-LIS, 7.4% for partial 
LIS) (Figure 4.13). The time to initiate Part D treatments was shorter among patients with full-
LIS as compared to those with partial LIS or with no subsidy. The mean time from diagnosis to 
initiation of orally-administered targeted therapies was 10.8 (SD: 0.04) months for full LIS, 11.1 
(SD: 0.03) months for non-LIS, and 11.3 (SD: 0.08) months for partial LIS, respectively 
(p<0.0001).  
Figure 4.13 Product-Limit Failurea Curves for Time-to-Initiate Part D Treatments by Low-
Income Subsidy (LIS) Status  
 
a “Failure” indicates the outcome of interest, which is the initiation of Part D treatments. 
Abbreviation: LIS, low-income subsidy; F as full LIS, N as non-LIS, and P as partial LIS. 
 
Further in the examination through Cox models, we found that, as compared to patients 
with full subsidy, those without full subsidy (i.e., non-LIS, partial LIS) were less likely to initiate 
 
105 
Part D treatments, particularly among the partial LIS group (Table 4.4). The effects remain even 
after controlling for other factors or applying IPTW to reduce the imbalance among groups (i.e., 
Non-LIS vs. Full LIS: HRadjusted: 0.87 (95% CI: 0.78-0.98); HRIPTW:0.87 (95% CI:0.79-0.95); 
Partial LIS vs. Full LIS: HRadjusted: 0.80 (95% CI:0.63-1.02); HRIPTW: 0.77 (95% CI:0.62-0.97)).  
Table 4.4 Effect of Low-Income Subsidy on Time from Diagnosis to Initiation of Part D 
Treatments 
 Model 1 
No IPTW, Crude 
Model 2 
No IPTW, Adjusted 
Model 3 
IPTW weighted 
 HR 95% CI HR 95% CI HR 95% CI 
Full LIS 1.00 Reference 1.00 Reference 1.00 Reference 
Partial LIS 0.61 (0.48-0.77) 0.80 (0.63-1.02) 0.77 (0.62-0.97) 
Non-LIS 0.79       (0.72-0.86)                        0.87 (0.78-0.98) 0.87 (0.79-0.95) 
Abbreviation: HR, hazard ratio; CI, confidence interval; IPTW, inverse probability of treatment weight; LIS, low-
income subsidy. 
 
Uptake of Part B drugs differed in important ways from what was observed for Part D 
drugs. As expected, Part B drugs were used more often by patients diagnosed with advanced 
NCSLC over our study period: 35.0% of patients initiated Part B treatment for full LIS, 51.6% 
for non-LIS, 40.6% for partial LIS during the 12-month period after being diagnosed with 
advanced NSCLC (Figure 4.14). The time to initiate Part B treatments were shorter among the 
non-LIS group as compared to those with any subsidy (i.e., partial LIS or full LIS); the mean 
time to initiation was 7.0 (SD: 0.04) months for non-LIS, 7.9 (SD: 0.15) months for partial LIS, 




Figure 4.14 Product-Limit Failurea Curves for Time-to-Initiate Part B Treatments by Low-
Income Subsidy (LIS) Status  
 
a “Failure” indicates the outcome of interest, which is the initiation of Part B treatments. 
Abbreviation: LIS, low-income subsidy; F as full LIS, N as non-LIS, and P as partial LIS. 
 
When considering covariate adjustment in the Cox model, we found that patients without 
any subsidy were more likely to initiate Part B treatments compared to those with full subsidy or 
partial subsidy (e.g., Non-LIS vs. Partial LIS: HRadjusted: 1.34 (95% CI: 1.21-1.50); HRIPTW: 1.34 
(95% CI: 1.21-1.49); Non-LIS vs. Full LIS: HRadjusted: 1.42 (95% CI: 1.34-1.50); HRIPTW: 1.41 
(95% CI: 1.35-1.48)) (Table 4.5). There was no difference in the Part B drug use between Partial 
LIS and Full LIS groups (Partial LIS vs. Full LIS: HRadjusted: 1.05 (95% CI: 0.95-1.17); HRIPTW: 




Table 4.5 Effect of Low-Income Subsidy on Time from Diagnosis to Initiation of Part B 
Treatments 
 Model 1 
No IPTW, Crude 
Model 2 
No IPTW, Adjusted 
Model 3 
IPTW weighted 
 HR 95% CI HR 95% CI HR 95% CI 
Full LIS 1.00 Reference 1.00 Reference 1.00 Reference 
Partial LIS 1.18 (1.06-1.31) 1.05 (0.95-1.17) 1.05 (0.94-1.17) 
Non-LIS 1.55       (1.48-1.63)                        1.42 (1.34-1.50) 1.41 (1.35-1.48) 




CHAPTER FIVE: DISCUSSION 
 
5.1 AIM 1 
 In Aim 1, we examined the changes in drug-specific prices for Part D medications 
approved for advanced NSCLC. We found higher entry prices at FDA approval in Part D 
advanced NSCLC drugs while older drugs also experienced considerable price hike by more than 
45% from approval. In addition, drug prices remained high even when new drugs were approved 
to provide more treatment options for advanced NSCLC.  
 Our findings are consistent with the growing evidence on pricing of anticancer drugs in 
recent years.198–201 An analysis of changes in reimbursements from the year of product launch for 
18 orally administered anticancer drugs indicated a substantial increase in the monthly drug 
spending during the first year on the market; the mean spending ranged from $1,869 in 2000 to 
$11,325 in 2014.198 In addition, most existing therapies have had substantial price increases since 
product launch.198 In another examination on the trends in post-launch prices for orally 
administered anticancer drugs, Bennette et al also found that inflation-adjusted per patient 
monthly drug prices increased 5 percent each year between 2007 and 2013 after accounting for 
other factors related to price increases.199 Our results point to this trend continuing. A separate 
study specifically focusing on targeted oral anticancer medications under Medicare even found 
an annually 12% increase in the mean drug prices.200  
The study by Bennete et al suggested a general 10% increase in the price of oral 
anticancer drugs after supplemental US Food and Drug Administration approvals that expand the
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 patient population for treatment.199 Our findings are lower, possibly because the subsequent 
approvals for the advanced NSCLC drugs in our study generally reduce the number of eligible 
patients rather than expand the drug indications. However, one drug is an exception, gefitinib. 
Gefitinib is the oldest tyrosine kinase inhibitor approved for advanced NSCLC. The use of 
gefitinib was restricted since 2005194 due to its failure to show improved outcomes for patients 
with lung cancer in clinical studies and the drug company voluntarily withdrew the drug in the 
U.S. in 2011(effective in 2012).195 The drug came back in 2015 with new evidence of its role in 
the treatment of a smaller but more specific patient population with EGFR mutations.202 The 
price, in return, rose by almost 250%, from $2,296/month before withdrawal to $7,898/month in 
2015, which is comparable to other EGFR-targeted agents at the time. 
Notably, we observe minimal differences in the prices set for different dosage forms of 
the same drug covered under Part D. Drugs with lower doses priced at comparably high levels as 
the same drugs with higher doses. For example, there is less than $20 difference in the price 
between afatinib 20mg and 40mg in 2017, $7,684 and $7,699, respectively. An identical price, 
over $14,000/month, was even set for osimertinib in both 40mg and 80mg formulations since its 
approval. 
These findings could suggest that current pricing strategies for novel oral advanced 
NSCLC drugs appears to follow the dominant price within the same therapeutic class. It is also 
possible that newer drugs are better than older agents and that the manufacturers set the drug 
prices according to the “value” the drugs could provide. However, in the context of Medicare 
Part D there are no current requirements that pricing reflect clinical benefit or other measures of 
“value.” The definition of value of treatment varies across stakeholders. For example, for 
patients, the most important elements of treatment value might be effectiveness and side effects 
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at an individual level. For insurance plans, they could place more emphasis on effects at the 
population level. For manufactures, value may be product-specific profits and drug market share.  
Our findings related to drug prices also reveal a lack of competitive pressure in the oral 
anticancer drug market. This might be contributed by the fact that cancer drugs are one of the six 
protected classes to cover under Medicare Part D (i.e., a Part D formulary should cover all or 
substantially all drugs in the protected therapeutic categories24), which aims to ensure patient 
access to their vital medications. By requiring all plans to offer anticancer medications, 
regardless of clinical benefit and cost, this may reduce plan negotiation power with 
manufacturers (and accordingly lower rebates / result in higher prices for these drugs9). The 
federal government is also prohibited from negotiating drug prices in the Part D program.9 Given 
patent protection, orally-administered anticancer medications are expected to face limited price 
competition from generics.10,71,203 Together, this leads to the high Part D cancer drug prices in 
the U.S. Further policy improvement to encourage the competitiveness of the marketplace, 
enhance price negotiation by governmental payers, and promote development of drug value 
assessment tools are necessary as part of the solution of high drug prices in cancer care.  
 We also examined formulary structure and the use of utilization management tools for 
Part D medications approved for advanced NSCLC. In this aspect, we found Part D coverage for 
advanced NSCLC drugs has improved in recent years; since 2015, almost all plans provide 
coverage for all advanced NSCLC drugs on the market. However, accessibility to available drug 
treatments remains a concern as utilization management tools were applied by most of the Part D 
plans and across treatment options (e.g., prior authorization and quantity limits). Further research 
to determine whether and how these utilization management tools affect patient timely access to 
drug treatment for advanced NSCLC is needed. 
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Although cancer drugs are one of the six protected classes in Medicare, we observed a 
lack of comprehensive coverage of all drugs during the first few years for our study period. This 
could be related to modifications of rules related to the treatment of the protected drug classes 
since the Part D programs went into effect, 24,204–206 possibly leading to fluctuations in benefit 
design. For example, in 2010 Congress made another modification to the so called “protected 
classes”, seeking to review the existing six protected classes and to examine whether or not an 
exceptions process to the protected class rule was necessary. This could potentially increase the 
uncertainty in plan’s decision in coverage for 2011. In addition, a coverage drop observed in 
2011 could be the result of regulations issued by CMS, which intended to eliminate duplicative 
plan offerings and plans with low enrollment or from mergers among plan sponsors207 or the 
withdrawal of gefitinib due to its failure in clinical trials and voluntary withdrawal by the drug 
company195.  
Concerns over affordability also continue due to the high use of percentage-based 
coinsurance as well as specialty / top tiering. In both cases, the patient’s financial responsibility 
is a percentage of the point-of-sale drug price (around 33% in initial coverage phase, 25% in the 
coverage gap in 2019 with the Bipartisan Budget Act of 2018 and planned for 2020 with the 
Affordable Care Act, and 5% in catastrophic phase, for each drug treatment across year). We 
observed that the use of coinsurance was high but consistent with the use of specialty / top 
tiering, similar to findings from a study using 2014 Part D formulary data for documenting 
coverage for other orally-administered anticancer medications.40 Under the current Part D 
benefit, combined with the very-high per-fill prices for orally-administered anticancer drugs, 
expected out-of-pocket costs for advanced NSCLC patients with no low-income subsidy to 
initiate a single fill of a Part D treatment could be more than $3,300. As cancer regimens 
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increasingly consist of multiple drugs of different mechanisms (versus single-drug therapy) for 
potentially improved clinical benefits, our OOP estimates likely to understate the financial 
burden faced by patients.  
On the other hand, we found that the prices of Part B drugs have been relatively stable 
over the same period. Part B drugs include traditional chemotherapies, the primary treatment 
strategy before targeted therapies increased options for advanced NSCLC. Among Part B drugs, 
older agents had consistently low prices (below $100/month) with the availability of generics 
while those older drugs in new formulations were priced substantially higher (to up to $8,000 for 
a month of treatment). Notably, immunotherapy, a new therapeutic class coming on market since 
2015 for treating advanced NSCLC, is priced at more than ten thousand dollars per month, which 
is comparable to the price of orally administered targeted therapies under Part D. Since the 
average sales prices we used for Part B drugs already included rebates, we expect these drugs’ 
prices could be even higher with a lower level of rebate.  
Under the assumption of 20% coinsurance for part B (a typical amount on coinsurance 
asked for Part B services), the patient out-of-pocket cost for immunotherapies could also be 
several thousand a month. It is worth noting that more patients are eligible for immunotherapy 
than were ever for other targeted therapies covered under Part D (e.g., EGFR-targeted agents) 
and these immunotherapies are expensive, Part B drugs) could be the major cost driver in the 
near future. Importantly, when considering the financial impact and access for patients to Part B 
covered treatments, up to 85% of Part B enrollees have some form of supplemental insurance to 
cover their out-of-pocket spending.26,27 This means that the vast majority of Medicare 
beneficiaries prescribed and initiating a Part B treatment will have good coverage that requires 
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little to no out-of-pocket spending. This is in contrast to Part D out-of-pocket protections which 
are available to only about 30% of all Part D enrollees.  
Overall, our findings support our hypothesis on the drug-specific prices, formulary structure, and 
the use of utilization management tools for Part D medications approved for advanced NSCLC 
from 2009 to 2017. We found that over time prices of Part D advanced NSCLC drug have 
increased in excess of inflation; that over time these drugs are more likely to be placed on the 
highest drug tier or specialty drug tier within the formulary; that over time these drugs are more 
likely to require coinsurance (rather than copayments) for calculating patient cost-sharing; and 
that over time these are more likely to be subject to utilization management (e.g., step therapy, 
prior authorization, quantity limits). 
 
5.2 AIM 2 
 In Aim 2, the goal was to examine the trends in the utilization of advanced NSCLC 
medications by coverage source (i.e., Medicare Part B or Part D). Particularly, we were 
interested in identifying clinical, sociodemographic, and health system factors associated with 
the use of Part D treatments among patients diagnosed with advanced NSCLC. 
 In this study, we found that the use of advanced NSCLC medications covered under Part 
D within the first year of diagnosis has been stable at around 10% and with slight decreases over 
the study period (2007-2014). This is true despite the approval of three new drugs (i.e., 
crizotinib, afatinib, ceritinib) during the study period evaluated. Although Part D treatments are 
usually indicated for cancer with specific genetic mutations, the use remains lower than expected 
based on the prevalence of gene mutations in the population (currently estimated to be around 
15%)208–213 in the advanced NSCLC population over time. Specifically, erlotinib accounted for 
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more than 90% of all use. This could be because erlotinib is the oldest drug with longest time of 
availability and more evidence on its clinical benefits. It might also reflect the broader indication 
for erlotinib; erlotinib was initially approved for unselected advanced NSCLC as second-line 
treatment (2004) or (maintenance treatment (2010) platinum-based chemotherapy (in 2016 the 
indication was restricted to EGFR mutant advanced NSCLC). In addition, a much higher 
prevalence of EGFR mutation, as compared to that of ALK mutation, may also contribute to the 
results. We have not observed the use of ceritinib possibly because it was approved in the last 
year of our study period (April, 2014) and was granted approval as a second-line therapy for 
metastatic ALK-positive NSCLC or due to the time lapse between approval and actual treatment 
adoption. 
 At the same time, the use of medications covered under Part B has slightly increased at 
around 45% of the advanced NSCLC population despite having only one new drug approved 
over the study period. The treatment rate has been improved since the 1990s when only 22 to 
31% of patients with advanced NSCLC ever received chemotherapy.145,146,214 Among Part B 
treatments, platinum-based regimens with traditional chemotherapies were the mainstream first-
line treatments (almost 80% of the use). Particularly carboplatin-based regimens accounted for 
65-70% of all use over time. Guidelines recommend platinum-based chemotherapy as the 
principle of systemic therapy for advanced and metastatic NSCLC.51 In addition, most of the 
recommended systemic therapies consist of a platinum agent (i.e., carboplatin or cisplatin). This 
could be the reason why we observe this prevalent use of platinum-based regimens. Regimens 
with targeted therapy accounted for another 10-14% of all use. These findings are consistent with 
previous studies.121,215  
 
115 
 Among the advanced NSCLC population, we observed more than 40% of the patients did 
not ever receive treatment, neither Part B nor Part D treatments, within the 12 months after 
diagnosis. These patients had lower social support (i.e., not marries) and poorer socioeconomic 
status (e.g., lower household income and education level at census tract level, more full LIS 
patients). In addition, these patients appeared to have poorer health status (e.g., higher 
comorbidity score or poorer disability score). We found that these patients had shorter survival 
time as compared to those who received treatments; the mean follow-up time since diagnosis 
were 7.5 and 15.3 months, respectively. It is possible that these patients did not have enough 
financial support to receive treatments. Patients might also decide not to take active treatments 
because of the poor prognosis of the cancer that curative treatments would not improve 
symptoms or extend survival much among these patients with advanced cancer. In the U.S., 
Medicare defines the need for hospice care at the end of life (with life expectancy of less than 6 
months).216 The focus of medical care for these patients with terminal lung cancer instead is to 
relieve symptom burden and enhance the quality of remaining life.51,217 
 In the examination of identifying key factors of Part D drug use, we found that many 
patient demographics, health status, tumor-related characteristics, and cost-sharing support are 
important in the use of Part D drug treatments following diagnosis of advanced NSCLC. We 
observed greater possibility of filling Part D drug prescription among adenocarcinoma histology, 
female sex, and “Other” race/ethnicity that includes Asians. These findings are consistent with 
previous research which suggested these are the most important factor associated with genetic 
mutation in NSCLC as well as the response to biological targeted therapies.161,210,218 It is 
important to note that the choice between Part B and D treatments is likely to be driven by 
clinical details that are not available in the claims, such as EGFR. 
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 Higher socioeconomic status was associated with higher possibility of Part D drug use; 
however, the effects were generally not significant after adjustment for other characteristics. 
Importantly, low-income subsidy, a federal cost-sharing assistance program that helps patients 
pay for Medicare Part D prescription drug costs, was associated with greater use of Part D drug 
treatments. This is especially true for those receiving full LIS. The association became even 
stronger when we restricted the examination to only treated patients (i.e., excluding patients who 
never received any Part B or Part D drugs within the year of diagnosis).  
 Overall, our findings do not affirm what we expect on the utilization of advanced NSCLC 
medications by coverage source (i.e., Medicare Part B or Part D). Instead of increases, we 
observed the use of advanced NSCLC medications covered under Part D has slightly decreased 
over the study period. On the other hand, we found a slight increase in the use of advanced 
NSCLC medications covered under Part B over the same period. Percentage of patients without 
any treatment remained stable over the study period.  
 
5.3 AIM 3 
 In Aim 3, we examined the effect of low-income subsidies for Medicare Part D 
medications on treatment initiation among patients with advanced NSCLC. Through the 
propensity score adjustment and time-to-event analysis, we found that cost-sharing support for 
Part D treatment (e.g., novel targeted therapies) appears to be a key factor impacting the 
affordability and accessibility of advanced NSCLC care. 
For Part D treatments, patients without full subsidy (i.e., non-LIS, partial LIS) were less 
likely to initiate Part D treatments as compared with those with full LIS. This is particularly true 
among the partial LIS group, who are not poor enough to receive the full subsidy and still 
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responsible for substantial amount of out-of-pocket cost for using Part D treatments despite their 
subsidy eligibility. The high upfront cost for initiating a Part D treatment may be limiting patient 
access to novel therapies. For a Part D drug priced at $14,000 per month, patients without cost-
sharing support could be responsible for close to $3,000 for initiating the treatment (and 
approximately $700 out-of-pocket for the remaining monthly treatment even after they reach the 
catastrophic phase of coverage), whereas patients with full cost-sharing support pay less than $10 
dollars for the same prescription. For those receiving the partial LIS, the cost of treatment could 
still reach almost $1000 for the first month for a single orally-administered anticancer 
presscription. Therefore, it is possible that patients without full cost-sharing support may delay 
their uptake of treatments while they seek funds to cover their drug cost. They may also settle for 
alternative treatments that have lower out-of-pocket costs. 
Our findings are consistent with previous research showing delays in initiation of oral 
anticancer agents or treatments covered under Part D among individuals with high out-of-pocket 
cost and those without low-income subsidies.114,170,219–221 Our results suggest that cost-sharing 
subsidies alleviate the financial barriers for Part D oral anticancer drug treatments and that the 
resulting difference in cost-sharing level appears to be associated with treatment uptake even 
after considering other important factors. Long-term health outcomes (e.g., survival), therefore, 
could be a concern without timely initiation of treatment in life-threatening conditions like 
advanced cancer. As the availability of oral anticancer treatment options continues to increase, 
access and affordability will be key determinants of the true benefit for patients.221  
In our corresponding sensitivity analysis on Part B drug treatments (i.e., traditional 
chemotherapies), a negative control scenario where low out-of-pocket cost is expected for both 
LIS and non-LIS groups, we found that receiving LIS does not improve treatment uptake. For 
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Part B treatments, patients without any subsidy (i.e., non-LIS) instead were more likely to initiate 
Part B treatments compared to those with full subsidy or partial subsidy. This limited effect of 
subsidies could be due to the reasons that most patients have out-of-pocket coverage for Part B 
treatments so they face lower costs to start Part B treatments. Moreover, people who are non-LIS 
could even start the treatment earlier because they have more resources and thus are able to 
obtain supplemental health insurance to cover those cost-sharing requirements, which make them 
less disadvantaged than those who are Medicaid-eligible. Previous Patterns of Care (POC) 
analyses by the National Cancer Institute (NCI) indicated that cancer patients with Medicaid or 
Medicare-only were often under treated222, which was confirm by several recent studies in the 
lung cancer population.121,223,224 This disparity in NSCLC treatment particularly existed in 
patients with Medicaid or no insurance.121,223,224 Our examination considered the low-income 
subsidy status, which separated out dual eligible and different levels of Medicaid, and extended 
the understanding to the realm of financial support in care. 
In addition, the findings also provide robust support for our findings of financial barriers 
to timely initiation of therapy among cancer population; lack of appropriate cost-sharing support, 
either through subsidy programs or supplemental coverage, patient access to treatments was 
more restricted with the greater out-of-pocket cost burden, particularly for treatment initiation. 
Overall, more attention should be paid towards affordable and equal access to high 
quality care for the advanced NSCLC population. Multiple factors contributing to high OOP 
costs for cancer patients, including high drug prices, benefit designs of health insurance (e.g., 
adoption specialty tier and coinsurance), and the increase in treatment complexity (e.g., 
combination therapy) could be avenues to reducing financial burden on patients. In the context of 
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current evolving health care reform, identifying fiscally sustainable strategies to improve patient 
affordability of and access to cancer medications is necessary. 
Overall, our findings support our hypothesis on the effect of low-income subsidies for 
Medicare Part D medications on treatment initiation among patients with advanced NSCLC from 
2007 to 2014. Specifically, we found that for Part D treatments, patients without full subsidy 
(i.e., non-LIS, partial LIS) were less likely to initiate Part D treatments as compared with those 
with full LIS. This is particularly true among the partial LIS group despite their subsidy 
eligibility. For Part B treatment, rather than no difference among groups, we found that patients 
without any subsidy (i.e., non-LIS) instead were more likely to initiate Part B treatments 
compared to those with full subsidy or partial subsidy. This finding provides robust support for 
our hypothesis that greater financial barriers are related to restricted access to treatment or 
reduced timely initiation of therapy among cancer population. 
 
5.4 STRENGTHS AND LIMITATIONS  
 Our study has several limitations. First, genetic susceptibility could potentially influence 
the need for and response to treatment for NSCLC.161,210,218 Unfortunately, information on 
genetic mutations and test results are not regularly collected in population-level registry-linked 
claim databases to date. However, the prevalence of gene mutations is not likely to vary by 
subsidy status, which minimizes the concern for Aim 3 of the study. It is critical that this 
information be incorporated in future studies as it becomes available to better understand who is 
eligible for therapy.  
 Secondly, given the nature of claims data, only filled prescriptions by patients could be 
observed. Therefore, we were not able to distinguish whether the difference in use was because 
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of physician prescribing behavior (the patient did not receive a prescription for a drug) or patient 
filling behavior (the patient received a prescription but did not fill the medication).  
 In addition, formulary information cannot be linked to current claims data available. 
Therefore, we were not able to determine the effects of Part D benefits designs on prescription 
drug uptake. Although some of the formulary features are provided in the SEER-Medicare 
prescription drug event (PDE) files (e.g., utilization management tools, benefit phase), we could 
only observe the information among patients who filled their prescriptions. 
 Lack of transparency in drug rebates is another limitation in our examination of Part D 
drug prices and patient out-of-pocket cost. In the current U.S. healthcare environment, the 
amount of rebate offered for Part D drugs is not required to be reported by plans, pharmacy 
benefit managers, or manufacturers and the amount could vary substantially. Greater 
transparency about the rebates could improve understanding of actual financial burden patients 
are facing from receiving essential treatments in the real world. 
 Lastly, due to the poor prognosis of lung cancer in general, some patients’ health status 
might be too poor to use curative treatments or patients might die before any drug treatment is 
received during the observation period. In our examination, we also found that those without any 
treatments with infused chemotherapy (Part B) or oral targeted therapy (Part D) during the first 
year of diagnosis generally had shorter life or observation time; on average, about 7.5 months 
since diagnosis. For these patients, the focus of care might need to shift from an aggressive life-
sustaining approach to an approach that prioritize symptom relief from the disease and achieves a 
better quality of life to the very end (e.g., palliative care). 
 There are, however, also several strengths of this study. This study used the most up-to-
date data with detailed plan-level (or formulary-level) information, (e.g., plan benefit design, 
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cost share tier level, application of utilization management, and cost-sharing arrangement for 
drugs) to examine the difference in coverage offered and restrictions applied across all new and 
traditional advanced NSCLC treatments covered under Part D as of today. Notably, we provided 
expected out-of-pocket cost for initiating first month of anticancer treatment in NSCLC. This 
offers an overview of actual financial burden a patient could face for receiving care in current 
days. 
 In addition, to examine the real-world health outcomes among advanced NSCLC 
population, we used a large population-based data with a linkage between the SEER cancer 
registries and Medicare claims for the older population aged 65 or older. It provides detailed and 
nationally representative data on cancer and healthcare utilization data for Medicare patients with 
cancer. Since lung cancer is primarily a disease of older populations, this database affords a more 
detailed treatment analyses among this population.  
 Third, performance status is an important prognostic factor for survival and could affect 
potential treatment decisions. Given the limited availability of cancer performance status in the 
data, we applied a valid claim-based algorithm for older adults, predicted disability status as a 
proxy measure. This predicted disability status was considered as a key covariate in our two 
examinations (Aim 2 and 3) regarding the real-world treatment utilization among NSCLC 
population. The ability to assess disability status should improve covariate control and reduce 
indication bias. In addition, we further applied propensity scores to reduce the imbalance among 
groups, which helped alleviate potential bias in our results.  
 Notably, we used the examination of Part B drugs to complement the knowledge on 
currently available drug options in advanced NSCLC. We also used Part B drugs to serve as a 
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negative control for a robustness check in the investigation of the effect of high out-of-pocket 
spending on treatment uptake by subsidy status.  
 To our knowledge, this project is the first study to apply a disease-specific perspective for 
understanding the scope of care affordability and accessibility in NSCLC, a population with 
significant unmet needs. Beyond focusing on drug prices alone, we also consider diverse angles 
behind the growing patient financial burden in cancer care, including the benefit structure of 
plans as well as financial assistance in prescription drug expenses through the Medicare part D 
low income subsidy program. We are also the first study to consider and confirm the level of 
cost-sharing support (i.e., full subsidy, partial subsidy, and no subsidy) on possible gaps in 




  Affordability of and accessibility to Part D treatments could continue to be a critical 
issue for advanced NSCLC patients with current plan benefits and ever-increasing drug prices. 
With more and more treatment breakthroughs for lung cancer emerging on the market combined 
with high launch drug prices and the aging of the U.S. population, out-of-pocket costs could 
present a considerable barrier to timely initiation of therapy among advanced NSCLC 
population. This is particularly true for those who are in need of treatments covered under Part D 
but do not have enough financial resources or support for receiving appropriate care. Restructure 
of Medicare’s benefit design and enforcement mechanisms to control/monitor the drug pricing 
(e.g., value-based pricing) under Part D could be avenues to reducing financial burden on 
patients. In the context of current evolving health care reform, policy movement identifying 
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sustainable strategies to improve patient affordability of and equal access to high quality care are 
needed for the cancer population. 
 
5.6 FUTURE RESEARCH  
Due to the availability of data, the current study focused on the utilization of advanced 
NSCLC drugs between 2007 and 2014. Several years ago, the focus of drug development was 
oral drugs (covered under Part D). However, with the emerging role of immunotherapy for 
advanced NSCLC, infusion drugs (covered under Part B) are once again increasing in use. 
Immunotherapy differs from traditional chemotherapy (targets rapidly dividing cells, including 
healthy cells) and targeted therapies (interferes with key molecular in tumor cells to prevent 
tumor growth and invasion). It helps the immune system to recognize cancer, stimulates immune 
responsiveness, and relieves suppression of anti-tumor immunity. With an improved 
understanding of the immune system and advances in drug development, this newer 
immunotherapy appeared to be a promising treatment option in the management of advanced 
NSCLC. In addition, there are more patients eligible for immunotherapy than were ever for the 
targeted therapies. The first immunotherapy, Nivolumab (Opdivo
○R ), was approved by the US 
FDA in 2015 for advanced NSCLC with progression on or after platinum-based chemotherapy in 
unselected populations. With the high prices of these drugs, Part B treatments may be a major 
cost burden to patients and society in the near future. Much work will be needed in this growing 
area – examining the affordability of and accessibility to novel high-priced drugs covered under 
Part B in addition to that in Part D. Further disentangling the factors behind the uptake of newer 
high-priced treatment by different coverage source (Part B or Part D) will potentially provide 
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more insights into the barriers to care and thus the approaches to improve appropriate care in the 
advanced NSCLC population. 
In addition, genetic mutation is an important factor in the treatment decision and response 
to treatment in advanced NSCLC, such as EGFR or ALK-targeted agents. It is important for 
future research to incorporate the genetic information, if available, into the evaluation, as 
currently this information and related test results are not regularly collected in population-level 
registry-linked claim databases. 
Among the three LIS groups, patients with partial LIS are still responsible for substantial 
amount of out-of-pocket cost for using Part D treatments (15% coinsurance) despite the subsidy 
eligibility. This group of patients tends to be those who have limited income and resources but 
are not poor enough to obtain full cost-sharing support for medical care. Our findings also 
suggest that the partial LIS group were particularly less likely to initiate Part D treatments 
despite their subsidy eligibility. Further investigation in the factors influencing the treatment 
uptake among these patients are needed, as most research to date has combined this subgroup 
into one subsidy group as a whole or excluded this subgroup from the examination. 
In addition to assessing the treatment initiation, further research needs to be done to 
examine detailed treatment patterns among those who had initiated treatment. Particularly, 
analyses are needed on the role of low-income subsidy in the length of treatment (i.e., adherence 
or compliance). Whether the availability of more powerful but high-priced novel treatment 
options (e.g., oral targeted therapy, immunotherapy) would affect the continuance of current 







APPENDIX TABLES AND FIGURE 
Appendix Table 3.1 Advanced Non-Small Cell Lung Cancer Drugs covered under Part D and approved by U.S. FDA by June 
2017 
Aim Drug Name Brand Name Year of Approval Therapeutic Class  













Gefitinib Iressa  2003  
2003a 
2015 
Targeted therapy – EGFR Tyrosine kinase inhibitor   





Targeted therapy – EGFR Tyrosine kinase inhibitora 
   Crizotinib Xalkori  2011  
2011c 
2016 
Targeted therapy – ALK Tyrosine kinase inhibitor 
   Afatinib  Gilotrif  2013  2013 Targeted therapy - EGFR Tyrosine kinase inhibitor 
   Ceritinib  Zykadia  2014  2014 Targeted therapy – ALK Tyrosine kinase inhibitor 
   Alectinib  Alecensa 2015 2015 Targeted therapy – ALK Tyrosine kinase inhibitor 
   osimertinib Tagrisso 2015  2015d 
Targeted therapy – EGFR T790M Tyrosine kinase 
inhibitor 
a On June 17, 2005, the U.S. Food and Drug Administration approved new labeling for gefitinib (Iressa®, a trademark of AstraZeneca) that limits the indication 
to cancer patients who, in the opinion of their treating physician, are currently benefiting, or have previously benefited, from gefitinib treatment. The decision is 
based on the data from two failed clinical studies of gefitinib that showed no survival benefit in the use of gefitinib among advanced NSCLC. 
b As of October 2016, this indication is no longer FDA-approved. For NSCLC, the FDA-approval is limited to metastatic cancer that has certain epidermal 
growth factor receptor (EGFR) mutations. 
c In 2011, accelerated approval for locally advanced or metastatic NSCLC that is anaplastic lymphoma kinase (ALK) -positive. In 2013, regular approval was 
granted for locally advanced or metastatic NSCLC that is ALK-positive. 
d Accelerated approval in 2015 and full approval for NSCLC With a Specific EGFR Mutation in 2017. 
d Specific NDC and HCPC codes are provided in Appendix Table 3.3. 
e 
 FDA gives thumbs up to Takeda's lung cancer drug. http://www.biopharmadive.com/news/fda-gives-thumbs-up-to-takedas-lung-cancer-drug/441653/ 
Abbreviation: ALK: Anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; mTOR: mammalian target of rapamycin; T790M: threonine at 











Appendix Table 3.2 Advanced Non-Small Cell Lung Cancer Drugs covered under Part B and approved by U.S. FDA by June 
2017a 
Aim Drug Name Brand Name Year of Approval Therapeutic Class  













Cistplatin Platinol  1978  
1994b 
Traditional Chemo – Platinum-based agent 






Traditional Chemo – DNA topoisomerase inhibitor 
   Carboplatin Paraplatin   1991 1999c Traditional Chemo – Platinum-based agent 






Traditional Chemo – Taxane 
   Vinorelbine Navelbine  1994  1994 Traditional Chemo – Vinca alkaloid and analog 
   Docetaxel Taxotere  1996  1999 Traditional Chemo – Taxane 
   Gemcitabine Gemzar  1996  1996 Traditional Chemo – Pyrimidine analog 
   Pemetrexed Alimta  2004  
2008 
2009 
Traditional Chemo – Folate analog metabolic inhibitor 
(i.e., antifolate) 
   Bevacizumab  Avastin  2004  2006 Targeted therapy – Monoclonal antibody on VEGF 
   Ramucirumab Cyramza  2014  2014 Targeted therapy – Monoclonal antibody on VEGF 
   Nivolumab  Opdivo  2014  
2015 
2016 
Targeted therapy/immunotherapy – PD-1 Inhibitor 
   Pembrolizumab   Keytruda  2014  
2015 
2016 
Targeted therapy/immunotherapy – PD-1 Inhibitor 
   Necitumumabb Portrazza 2015 2015 
Targeted therapy/immunotherapy – monoclonal antibody 
on EGFR 
a Specific NDC and HCPC codes are provided in Appendix Table 3.4. 
b Indication for NSCLC is not specified in the cisplatin’s labeling. However, within the approval of vinorelbine in 1994, cisplatin was used as combination 
treatment for advanced NSCLC. 
c Indication for NSCLC is not specified in the etoposide’s labeling. However, etoposide has long been recommended in combination use with platinum-based 
agent by the NCCN Guidelines. 
d Indication for NSCLC is not specified in the carboplatin’s labeling. However, within the approval of decetaxel in 1999, carboplatin was used as combination 
treatment for advanced NSCLC. 
Abbreviation: EGFR: epidermal growth factor receptor; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1; VEGF: Vascular 








Appendix Table 3.3 Oral Anticancer Drug for Advanced Non-Small Cell Lung Cancer by April 2017 
Drug name Brand Name HCPCSa NDCa,b ATC b 
     
Gefitinib Iressa  J8565 00310048230 L01XE02 
Erlotinib  Tarceva  
N/A 50242006301, 54868547400, 50242006401, 54868544700, 
50242006201, 54868529000 
L01XE03 
Crizotinib Xalkori  N/A 00069814120, 00069814020 L01XE16 
Afatinib  Gilotrif  N/A 00597014130, 00597013730, 00597013830 L01XE13 
Ceritinib  Zykadia  N/A 00078064070 L01XE28 
Alectinib  Alecensa N/A 50242013001 L01XE36 
Osimertinib Tagrisso N/A 00310134930, 00310135030 L01XE35 
a HIPAA Space (https://www.hipaaspace.com/Medical_Billing/Coding/); HCPCS CODES (http://hcpcs.codes/)  
b The Integrated Cancer Information and Surveillance System (ICISS, https://iciss.unc.edu); WHO Collaborating Centre for Drug Statistics Methodology, 
International language for drug utilization research – The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) 
(https://www.whocc.no/atc_ddd_index/) 
Abbreviation: HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Code; NSCLC: non-small cell lung cancer; ATC, the Anatomical 









Appendix Table 3.4 Infused Anticancer Drug for Advanced Non-Small Cell Lung Cancer by April 2017 
Drug name Brand Name HCPCSa NDCa,b ATC b 
Cisplatin Platinol  
J9060, 
J9062 
00015322022, 00015322026, 00015322097, 00015322122, 00015322126, 00015322197, 
00069008101, 00069008407, 00703574711, 00703574811, 10019091001, 10019091002, 
16729028811, 16729028838, 44567050901, 44567051001, 44567051101, 55390009901, 
55390011250, 55390011299, 55390018701, 55390041450, 55390041499, 63323010351, 
63323010364, 63323010365, 63323010391, 63323010395, 67457042410, 67457042551, 








00015340420, 00013733691, 00013734694, 00013735688, 00703565301, 00703565601, 
00703565691, 00703565701, 00703565791, 00015306120, 00015306124, 00015306220, 
00015306224, 00015308420, 00015309520, 00015309530, 00015309595, 54569296300, 
00015309145, 00074148501, 00074148502, 00074148503, 00074564301, 00074564601, 
00074565301, 00074565601, 00074565701, 00074566701, 00186157131, 00209306022, 
00209307020, 00209308020, 00209309020, 00364302853, 00703564301, 00703564601, 
00703566701, 00703566801, 10019093001, 10019093002, 16729011408, 16729011411, 
16729011431, 16729026231, 53905029101, 55390029101, 55390029201, 55390029301, 
55390049101, 55390049201, 55390049301, 58406071112, 58406071418, 63323010405, 
63323010425, 63323010450, 63323010465, 68001026522, 68001026523, 68001026524, 
68001026525, 68001026526, 68001026527, 00378326694, 51079096501, 51079096505, 
54569571800, 54868535500, 54868535502, 51927277200 
L01CB01 
Carboplatin Paraplatin   
J9045 00015321030, 00015321076, 00015321130, 00015321176, 00015321230, 00015321276, 
00015321630, 00015321429, 00015321430, 00015321529, 00015321530, 00015321329, 
00015321330, 00015323011, 00015323111, 00015323211, 00015323311, 00409112910, 
00409112911, 00409112912, 00591333626, 00591333712, 00591333889, 00591345460, 
00703324411, 00703324611, 00703324811, 00703324911, 00703423901, 00703423981, 
00703424401, 00703424481, 00703424601, 00703424681, 00703424801, 00703424881, 
00703424891, 10019091201, 10019091202, 10019091203, 10139006005, 10139006015, 
10139006045, 15210006112, 15210006312, 15210006612, 15210006712, 25021020205, 
25021020215, 25021020245, 25021020251, 47335015040, 47335015140, 47335028440, 
47335030040, 55390015301, 55390015401, 55390015501, 55390015601, 55390022001, 
55390022101, 55390022201, 61703033918, 61703033922, 61703033950, 61703033956, 
61703033961, 61703033962, 61703033963, 61703036018, 61703036022, 61703036050, 
63323016905, 63323016915, 63323016945, 63323017205, 63323017215, 63323017245, 
63323017260, 66758004701, 66758004702 
66758004703, 66758004704, 66860010001, 66860010101, 66860010201, 67457049154, 
67457049215, 67457049346, 67457049461, 67457060820, 67817006112, 67817006312 
67817006612, 67817006712, 00591222011, 00703326601, 00703327601, 10019091601, 
10019091615, 50111096676, 55390015101, 63323016720, 63323016721, 00591368711 
00703326801, 00703326871, 00703327801, 10019091701, 50111096776, 55390015201, 
63323016800, 00591221911, 00703326401, 00703327401, 10019091501, 50111096576, 
55390015001, 63323016610 
L01XA02 
Paclitaxel Taxol  
J9264, 
J9265 
68817013450, 00172375377, 00172375396, 00172375473, 00172375494, 00172375531, 
00172375576, 00172375675, 00172375695, 00015345620, 00015345699, 00015347520, 
00015347527, 00015347530, 00015347620, 00015347627, 00015347630, 00015347911, 
00069007601, 00069007801, 00069007901, 00074433501, 00074433502, 00074433504, 
00555198414, 00555198514, 00703476401, 00703476481, 00703476601, 00703476681, 
00703476701, 00703476801, 00703476881, 10518010207, 10518010208, 10518010209, 
25021021305, 25021021317, 25021021350, 44567050501, 44567050601, 45963061353, 
45963061356, 45963061359, 51079096101, 51079096201, 51079096301, 55390011405, 
55390011420, 55390011450, 55390030405, 55390030420, 55390030450, 55390031405, 
55390031420, 55390031450, 55390051405, 55390051420, 55390051450, 61703034209 
61703034222, 61703034250, 63323076305, 63323076306, 63323076316, 63323076317, 










Vinorelbine Navelbine  
J9390 00081065601, 00081065644, 00173065601, 00173065644, 60831308601, 64370053201, 
64370308601, 60831308602, 64370053202, 64370308602, 00069009901, 00069020510, 
00703418201, 00703418281, 00703418291, 10019097001, 25021020401, 45963060755, 
55390006901, 55390026701, 59911595801, 61703034106, 63323014801, 64370021001 
66758004501, 67457043111, 67457048101, 00069010303, 00069020550, 00703418301, 
00703418381, 00703418391, 10019097002, 25021020405, 45963060756, 55390007001, 
55390026801, 59911595901, 61703034109, 63323014805, 64370025001, 66758004502, 
67457047953 
L01CA04 
Docetaxel Taxotere  
J9170, 
J9171 
47335028541, 47335028641, 00075800301, 00075800404, 00075800120, 00075800180, 
00069914411, 00409020120, 00409020127, 66758005003, 66758095004, 00955102208 
16729023165, 16729026765, 42367012129 
45963079056, 00409036601, 00703572001, 00955102001, 16714046501, 16729023163, 
16729026763, 25021022201, 42367012121, 43598025811, 45963073454, 63739093211, 
00069914111, 00069914122, 00409020102, 00409020125, 66758005001, 66758095002, 
00409036701, 00703573001, 00955102104, 16714050001, 16729023164, 16729026764, 
25021022204, 42367012125, 43598025940, 45963073452, 45963076552, 63739097117, 
00069914211, 00069914222, 00409020110, 00409020126, 66758005002, 66758095003, 
25021022207, 45963073474, 16729012049, 60505603500, 60505603506, 16729022850, 
60505603700, 60505603706 
L01CD02 
Gemcitabine Gemzar  
J9201 00002750201, 00002750101, 00069385810, 00409018601, 00591356355, 00703577801, 
00781328379, 16729011711, 23155021431, 23155048431, 23155052931, 25021020950, 
25021023550, 45963061959, 47335015440, 55111068725, 55390039150, 63323012550 
63323012553, 63323012594, 67457046201, 68001028223, 68001028226, 00409018101, 
00409018125, 45963062458, 00069385910, 00409018701, 16729011838, 45963062060, 
63323012600, 67457046302, 68001028224, 68001028227, 00409018201, 00409018225, 
45963063660, 00069385710, 00409018501, 00591356279, 00703577501, 00781328275, 
16729009203, 23155021331, 23155048331, 23155052831, 25021020810, 25021023410, 
45963061257, 47335015340, 55111068607, 55390039110, 63323010210, 63323010213, 
63323010294, 67457046420, 68001028222, 68001028225, 00409018301, 00409018325, 
45963062357 
L01BC05 
























































Abbreviation: HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Code; NSCLC: non-small cell lung cancer; ATC, the Anatomical 
Therapeutic Chemical Classification system by the World Health Organization Collaborating Centre (WHO). 
Note: J9999, J3490,and J3590 are unspecified codes used before specific codes available for the approved drugs. 
a HIPAASpace (https://www.hipaaspace.com/Medical_Billing/Coding/); HCPCS CODES (http://hcpcs.codes/)  
b The Integrated Cancer Information and Surveillance System (ICISS, https://iciss.unc.edu); WHO Collaborating Centre for Drug Statistics Methodology, 
International language for drug utilization research – The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) 
(https://www.whocc.no/atc_ddd_index/) 
c Coding information: https://www.accc-cancer.org/ossn_network/pdf/cyramza-announcement.pdf  
d Coding information: http://www.bmsaccesssupport.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00Pi000000FtTI9EAN;   
e Coding information: https://www.merckaccessprogram-keytruda.com/static/pdf/keytruda-billing-ndc-codes.pdf; 
https://www2.ncdhhs.gov/DMA/bulletin/0115bulletin.htm#keytruda   










Appendix Table 3.5 Summary of Surgery for Non-Small Cell Lung Cancer 
 Healthcare Common Procedure 
Coding System (HCPCS) 
International Classification of 














31625, 31628, 31629, 31632, 31633, 
32095, 32400, 32402, 32405, 32602, 
32604, 32606, 32607, 32608, 32609, 




32442, 32480, 32482, 32484, 32486, 
32488, 32500, 32503, 32520, 32522, 
32525, 32657, 32663, 32440, 32445, 
















Appendix Table 3.6 Summary of Radiation Therapy for Non-Small Cell Lung Cancer 




774xx, 7775x, 7776x, 7777x, 
7778x, 7779x 
 
92.2x V58.0, V66.1 V67.1 Revenue Center: 
0330, 0333 
Abbreviation: HCPCS, Healthcare Common Procedure Coding System; ICD-9-Procedure, International Classification of Diseases, 9th revision – Procedure; 









Appendix Table 4.1 Median Prices of Advanced Non-Small Cell Lung Cancer Drugs Covered under Part D, 2010Q1-2017Q1 
(2017 USD) 
  



























































































































































































































Appendix Table 4.2 Average Sales Prices for Advanced NSCLC Drugs Covered under Part B (2017 USD) 
GENERIC NAME STRENGTH & 
FORMULATI
ON 
2010Q1 2011Q1 2012Q1 2013Q1 2014Q1 2015Q1 2016Q1 2017Q1 NOTES 
CISPLATIN 10 MG IV $52.46 $53.1 $41.4 $48.4 $46.9 $46.7 $32.21 $40.5  








10 MG IV $44.9 $70.5 $71.0 $72.2 $65.9 $56.9 $52.4 $48.4 
 




$9,453.0 $9,090.7 $8,955.5 $8,708.6 $8,598.6 $8,293.2 $8,328.1 $8,081.3 
 
PACLITAXEL 30 MG IV $142.7 $102.0 $105.3 $78.6 $59.3       
J code not valid since 
2015 
PACLITAXEL 1 MG IV           $62.0 $57.2 $63.9 
J code valid since 
January 2015 
VINORELBINE 10 MG IV $194.7 $212.1 $179.7 $168.7 $143.5 $148.4 $152.2 $113.6  
DOCETAXEL 1 MG IV $4,441.5 $4,469.7 $3,244.9 $1,457.8 $1,045.5 $852.5 $538.5 $499.0  
GEMCITABINE 200 MG IV $4,870.5 $4,906.9 $1,586.7 $331.1 $222.9 $203.2 $241.2 $144.5  
PEMETREXED 10 MG IV $8,499.7 $8,460.7 $8,533.2 $8,853.2 $9,043.0 $8,660.5 $8,544.2 $8,035.5  
BEVACIZUMAB  10 MG IV $11,925.7 $11,915.5 $11,695.7 $11,951.4 $12,210.6 $11,967.6 $12,106.6 $11,849.4  
RAMUCIRUMAB 5 MG IV             $12,307.9 $12,083.1 
J code valid since 
January 2016 
NIVOLUMAB  1 MG IV             $14,865.0 $14,353.1 
J code valid since 
January 2016 
PEMBROLIZUM
AB   
1 MG IV             $10,412.1 $9,973.6 
J code valid since 
January 2016 
NECITUMUMAB 1 MG IV               $12,870.0 
J code valid since 
January 2017 








Appendix Table 4.3 Coverage of Advanced Non-Small Cell Lung Cancer Drugs among Part D Plans, 2010Q1-2017Q1.  
  
2010Q1 2011Q1 2012Q1 2013Q1 2014Q1 2015Q1 2016Q1 2017Q1   
MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs 
# of plans on the 
market N=1908 N=1594 N=1642 N=1136 N=1699 N=1063 N=1768 N=1051 N=1787 N=1186 N=1867 N=1013 N=1950 N=897 N=2031 N=757 
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Appendix Table 4.4 Application of Utilization Management Tools and Drug Tiering in Part D Plans, by Drug, 2010Q1-2017Q1 
  
2010Q1 2011Q1 2012Q1 2013Q1 2014Q1 2015Q1 2016Q1 2017Q1 
PLANS COVERING ERLOTINIB 
  
MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs 





























































































































































































































































































































































































































































































































































































































































PLANS COVERING GEFITINIB 
 
 MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs 





































































































































































































































































































































































































PLANS COVERING CRIZOTINIB 
 
         MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs MAs PDPs 










































































































































































































































































































































































































































































































PLANS COVERING AFATINIB  
 
                     MAs PDPs MAs PDPs MAs PDPs 
                                          N=1857 N=1013 N=1942 N=897 N=1984 N=689 
PA 




















































































































































































































































PLANS COVERING CERITINIB 
 
                     MAs PDPs MAs PDPs MAs PDPs 
                                          N=1857 N=1013 N=1942 N=897 N=1984 N=689 
PA 


























































































































































































































































PLANS COVERING ALECTINIB 
 
                         MAs PDPs MAs PDPs 
                          N=1824 N=897 N=1984 N=689 
PA 
































































































































































PLANS COVERING OSIMERTINIB  
 
                         MAs PDPs MAs PDPs 
                                                   N=1885 N=897 N=1984 N=689 
PA 





































































































































































Abbreviation: PA: prior authorization; QL: quantity limit; ST: step therapy. 
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Appendix Figure 4.1A Composition of NSCLC Drugs Utilization on Medicare Part D 
within 12-month after Diagnosis of Advanced NSCLC, 2007-2014a 
 
a The numbers above the bars indicates the total number of people ever using a Part D drug during the 12-month 
period after Diagnosis of Advanced NSCLC 
 
Appendix Figure 4.1B. Composition of NSCLC Drugs Utilization on Medicare Part B 
within 12-month after Diagnosis of Advanced NSCLC, 2007-2014a 
 
a The numbers above the bars indicates the total number of people ever using a Part B drug during the 12-month 
period after Diagnosis of Advanced NSCLC 
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Appendix Table 4.5 Standard Differences Before and After Inverse Probability of 
Treatment Weighting (IPTW) 
  Standardized differencea 
  Before IPTW After IPTW 
  Partial vs Full Non vs Full Partial vs Full Non vs Full 
Age    0.0776 0.1483 0.0349 0.0708 
Sex   0.0190 0.0401 -0.0047 0.0085 
Race/Ethnicity 
 
0.5137 0.8849 0.0645 0.0488 
Marital Status 
 
0.0836 0.5108 0.0124 0.0598 
Region   0.6018 0.4135 0.0599 0.1085 
Urban/Rural Residence 0.1889 0.0910 0.0252 0.0402 
Census Tract % of Non-High School 
Degree 0.2305 0.8145 0.0207 0.0633 
Census Tract % below poverty 0.2449 0.7370 0.0240 0.0754 
Census Tract Household Median Income 0.1374 0.6526 0.0197 0.0942 
Comorbidity Index 0.1229 0.2507 0.0027 0.0621 
Predicted DS  
-0.3652 
 
-0.4119 0.0050 -0.0282 
Year of Diagnosis 0.1595 0.1067 0.0213 0.0543 
Quarter of Year of Diagnosis 0.0490 0.0171 0.0102 0.0478 
Cancer Stage  0.1125 0.2003 -0.0009 0.0248 
Cancer Histology     
 Adenocarcinoma -0.0411 0.1222 0.0079 0.0119 
 Squamous 0.0075 -0.1348 -0.0011 0.0096 
 Large cell 0.0059 0.0093 -0.0031 -0.0015 
 Others 0.0403 -0.0067 -0.0075 -0.0251 
Radiation as First Course of Therapy 0.1156 0.1563 0.0229 0.0528 
Surgery as First Course of Therapy 0.0356 0.1070 0.0201 0.0416 
Receipt of Care from Hospital Affiliation 
with 
    
 NCI Designation -0.0524 0.1490 -0.0145 -0.0358 
 ECOG 0.1970 0.2684 -0.0085 -0.0844 
 Teaching Hospital 0.0246 0.1000 0.0049 -0.0392 
 Major Affiliation 
with Medical 
School 0.1441 0.1684 -0.0037 -0.0386 
a Standardized difference197 represents the difference in the means of two groups in units of standard deviation of the 
variable. The values allow for an assessment of differences between two groups. As a rule of thumb, standardized 
differences greater than 0.10. indicate a meaningful imbalance in the baseline covariate. For this study, the 
standardized mean differences post IPTW were all below 0.10 between groups (Non-LIS vs Full LIS; Partial LIS vs 
LIS), suggesting negligible imbalance in patient baseline characteristics between groups for the analysis. 
Abbreviation: 95% CI, 95% Confidence Interval; DS, Disability Status; ECOG: the Eastern Cooperative Oncology 
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